US20170218332A1 - Regionalised Endoderm Cells and Uses Thereof - Google Patents
Regionalised Endoderm Cells and Uses Thereof Download PDFInfo
- Publication number
- US20170218332A1 US20170218332A1 US15/423,126 US201715423126A US2017218332A1 US 20170218332 A1 US20170218332 A1 US 20170218332A1 US 201715423126 A US201715423126 A US 201715423126A US 2017218332 A1 US2017218332 A1 US 2017218332A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- ade
- hex
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004039 endoderm cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 738
- 210000001900 endoderm Anatomy 0.000 claims abstract description 98
- 238000004113 cell culture Methods 0.000 claims abstract description 33
- 210000005229 liver cell Anatomy 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 72
- 108010059616 Activins Proteins 0.000 claims description 62
- 239000000488 activin Substances 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 53
- 239000002609 medium Substances 0.000 claims description 49
- 210000002966 serum Anatomy 0.000 claims description 48
- 239000003550 marker Substances 0.000 claims description 41
- -1 xph5 Proteins 0.000 claims description 34
- 101150067309 bmp4 gene Proteins 0.000 claims description 28
- 238000004264 monolayer culture Methods 0.000 claims description 27
- 210000004185 liver Anatomy 0.000 claims description 23
- 101100005911 Mus musculus Cer1 gene Proteins 0.000 claims description 22
- 102100038126 Tenascin Human genes 0.000 claims description 22
- 108010008125 Tenascin Proteins 0.000 claims description 22
- 101150057663 Foxa2 gene Proteins 0.000 claims description 19
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 15
- 241000699670 Mus sp. Species 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- 101150051439 Clic6 gene Proteins 0.000 claims description 12
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
- 210000000496 pancreas Anatomy 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 101150078182 FXYD3 gene Proteins 0.000 claims description 9
- 101100207058 Mus musculus Tmprss2 gene Proteins 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 9
- 101150038447 Sstr2 gene Proteins 0.000 claims description 9
- 101150110248 fzd5 gene Proteins 0.000 claims description 9
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 101150097704 HHEX gene Proteins 0.000 claims description 7
- 101150092239 OTX2 gene Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 101150071783 APOA1 gene Proteins 0.000 claims description 5
- 101150074911 CTSH gene Proteins 0.000 claims description 5
- 101150028741 Enpp5 gene Proteins 0.000 claims description 5
- 101100094992 Mus musculus Sapcd1 gene Proteins 0.000 claims description 5
- 101150030456 RNASE4 gene Proteins 0.000 claims description 5
- 102000028676 Rab15 Human genes 0.000 claims description 5
- 108700039173 Rab15 Proteins 0.000 claims description 5
- 101150065720 Rab15 gene Proteins 0.000 claims description 5
- 101150097792 Robo1 gene Proteins 0.000 claims description 5
- 101150064119 SEC14L2 gene Proteins 0.000 claims description 5
- 101150095230 SLC7A8 gene Proteins 0.000 claims description 5
- 101150077847 SYT9 gene Proteins 0.000 claims description 5
- 101150028423 Slc6a4 gene Proteins 0.000 claims description 5
- 101150089233 Syt5 gene Proteins 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 101150109056 gckr gene Proteins 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 101150075558 CHGA gene Proteins 0.000 claims description 4
- 101100246972 Danio rerio pyya gene Proteins 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 101150042912 Krt7 gene Proteins 0.000 claims description 4
- 101150032143 SLC38A5 gene Proteins 0.000 claims description 4
- 101150113268 ghrl gene Proteins 0.000 claims description 4
- 101150036871 pyy gene Proteins 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 101150117946 Foxa1 gene Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000005606 Activins Human genes 0.000 claims 4
- 210000001082 somatic cell Anatomy 0.000 claims 4
- 230000008672 reprogramming Effects 0.000 claims 2
- 101150043532 CISH gene Proteins 0.000 claims 1
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 claims 1
- 101150090933 PIK3CB gene Proteins 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 143
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 128
- 101001082391 Aspergillus oryzae Beta-hexosaminidase Proteins 0.000 description 104
- 240000003978 Ipomoea coccinea Species 0.000 description 76
- 230000006698 induction Effects 0.000 description 65
- 102100026818 Inhibin beta E chain Human genes 0.000 description 58
- 101150021185 FGF gene Proteins 0.000 description 43
- 230000011664 signaling Effects 0.000 description 38
- 238000004458 analytical method Methods 0.000 description 35
- 238000000684 flow cytometry Methods 0.000 description 35
- 101150066398 CXCR4 gene Proteins 0.000 description 34
- 238000000338 in vitro Methods 0.000 description 34
- 210000003494 hepatocyte Anatomy 0.000 description 31
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 30
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 30
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 30
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 210000003716 mesoderm Anatomy 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000012010 growth Effects 0.000 description 24
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 23
- 108010023082 activin A Proteins 0.000 description 23
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 22
- 101710123134 Ice-binding protein Proteins 0.000 description 22
- 101710082837 Ice-structuring protein Proteins 0.000 description 22
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 22
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 22
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 102000000905 Cadherin Human genes 0.000 description 21
- 108050007957 Cadherin Proteins 0.000 description 21
- 239000002356 single layer Substances 0.000 description 21
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 238000011529 RT qPCR Methods 0.000 description 18
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 210000001811 primitive streak Anatomy 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 230000009278 visceral effect Effects 0.000 description 15
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 14
- 230000001464 adherent effect Effects 0.000 description 14
- 229920000159 gelatin Polymers 0.000 description 14
- 235000019322 gelatine Nutrition 0.000 description 14
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 14
- 108010088751 Albumins Proteins 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 13
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 13
- 210000002257 embryonic structure Anatomy 0.000 description 13
- 239000008273 gelatin Substances 0.000 description 13
- 235000011852 gelatine desserts Nutrition 0.000 description 13
- 239000002243 precursor Substances 0.000 description 13
- 229930002330 retinoic acid Natural products 0.000 description 13
- 210000002242 embryoid body Anatomy 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 230000013020 embryo development Effects 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 230000002440 hepatic effect Effects 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 10
- 230000007045 gastrulation Effects 0.000 description 10
- 210000001654 germ layer Anatomy 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 102100025745 Cerberus Human genes 0.000 description 8
- 101150075625 Gsc gene Proteins 0.000 description 8
- 206010043276 Teratoma Diseases 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 7
- 229930040373 Paraformaldehyde Natural products 0.000 description 7
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000001161 mammalian embryo Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920002866 paraformaldehyde Polymers 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000004739 secretory vesicle Anatomy 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 102000052549 Wnt-3 Human genes 0.000 description 5
- 108700020985 Wnt-3 Proteins 0.000 description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000003981 ectoderm Anatomy 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 5
- 230000001936 parietal effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000004017 serum-free culture medium Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 4
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 4
- 241000202252 Cerberus Species 0.000 description 4
- 101710010675 Cerberus Proteins 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 4
- 108700031316 Goosecoid Proteins 0.000 description 4
- 102000050057 Goosecoid Human genes 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 101150068639 Hnf4a gene Proteins 0.000 description 4
- 101000914195 Homo sapiens Cerberus Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 101150097504 LHX1 gene Proteins 0.000 description 4
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 210000003999 epithelial cell of bile duct Anatomy 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001325 yolk sac Anatomy 0.000 description 4
- 238000011714 129 mouse Methods 0.000 description 3
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 3
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 3
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 description 3
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 3
- 208000016222 Pancreatic disease Diseases 0.000 description 3
- 101150081875 Slc7a10 gene Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 101150003286 gata4 gene Proteins 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000011551 log transformation method Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000001002 morphogenetic effect Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 101100339677 Arabidopsis thaliana HRS1 gene Proteins 0.000 description 2
- 102100023506 Chloride intracellular channel protein 6 Human genes 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150089574 FOXA3 gene Proteins 0.000 description 2
- 102000004641 Fetal Proteins Human genes 0.000 description 2
- 108010003471 Fetal Proteins Proteins 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 101150084579 GATA1 gene Proteins 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- 101000906631 Homo sapiens Chloride intracellular channel protein 6 Proteins 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101150023976 Krt19 gene Proteins 0.000 description 2
- 101150074224 Onecut1 gene Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101100082623 Rattus norvegicus Pdlim7 gene Proteins 0.000 description 2
- 101100129874 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGD1 gene Proteins 0.000 description 2
- 101100129591 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcp6 gene Proteins 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- WDHRPWOAMDJICD-FOAQWNCLSA-N n-[2-[(3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide Chemical compound C([C@@H](C)C[C@@H]1[C@@H]2[C@H]([C@]3(C(=C4C[C@@H]5[C@@]6(C)CCC(=O)CC6=CC[C@H]5[C@@H]4CC3)C)O1)C)N2CCNC(=O)CCCCCNC(=O)CCC1=CC=CC=C1 WDHRPWOAMDJICD-FOAQWNCLSA-N 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000003458 notochord Anatomy 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102220277674 rs1554067113 Human genes 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000608669 Bos taurus Uveal autoantigen with coiled-coil domains and ankyrin repeats protein Proteins 0.000 description 1
- 101100173447 Caenorhabditis elegans ger-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100039818 Frizzled-5 Human genes 0.000 description 1
- 101710140951 Frizzled-5 Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 241000251188 Holocephali Species 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150104227 PDLIM4 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 101150001038 ade gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000010454 developmental mechanism Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells.
- ADE anterior definitive endoderm
- the invention also relates to cell lines, cell culture methods, cell markers and the like and their potential uses in a variety of applications.
- Embryonic stem (ES) cells hold tremendous promise as a source of functional differentiated cell types for regenerative medicine.
- ES have great potential as an in vitro system for the study of developmental biology, allowing the effective isolation of distinct populations of cells that normal exist very close together in both space and time during embryonic development.
- Both the efficient directed differentiation of ES cells to specific lineages and studies of developmental mechanism require the in vitro recapitulation of the appropriate intermediate cell types formed in embryonic development.
- the successful differentiation of ES cells to neural, haematopoetic and epidermal cell types involve a progression through intermediate progenitor states prior to terminal differentiation (Bagutti et al. 1996; Nishikawa et al. 1998; Conti et al. 2005) [Conti 2005, Nishikawa 1998, Bagutti 1996]. It is likely that successful differentiation of endodermal lineages from ES cells will also depend on efficiently recapitulating the step-wise progression that occurs during normal embryogenesis.
- the anterior definitive endoderm is one the first defined lineages to emerge from the primitive streak during gastrulation. It originates in the node, the mammalian equivalent of the Spemman Organiser (also referred to as axial mesendoderm) and these cells migrate anteriorly during embryogenesis and have an important role in patterning the anterior neural axis (Lu et al. 2001). Later during gut tube formation they migrate ventrally to form the ventral foregut, a unique population of bipotent precursors of the liver and pancreas (Deutsch et al. 2001). Thus the ADE not only represents an essential signalling centre for embryogenesis, but an important intermediate in the production of liver and pancreas.
- mesendoderm In vertebrate developmental contexts mesendoderm is often used to refer to the derivatives of the node or Spemman Organiser (here referred to as axial mesendoderm), structures that can be associated with both the mesoderm and endoderm. However, mesendoderm can also be used to refer globally to the migrating lineages at gastrulation, mesoderm and endoderm. These lineages may have evolved from a common ancestor and are induced by the same signalling pathways (Rodaway and Patient 2001), suggesting that in some instances the mesoderm and endoderm may develop from a common precursor population during embryonic development. In C.
- perturbation of these signalling pathways in the embryo may disrupt cell movements and produce a phenotype in the mesendoderm, without being directly involved in mesendoderm induction. Studying the induction of endoderm using an in vitro cell system would avoid this complication.
- ADE cells ADE cells
- differentiated cells such as pancreatic or liver cells for transplantation but the persistence of ES and other non-pancreatic/non-liver cells in ES-derived cell populations can give rise to tumours in recipient animals.
- a complete understanding of the molecular and cellular events controlling the behaviour of ADE cells is essential, not only as a route for understanding embryogenesis, but also as a framework upon which ADE cells can be isolated, expanded and controlled for future therapeutic and research applications. It is desirable to develop methods and conditions for culturing large quantities of ADE cells that allow the cells to be differentiated into, for example, pancreatic or liver cells. It is particularly desirable to have defined culture media, which enable this as the use of defined media is highly desirable in a clinical or research setting.
- the present invention seeks to solve one or more of the above described disadvantages.
- ADE anterior definitive endoderm
- the present invention is based on a novel strategy to isolate ADE from ES cells by detecting Hex expression in conjunction with the cell surface marker CXCR4.
- CXCR4 is expressed in the embryonic definitive endoderm but not anterior visceral endoderm (AVE) and thus, when coupled to Hex, defines prospective ADE.
- Hex is a homeobox transcriptional repressor that is one of the earliest markers of ADE and has also been shown to suppress more posterior, pan-mesodermal identities (Thomas et al. 1998; Brickman et al. 2000; Zamparini et al. 2006).
- Hex is neither a marker of the earlier transient mesendoderm cell population (Brachyury (Kubo et al. 2004), Goosecoid (Tada et al. 2005), of all axial mesendoderm (Foxa2 (Gadue et al. 2006)) or of all endoderm at particular time points (Sox17 (Yasunaga et al. 2005)).
- Hex is expressed in the extra-embryonic visceral endoderm, in an early patterning centre known as the anterior visceral endoderm (AVE) (Thomas et al. 1998). It is not hitherto been suggested that the detection of Hex and CXCR4 expression could be used as a marker of ADE cell generation.
- the inventors show that significant numbers of cells in differentiating ES cell cultures can be induced to express Hex and CXCR4 and present extensive expression analysis of these in vitro derived populations allowing further ADE markers to be identified. They further disclose culture conditions and present a serum free cell culture regime for the differentiation of ES cells towards ADE.
- a method of identifying anterior definitive endoderm (ADE) cells derived from a population of ES cells comprising the step of detecting two or more ADE cell markers, in a cell population derived from said ES cell population, in order to identify said ADE cells.
- the method of identifying ADE comprises the step of detecting expression of Hex and CXCR4, in a cell population derived from said ES cell population, in order to identify said ADE cells.
- ADE markers which have been identified by the inventors include.
- Preferred cell surface markers which have been identified and may be used to identified and/or isolate ADE cells include Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4sf2, Fzd5, Cklfsf8 (aka Cmtm8), Rarres1, Sic7a8, Sfrp5 and Cxcr4.
- the present inventors have been able to generate cell populations comprising greater than 5%, 10%, 15%, 20%, 30% or 40% ADE cells from a cell population substantially initially consisting essentially of ES cells.
- a mixed cell population obtained directly from an ES cell culture comprising at least 5%, 10%, 15%, 20%, 30% or 40% ADE cells.
- the ADE cells in said mixed population may be subsequently enriched or purified in order to provide substantially pure ADE cell populations.
- a substantially pure population of ADE cells which i) will proliferate in an in vitro culture without further differentiation for at least 8 passages and/or over 2 months; and ii) maintains the potential to differentiate into derivatives of ADE cells.
- the cell line comprises cells which are not genetically modified.
- the present inventors were able to further differentiate the ADE cells into cells of pancreatic or liver lineage, using appropriate differentiating factors.
- the inventors were able to generate a differentiated cell culture from a cell culture comprising ADE cells obtained using the methods described herein in which >40%, such or 50%, 60%, 70% or even 80% or 90% of the cells differentiated in the cell culture were pancreatic cells, or separately, in which >10%, such as 15% or 20%, 30%, 40%, 50% or 60% were liver cells.
- Such cell populations can be essentially free of ES cells and/or other progenitor cells, such as mesendoderm progenitor cells.
- cells are cultured in the absence of serum, e.g. in medium that is free of serum and/or free of serum extract. It is preferred in some embodiments that cells are cultured attached to a substrate, otherwise referred to as in an adherent culture.
- the invention further provides methods of obtaining ADE cells or cells differentiated therefrom, and specifically as set out in the protocols herein, and additionally provides cells obtained by such methods.
- ADE cells of the invention and cells derived therefrom can be derived from, inter alia, humans, primates, rodents and birds.
- the ADE cells are derived from mammals, especially mice, rats and humans.
- ES cells from which the ADE cells are derived may be either wild-type or genetically modified ES cells.
- Embryonic stem cells have been reported from a number of mammalian sources include mouse (Bradley et al (1984) Nature 309: 255-56), human (Thomson et al (1998), Science 202, p 1145-1147), American mink (Mol Reprod Dev (1992) December; 33(4): 418-31), pig and sheep (J Reprod Fertil Suppl (1991); 43: 255-60), hamster (Dev Biol (1988) May; 127(1): 224-7) and cow (Roux Arch Dev Biol (1992); 201: 1340141). Specific examples herein use mouse and ES cells.
- compositions of the present invention are suitable for adaptation to culturing of other mammalian pluripotent cell cultures, thus including primate, especially human, rodent, especially mouse and rat, and avian pluripotent stem cells, especially ES cells.
- the present inventors have generated a genetically modified mouse ES cell line which may be of use in the present invention.
- the mouse ES cell line comprises a nucleic acid construct comprising a marker gene which has been inserted within the Hex locus such that the marker gene is under control of the Hex promoter.
- the marker gene is preferably inserted into the first exon of the Hex locus by homologous recombination.
- a suitable marker is the RedStar (RS) marker gene and this may be introduced by use of an appropriate selection cassette which may be excised from the genome following marker gene insertion. This may be achieved for example using the Cre-LoxP system, or the Flp recombinase system, or other recombinase system.
- Suitable ES cells may be used to generate a Hex RS mouse cell line which is heterozygous for the RS gene.
- the present inventors also provide a Hex marker gene/+ embryo or a mouse especially a Hex RS/+ embryo or a mouse for use in obtaining ADE cells.
- ADE cells By using ES cells derived by using the above described mouse, the present inventors were able to obtain ADE cells by detecting for Hex RS expression and CXCR4 expression. However, the skilled addressee can easily adapt this, using homologous genes, such that the technique can be carried out in order to obtain ADE cells from other organisms, especially other mammals including human.
- the cells of the present invention are grown in contact with culture media.
- Culture media used in the present invention preferably comprise a basal medium, optionally supplemented with additional components.
- Basal medium is a medium that supplies essential sources of carbon and/or vitamins and/or minerals for ES cells.
- the basal medium is generally free of protein and incapable on its own of supporting self-renewal/symmetrical division of ES cells. Examples of such media include GMEM, and DMEM.
- culture media used in the invention do not contain any components which are undefined (e.g. serum and/or feeder cells), that is to say components whose content is unknown or which may contain undefined or varying factors that are unspecified.
- undefined e.g. serum and/or feeder cells
- An advantage of using fully defined media, free of serum and free of serum extracts, is that efficient and consistent protocols for culture and subsequent manipulation of ADE cells and cells derived therefrom can be obtained.
- Typical substrates for culture of the cells in all aspects of the invention are culture surfaces recognized in this field as useful for cell culture, and these include surfaces of plastics, metal, composites, though commonly a surface such as a plastic tissue culture plate, widely commercially available, is used. Such plates are often a few centimetres in diameter. For scale up, this type of plate can be used at much larger diameters and many repeat plate units used.
- the culture surface may further comprise a cell adhesion protein, usually coated onto the surface.
- Receptors or other molecules present on the stem cells bind to the protein or other cell culture substrate and this promotes adhesion to the surface and promotes growth.
- Gelatin coated plates are particularly preferred.
- the cultures of the invention are preferably adherent cultures, i.e. the cells are attached to a substrate.
- Methods of the invention can be used for stimulating differentiation of ES cells to ADE cells in medium which is free of serum and free of serum extract. Preferably, such methods are also carried out in the absence of feeder cells and/or feeder cell extracts.
- differentiation of ES cells to ADE cells can be carried out comprising the steps of:—
- ES cells in a first culture medium for a period of time, optionally on feeders, in the presence of serum or an extract of serum or in a serum free/serum extract free medium;
- replacing the first medium with a second serum free medium comprising activin or removing the serum or the serum extract from the first medium and withdrawing the feeders (if present) and adding activin, so that the first medium is free of feeders, serum and serum extract;
- SF03 medium has been described previously by Tada et al 2005 and is available from Iwai Chemicals Company, Japan.
- Suitable culture media includes GMEM, DMEM, F12 and N2B27.
- N2B27 is preferred and is available from Invitrogen, Paisley, UK.
- Further agents may be included in the first or second medium such as EGF and/or an agonist of a receptor of the TGF- ⁇ superfamily.
- An agonist of a receptor of the TGF- ⁇ superfamily is suitably a member of the TGF- ⁇ superfamily of signalling factors, and is preferably a bone morphogenetic protein (BMP) such as BMP-4.
- BMP bone morphogenetic protein
- Known homologues of BMP4, such as BMP2 and BMP7, may also be suitable, as are homologues from non-mammalian species such as decapentaplegic (dpp) from Drosophila melanogaster .
- the term “agonist” is also intended to embrace mimetics, fusion proteins or chimaeras of TGF- ⁇ superfamily signalling polypeptides, and fragments, variants and derivatives thereof, capable of activating receptors of the TGF- ⁇ superfamily.
- a preferred protocol comprises maintaining cells in a medium comprising serum such as, fetal calf serum, following by maintaining the cells in a serum free medium comprising activin in order to obtain ADE cells.
- the cells are grown in serum comprising medium for 1-3 days, e.g. 2 days followed by culture in serum free medium for 3-6 days such as 5 days.
- the medium comprising serum is GMEM.
- the medium comprising activin is N2B27.
- the initial cell density in medium containing serum or serum extract is less than 1 ⁇ 10 5 cells/ml, typically between 1 ⁇ 10 3 cells/ml to 7 ⁇ 10 4 cells/ml, such as 3 ⁇ 10 3 cells/ml to 5 ⁇ 10 4 cells/ml especially 5 ⁇ 10 3 cells/ml.
- the cells may be grown as adherent monolayer cultures, or may be allowed to form embryoid bodies in suspension.
- Cells grown in monolayer may initially be grown for 1-3 days, e.g. 2 days in a first medium which may comprise one or more of activin, Fgf4, Bmp4 or CHIR99021. Thereafter, the cells may be grown for 3-6 days e.g. 5 days, in a second medium supplemented with activin and further optionally comprising EGF and/or Fgf4.
- a first medium which may comprise one or more of activin, Fgf4, Bmp4 or CHIR99021.
- the cells may be grown for 3-6 days e.g. 5 days, in a second medium supplemented with activin and further optionally comprising EGF and/or Fgf4.
- the first medium comprises activin and Bmp4 and optionally Fgf4.
- the second medium comprises EGF and optionally Fgf4.
- the first medium is N2B7.
- the second medium is SF03.
- Cells grown in serum free solution and which are allowed to form embroid bodies may be initially grown for 1-3 days such as 2 days in a medium which may optionally comprise activin and may further comprise Bmp4.
- a preferred medium is N2B27.
- cells may be grown for 3-6 days especially 5 days in a second medium comprising activin and preferably further comprising Egf4, and optionally Bmp4 and/or GI.
- the first medium is N2B7.
- the second medium is SF03.
- the present inventors Using appropriate cell sorting techniques to detect Hex and CXCR 4 expression, the present inventors have been able to further purify the ADE cells obtained, in order to obtain ADE cells substantially free of other cells, such as ES cells.
- ADE cells have been observed to display a number of genes which can serve as unique markers of ADE cells or may be used to reprogramme cells using iPS techniques known in the art.
- the genes which have been observed to be upregulated in ADE cells may therefore be of use as unique ADE cell markers or used to generate ADE cells are Sst, Pyy, Ghrl, Slc38a5, Chga, Exph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4sf2, 0610040B21Rik (aka txndc12), Apoa1, 2410021P16Rik (aka acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (aka Cmtm8), Robo1, C
- proteins from the list above, which are cell surface expressed, may be used to identify and/or purify ADE cells.
- the genes/proteins which are cell surface expressed include Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4sf2, Fzd5, Cklfsf8 (aka Cmtm8), Rarres1, Sic7a8, Sfrp5 and Cxcr4
- the ADE cells may be identified an/or purify using such cell surface expressed proteins using, for example, protein specific antibodies, using techniques well known to those of skill in the art.
- the ADE cells of the present invention may be allowed to differentiate and the present inventors have been able to obtain, through use of appropriate differentiation factors, pancreatic and liver cells.
- pancreatic cells and liver cells in the treatment of pancreatic and liver diseases; in particular in the treatment of diseases such as diabetes, hepatitis and cirrhosis.
- the methods, compositions, cell populations, cell lines and single cells of the present invention are all capable of being used in such treatment, as well as in the manufacture of preparations for such treatment.
- the invention provides for the use of cell lines, cell populations, single cells and compositions described above for cell therapy and for the manufacture of a preparation for the treatment of pancreatic and liver disease and injury.
- Such preparations may be formulated in phosphate buffered saline (PBS).
- Methods of treatment of the diseases listed above can comprise the transplantation of single cells, cell lines, compositions, or cell populations of the invention into a patient.
- the patient is mammalian, more preferably the patient is human.
- the cells of the invention can be used to assay the effective of inductive or blocking factors on the differentiation of ADE cells.
- Such an assay may comprise contacting an ADE cell of the invention (i.e. as present in the compositions, cell lines, and populations, or a single ADE cell) with the factor to be tested.
- the effect of the factor on the differentiation of the ADE cell can be suitably assessed by determining the marker profile of the resultant cells, i.e. to show whether the cells have a similar marker profile to the cells of the invention, or whether these markers have been lost.
- the cells of the invention are also suitable for assaying pharmaceuticals for, for example, the treatment of pancreatic or liver disease.
- FIG. 1 shows that RS protein recapitulates endogenous Hex expression.
- (B) Southern blot indicating the correct insertion of the RedStar cassette into the Hex allele (9 kb band). Targeting frequency 40%.
- FIG. 2 shows In vitro expression of RS is specific to Hex expressing cell lineages.
- HRS and E14Tg2a (parental) ES cells cultured in serum containing media for 2 days followed by N2B27 plus or minus activin for 5 days. Percentages of RS expressing cells are indicated.
- B HRS ES cells cultured in endoderm inducing conditions for 7 days and sorted for CD45 (haematopoietic) and CD31 (endothelial) expression.
- C Sox1GFP/+ES cells cultured in endoderm inducing conditions for 7 days.
- sox 1 positive cells in the ES cell culture is typically encountered when culturing the cells in serum containing media (ref or personal communication?)
- D HRS and E14Tg2a (parental) ES cells cultured in early haematopoietic progenitor inducing conditions. Percentages of RS expressing cells are indicated.
- E Semi-quantitative RT-PCR for a range of markers associated with endoderm (Sox17, Cerl1, Ecadherin, Gata4), mesoderm (Tbra, Mixl1, Meox1, Gata1), ectoderm (Zic1) and parietal endoderm (Sox7) on RS positive and RS negative cell fractions sorted by flow cytometry. Samples were first analysed by quantitative RT-PCR for B-actin expression and normalised accordingly.
- FIG. 3 shows that Activin and EGF induce H+C+ cells following culture in serum containing media.
- FIG. 4 shows In vitro differentiating cell cultures produce a gene expression dynamic similar to that observed during ADE induction in vivo.
- FIG. 5 shows Hex and CXCR4 marks the emerging ADE cell population.
- A Quantitative real-time RT-PCR.
- the y axis represents relative expression calculated by normalising the transcript number to the b-actin transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations.
- B Immunocytochemistry on ADE differentiated cells. The four cell fractions were sorted by flow cytometry following 7 days of differentiation as described in FIG. 4 . Cells were immunostained by anti-Cerl1, anti-Foxa2, anti-Oct4 and anti-Ecad. Nuclei were stained with DAPI. Green Cerl1, Oct4 and Ecad positive cells were detected using an Alexa-488 secondary antibody and red Foxa2 positive cells were detected using an Alexa-568 secondary antibody.
- FIG. 6 shows Gene expression profiling of RS and CXCR4 cell populations.
- RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in FIG. 4 .
- the y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean relative expression value from 3 independent experiments. Error bars represent standard deviations.
- FIG. 7 shows ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo.
- RS protein was only observed in the H+C+ and H+C ⁇ cell aggregates.
- C 2 day hepatocyte cell aggregates were plated on gelatin for a further 3 days. Cells were immunostained with anti-albumen, anti-AFP and nuclei stained with DAPI. Green albumen positive cells were detected using an Alexa-488 secondary antibody and red AFP positive cells were detected using an Alexa-568 secondary antibody. A few albumen positive cells were observed in the H+C+ and H+C ⁇ samples and these samples contained the highest percentage of AFP positive cells.
- D By day 13 of the hepatocyte culture (day 20 of the total culture period) many albumen positive cells were present in the H+C+ cultures.
- FIG. 8 shows Defining the requirements for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling.
- (A) Flow cytometry showing the proportion of H+C+ cells induced under a series of conditions. All differentiation was done in N2B27 for two days, followed by five days in SF03. The minimum set of cytokines is indicated on top of each panel. The presence or absence of the FGF antagonist, PD173074 is indicated.
- FIG. 9 shows Verification of microarray gene expression profiles by quantitative real-time RT-PCR.
- RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in Figure. 4.
- the y axis represents relative expression calculated by normalising the transcript number to the TBP transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations.
- FIG. 10 Hex and Cxcr4 marks the emerging ADE cell population
- the y axis represents relative expression calculated by normalising the transcript number to the ⁇ -actin transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations. Purity checks on these populations were typically greater than 96% for the H+C+ and H ⁇ C+ populations and 91-93% for the H+C ⁇ and H ⁇ C ⁇ populations.
- B immunocytochemistry on ADE differentiated cells. The four cell fractions were sorted by flow cytometry following 7 days off differentiation as described in FIG. 2 d .
- C Gene expression profiling of Hex (RS) and CXCR4 sorted cell populations. Cluster dendagram showing the relationship between the different cell populations and ES cells. Clustered normalised data using the 1-Perason's correlation coefficient as a measure of similarity.
- D Hierarchical clustering of the differentially expressed genes identified in a pairwise analysis of populations A, B, C and D (see methods). Based on the observations in C, this comparison is made in the absence of these cell dataset. Red bars indicate expression cluster.
- E Quantitative real-time RT-PCR of genes differentially expressed in the ADE-like fraction by microarray analysis.
- RNA was prepared from the four Hex/Cxcr4 cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in FIG. 2 d .
- the y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean relative expression value from 3 independent experiments. Error bars represent standard derivations.
- FIG. 11 ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo
- TBP box-binding protein
- Day 7 differentiated cultures were sorted into 4 cell fractions and plated in pancreatic progenitor inducting conditions for 5 days (see methods). Cells were immunostained with anti-Pdx1 and anti-HNF4 ⁇ and nucleic stained with DAPI.
- the H ⁇ C ⁇ fraction produced a single Pdx1/HNF4 ⁇ positive cluster, while the H+C ⁇ fraction did not produce any. Green Pdx1 positive cells were detected using an Alexa-488 secondary antibody and red Hnf4 ⁇ positive cells were detected using an Alexa-568 secondary antibody.
- FIG. 12 Expansion of ADE progenitors derived from differentiating ES cell culture
- A FACS purified fractions from differentiating ES cell cultures plated and grown in culture for 12 days. The images are overlays of phase contrast and red fluorescence. Images captured with 10 ⁇ objective
- B Images of colonies and cells in culture from the double positive H+C+ fraction. Top left 20 ⁇ , bottom left 10 ⁇ , top right 40 ⁇ , bottom right 40 ⁇ . Passage numbers 2, 4 and 5 are indicated on the figure.
- C Antibody staining of H+C+ cells in culture for six passages compared to ES cell controls.
- FIG. 13 Defining the requirement for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling
- (A) Flow cytometry of Hex RS and E14Tg2a ES cells differentiated in monolayer culture. All differentiation was carried out in N2B27 plus activin and Bmp4 for two days, followed by five days in SF03 plus activin and EGF or the FGF antagonist, PD173074 as indicated.
- Optimal levels of H+C+ correlates with optimal levels of ADE marker expression.
- Real time quantitative PCR indicating the relative level of transcription of a representative set of markers in response to different periods of exposure to FGF4 in monolayer culture.
- FIG. 14 shows the differentiation of human ES cells to anterior definitive endoderm
- Top panel (A) was differentiation with sodium burate and active as described in (Hay et al., 2008b) and the image in (B) is of cells differentiated with activin A and Wnt3a (Hay et al., 2008a). Cells were stained with anti-CER1 (Santa Cruz) in green and anti-Cxcr4 (BD Biosystems, APC conjugate) red. The figure shows that both protocols produce heterogeneous endodermal differentiation, with the activin and Wnt protocol producing higher numbers of CER1 positive cells. Flow cytometry is also shown in (B).
- FIG. 15 shows an illustration of ADE staining by new cell surface markers identified in this work.
- Embryiod bodies were differentiated to make ADE and either stained with individual markers (top panel) or disassociated and stained with a combination of two antibodies (bottom panel).
- EBs differentiated under conditions used to generate ADE show an abundance of cells staining at their membrane (green) for either Frzd5 or Clic6. Nuclei are in blue and stained with Dapi. In the bottom panel, clumps of cells express both the ADE marker Cerl (red or purple in the overlay) and either Frzd5 or Clic6.
- FIG. 16 RS protein recapitulates endogenous Hex expression
- (B) Southern blot indicating the correct insertion of the RedStar cassette into the Hex allele (9 kb band). Targeting frequency 40%.
- FIG. 17 In vitro expression of RS is specific to Hex expressing cell lineages.
- C HRS and E14Tg2a ES cells cultured in early haematopoietic progenitor inducing conditions. Percentages of RS expressing cells are indicated.
- D Induction of H+C+ cells. Flow cytometry for RS and Cxcr4 (FITC) on day 7 cells differentiated as in 2A with the addition of activin and EGF.
- FIG. 18 In vitro differentiating cell cultures produce a gene expression dynamic similar to that observed during ADE induction in vivo
- the y axis represents relative expression calculated by normalising the transcript number by the ⁇ -actin transcript number. Values represent the mean of 2 independent experiments. Error bars represent the standard deviation.
- FIG. 19 Hex and Cxcr4 marks the emerging ADE cell population
- the y axis represents relative expression calculated by normalising the transcript number to the ⁇ -actin transcript number. Values represent the mean from 2 independent experiments. Error bars represent standard deviations. Purity checks on these populations were typically greater than 96% for the H+C+ and H ⁇ C+ populations and 91-93% for the H+C ⁇ and H ⁇ C ⁇ populations.
- RT-PCR values for cells prior to sorting (PS) and ES cells (ES) are included for reference.
- B Immunostaining on ADE differentiated cells.
- the four cell fractions were sorted by flow cytometry following 7 days of differentiation.
- Cells were immunostained by anti-Cerl (green), anti-Foxa2 (red), anti-Oct4 (green) and anti-Ecadherin (green). Nuclei were stained with DAPI (blue). Images captured using a 20 ⁇ objective.
- C Gene expression profiling of Hex (RS) and CXCR4 sorted cell populations. Cluster dendrogram showing the relationships between the different cell populations and ES cells. Clustered normalised data using the 1-Pearson's correlation coefficient as a measure of similarity.
- D Hierarchical clustering of the differentially expressed genes identified in a pairwise analysis of populations A, B, C and D (see methods). Based on the observations in C, this comparison is made in the absence of the ES cell dataset. Red bars indicate expression cluster.
- E Quantitative real-time RT-PCR of genes differentially expressed in the ADE-like fraction by micorarray analysis.
- RT-PCR values for cells prior to sorting (PS) and ES cells (ES) are included for reference.
- the y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean from 3 independent experiments. Error bars represent standard deviations.
- FIG. 20 ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo
- TBP box-binding protein
- C Hepatocyte cell outgrowths on day 12 of total culture period. Cells were immunostained with anti-Albumin (green), anti-AFP (red) and nuclei stained with DAPI (blue). A few Albumin positive cells were observed in the H+C+ and H+C ⁇ samples and these samples contained the highest percentage of AFP positive cells. Images captured using a 10 ⁇ objective.
- D Hepatocyte cultures on day 20 of the total culture period. Many Albumin positive cells can be observed in the H+C+ cultures. Images captured using a 10 ⁇ objective.
- E Capacity for cardiomyocyte induction. Quantification of beating foci. Data represents the average of four independent wells and error bars the standard deviation. Cells were differentiated as in C and D.
- Sections of growths were stained with PAS and counterstained with Hematoxylin and Eosin.
- Gut-like epithelial structures containing PAS positive secretory granules were present in H+C+ and H+C ⁇ growths.
- Cartilage black arrow was observed in the H ⁇ C+ growths. Images captured using a 20 ⁇ objective.
- FIG. 21 Expansion of ADE-like progenitors purified from differentiating ES cell culture.
- A Flow cytometry purified fractions from differentiating ES cell cultures plated and grown on gelatin for 12 days. The images are overlays of phase contrast and red fluorescence. Images captured with 10 ⁇ objective
- B Images of colonies and cells growing in culture from the double positive H+C+ fraction. Images captured using the following objectives: top left 20 ⁇ , bottom left 10 ⁇ , top right 20 ⁇ , bottom right 40 ⁇ . Passage numbers (P) are as indicated.
- C Immunostaining of H+C+ cells in culture for five passages compared to ES cell controls.
- FIG. 22 Defining the requirements for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling
- (A) Flow cytometry of Hex RS and E14Tg2a ES cells differentiated in monolayer culture. All differentiation was carried out in N2B27 plus activin and Bmp4 for two days, followed by four to five days in SF03 plus activin and EGF. FGF4 or the FGF antagonist, PD173074 were added as indicated. Flow cytometry was used to quantitate the size of the H+C+ fraction on day 6.
- FIG. 23 Activin treated ES cell cultures do not produce haematopoeitic, endothelial or neurectodermal cells.
- A Hex RS ES cells cultured in endoderm inducing conditions for 7 days and sorted for CD45 (haematopoietic) and CD31 (endothelial) expression.
- B Sox1 GFP /+ES cells cultured in endoderm inducing conditions for 7 days. The presence of Sox1 positive cells in the ES cell culture is typically encountered when culturing the cells in serum containing media (Stavridis et al., 2007).
- FIG. 24 Quantitation of the number of Hex positive cells, derived from the H+C+ ADE fraction, maintained in culture over multiple passages. The number of Hex RS positive cells was assessed at each passage using fluorescent microscopy and expressed as a percentage of the total number of cells in the culture. The passage number and time point (days) is indicated on the X axis of the graph. Three or four representative fields were counted and the error bars represent the standard deviation between the measurements.
- FIG. 25 Treatment of monolayer cultures with FGF2 and FGFR inhibitor SU5402 provide additional evidence that FGF signalling promotes ADE production. Treatment of cultures with different FGFs, suggest that FGF2 and FGF4 but not FGF5, 8b and 10 have the ability to promote ADE formation. Inhibition of ADE by a second FGF receptor inhibitor, SU5402 further supports a requirement for FGF signalling during ADE differentiation. Both PD173074 and SU5402 were added to cultures for days 3-4 or days 3-7 and found to inhibit ADE differentiation. Inhibitors and FGFs are indicated above each graph.
- the 5′ and 3′ targeting arms of the targeting construct homologous to the Hex genomic sequence were as described previously (Martinez Barbera et al. 2000) with an Asc1 and Pac1 site engineered downstream of the ATG at the Hex translation initiation site (a gift from Shankarshrinivas).
- the RedStar gene was linked via an internal ribosome entry site (IRES) to the gene encoding blasticidin resistance (BSD) followed by a cytomegalovirus promoter-driven hygromycinR-thymidine kinase dual selection cassette flanked by loxP sites. This cassette was fused in frame with the ATG at the Hex translation initiation site via the engineered Asc1 and Pac1 restriction enzyme sites ( FIG. 1A ).
- Mouse ES cells were cultured in serum according to (Li et al. 1995) or serum-free according to (Ying et al. 2003). All ES cells and differentiated cultures were maintained in a 7% CO 2 -air mixture at 37° C.
- ADE was induced under serum-containing conditions using a 2-step protocol.
- ES cells were seeded onto non-coated 10 cm petri dishes (sterilin) at a density of 5 ⁇ 10 3 cells/ml in Glasgow minimum essential medium (G-MEM; GIBCO-BRL) supplemented with 10% fetal calf serum (FCS), 0.1 mM nonessential amino acids (GIBCO-BRL), 1 mM sodium pyruvate, 2 mM glutamine and 0.1 mM 2-mercaptoethanol (2ME).
- G-MEM Glasgow minimum essential medium
- FCS fetal calf serum
- GIBCO-BRL fetal calf serum
- 1 mM sodium pyruvate 2 mM glutamine
- 2ME 2-mercaptoethanol
- EBs embryoid bodies
- N2B27 culture medium StemCellSciences
- R&D 20 ng/ml activin A
- the media was replaced 2 days later and then every 3 days for the duration of the experiment.
- 20 ng/ml EGF, 10 ng/ml Bmp4, 20 ng/ml activin A (R&D), 1 ⁇ 10 ⁇ 5 M all-trans retinoic acid (Sigma) and 3 ⁇ M CHIR99021 (a gift from StemCellSciences) were added to the culture at the indicated timepoints.
- ES cells were seeded onto non-coated 10 cm Petri dishes at 5 ⁇ 10 3 cells/ml in N2B27 culture medium supplemented with 10 ng/ml Bmp4 and 20 ng/ml activin A. Following 2 days of culture the resulting EBs were harvested as above and replated on non-coated Petri dishes at the same density in SF03 culture medium (ref Tada 2005) supplemented with 20 ng/ml activin A and 20 ng/ml EGF. The media was replaced 2 days later and then every 3 days for the duration of the experiment.
- ES cells were seeded onto gelatin coated 3 cm 6 well dishes (Iwaki) at a density of 1 ⁇ 10 4 cells/ml in N2B27 medium (StemCellSciences) supplemented with 10 ng/ml Bmp4, 20 ng/ml activin A and 10 ng/ml Fgf4.
- N2B27 medium StemCellSciences
- 10 ng/ml Bmp4 20 ng/ml activin A
- 10 ng/ml Fgf4 10 ng/ml Fgf4
- EGF ng/ml EGF
- pancreatic progenitor cells For the induction of pancreatic progenitor cells, sorted cell fractions were seeded onto gelatin coated 3 cm 6 well dishes (Iwaki) at 2.5 ⁇ 10 5 cells/ml in N2B27 media supplemented with 10 ng/ml Fgf4, 2 ⁇ M all trans retinoic acid and 0.25 ⁇ M KAAD-cyclopamine (Toronto Research Chemicals). Similar results were obtained with 1 ⁇ 10 5 cells in the absence of KAAK-cyclopmaine. Pdx positive cells appear within 3-5 days of plating onto Gelatin.
- Aggregates were harvested at 48 hr and replated in N2B27 medium supplemented with 10 ng/ml EGF, 10 ng/ml bFGF, 20 ng/ml HGF (Autogen Bioclear), 20 ng/ml TGF- ⁇ (AMS Biotechnology Ltd), 10 ng/ml VEGF and 10 ⁇ 7 M dexamethasone (Sigma) on gelatin-coated 3 cm tissue culture coated dishes (Nunc). The media was replaced every 3 days for the duration of the experiment.
- ES cells were seeded onto non-coated 10 cm petri dishes at a density of 1 ⁇ 10 4 cells/ml in IMDM (GIBCO-BRL) supplemented with 15% FCS, 2 mM glutamine, 300 ⁇ g/ml transferrin (Roche), 4 ⁇ 10 ⁇ 4 M MTG (Sigma), 50 ⁇ g/ml ascorbic acid (Sigma) and the cells analysed at 48 hr and 72 hr.
- FITC-conjugated rat anti-CD184 CXCR4
- FITC-conjugated rat anti-CD31 FITC conjugated rat anti-CD45
- EBs generated under various different differentiation conditions were dissociated by treatment with cell dissociation buffer (PBS based) (GIBCO-BRL). Cells were washed in PBS supplemented with 10% FCS (FB) and resuspended at a maximum density of 5 ⁇ 10 6 cells/ml.
- FB FCS
- the FITC-conjugated antibody or a FITC-conjugated isotype control was added at a 1:100 dilution.
- Cells were incubated in the dark for 20 mins, washed 3 times with FB and resuspended in FB supplemented with Topro3-iodide (Invitrogen) to exclude dead cell from the analysis.
- Cells were analysed using a FACS Calibur (BD Biosciences) or sorted using a MoFlo MLS flow cytometer (DakoCytomation).
- RNA was prepared from a minimum of 1 ⁇ 10 4 cells from sorted cell fractions, EBs, monolayer differentiated cells or ES cells using Trizol reagent (Invitrogen). 1 ⁇ g of RNA was used as a template for cDNA synthesis using Superscript III (Invitrogen).
- Real-time RT-PCR was performed using a LightCycler 480 (Roche) and LightCycler 480 SYBR Green 1 Master (Roche). The following cycling conditions were used: denaturation: 95° C. 5 sec, amplification: 95° C. 5 sec, 58° C. 10 sec, 72° C. 20 sec (45 cycles), 81° C. 1 sec, melt: 95° C. 1 sec, 65° C.
- Sorted cells were seeded onto gelatin coated 24 well dishes (Iwaki). Adherence of cells to the substrate was enhanced by centrifugation at 1200 rpm for 3 mins. Sorted cells, monolayer differentiated cells and ES cells were washed in PBS, fixed in 4% paraformaldehyde for 10 mins and permeabilised by washing in PBS supplemented with 0.1% Triton X (PBST). Cells were treated with a blocking reagent (3% serum of same species as secondary antibody, 1% BSA in PBST) for 15 min before incubation with the primary antibody at 4° C. overnight. The cells were washed with PBST and incubated with the appropriate fluorescence-tagged secondary antibody for 2 hr at room temperature.
- PBST Triton X
- the cells were washed with PBST and DAPI added during the final wash.
- the following primary antibodies were used, all are anti-mouse: anti-Oct3/4, anti-HNF-3 ⁇ (Foxa2), anti-HNF-4 ⁇ (Santa Cruz), anti-Cerl1 (R&D), anti-E-cadherin (Takara Bio Inc) anti-alpha fetoprotein (NeoMarkers), anti-albumin (Bethyl laboratories inc).
- Anti-Pdx1 was a gift from P. Serup.
- Hex is expressed in the newly specified ADE cells and therefore represents an ideal early marker for anterior endoderm formation.
- ES cell line containing the marker gene, RedStar (RS) (Knop et al. 2002) under the control of the Hex locus ( FIG. 1A ). These cells allowed us to monitor the emergence of newly formed ADE cells during in vitro differentiation.
- the RS coding sequence was introduced into the first exon of the Hex locus by homologuous recombination in ES cells. The insertion of the RS targeting cassette into this exon terminates the endogenous Hex transcript and should produce a null Hex allele.
- Correctly targeted clones FIG. 1B ) were transfected with Cre recombinase to remove the selection cassette and two independent clones with normal karotype, HexRedStar (Hex RS ) 1-2, were selected for further analysis.
- Hex RS 1 ES cells were used to generate a Hex RS mouse line. Embryos from Hex RS /+ intercrosses are shown in FIG. 1C . At E8.5 red fluorescence was detected in the foregut and by E9.5 was present in the liver and thyroid primordia and weakly expressed in the intersomitic blood vessels. Thus, RS protein reflects the expression of endogenous Hex protein as reported by Thomas et al, (Thomas et al. 1998). No live Hex RS /Hex RS mice were born (Table 1) and Hex RS /Hex RS embryos exhibited anterior defects and reduced hepatic tissue mass ( FIG.
- TGF ⁇ ligand activin has previously been shown to induce markers of endoderm in Xenopus animal cap assays (reviewed by (Okabayashi and Asashima 2003)) and to induce a mesendodermal cell population from ES cells in culture (Kubo et al. 2004; Tada et al. 2005). In these early embryonic tissues, activin can induce the same spectrum of mesendodermal gene expression as the endogenous inducer, Nodal.
- ES cells were differentiated in a two-step aggregation culture system in serum containing media for 48 hr followed by serum free media supplemented with activin for 5 days. Under these conditions, 6.8-8.6% of cells were RS positive at day 7 ( FIG. 2A ). This induction was shown to be dependent upon activin treatment and was consistent in two independently derived Hex RS ES cell lines ( FIG. 2A ).
- Hex expression in the developing embryo is not exclusive to endodermally derived cells since it is also expressed in a specific mesodermal cell population that may represent a bipotent haematopoietic and endothelial precursor often termed a haemangioblast (Kubo et al. 2005).
- Hex is also expressed in angioblastic and endothelial precursor populations in the dorsal aorta, in intersomitic vessels and the visceral yolk sac and later in the endocaridium of the heart (Thomas et al. 1998; Rodriguez et al. 2001).
- FIG. 2B shows that our activin treated cell cultures do not contain significant numbers of endothelial (CD31 positive) or haematopoietic (CD45 positive) cells.
- a Sox-1 GFP reporter ES cell line was used to demonstrate the absence of neurectodermal cell types during our activin induced differentiation protocol ( FIG. 2C ).
- Hex is also expressed in the extra-embryonic primitive and visceral endoderm lineages.
- Hex is expressed in a visceral endoderm population known to have similar signalling properties to the ADE, the anterior visceral endoderm (AVE) (Thomas and Beddington 1996; Beddington and Robertson 1998).
- AVE anterior visceral endoderm
- AVE will contribute predominately to the visceral yolk sac (Lawson and Pedersen 1987).
- the AVE is very difficult to distinguish from the ADE. While expression levels of the visceral endoderm associated gene Sox7, was low during our differentiation protocol (FIG.
- this marker is not expressed in the AVE region of the visceral endoderm in vivo.
- Cxcr4 is expressed in definitive mesoderm and endoderm populations, but excluded from all yolk sac visceral endoderm (McGrath et al. 1999; Yusuf et al. 2005).
- flow cytometry was used to analyze a Cxcr4, RS double positive cell population we believed was putative ADE ( FIG. 3 ).
- FIGS. 4B and C show that both RS fluoresence and CXCR4 protein were produced several days after activin treatment and that CXCR4 production precedes Hex. This is consistent with the expression of these markers in vivo (McGrath et al. 1999; Yasunaga et al. 2005; Yusuf et al. 2005) and suggests that the Cxcr4 single positive population may represent non-committed mesendoderm, whereas the H+C+ population is committed ADE.
- Sox17 is expressed during ADE induction and is expressed with similar kinetics to Hex during differentiation.
- ADE identity is therefore also consistent with the expression of Sox17 in the H+C+ population (see FIG. 5A ).
- the parietal endoderm marker, Sox7 was barely detectable by Q-PCR during the differentiation process and therefore not considered to be significantly expressed (see FIG. 9 ).
- E-cadherin is expressed in ES cells and in the preimplantation stage embryo. Cells destined to become mesoderm lose E-cadherin expression at the gastrulation stage whereas cells destined to become endoderm remain E-cadherin positive. E-cadherin expression can therefore be used to distinguish mesoderm cells from ectoderm and endoderm (Huber et al. 1996). We found E-cadherin to be expressed at significant levels during the late stages of the differentiation protocol, indicating that this protocol did not favour the production of mesoderm. Immunostaining confirmed that the majority of cells in the day 7 cultures were E-cadherin positive (see FIG. 5B ).
- Hex RS cultures were sorted into four populations based on RS and CXCR4 protein levels and profiled by quantitative RT-PCR, immunostaining and microarray.
- the transcript level of Hex in the RShigh/CXCR4low (H+C ⁇ ) and RSlow/CXCR4high (H ⁇ C+) populations were very similar and significantly less than the RShigh/CXCR4high (H+C+) population ( FIG. 5A ). This may reflect the time lag between the production of Hex transcript and mature RS protein.
- the H+C ⁇ cell population which appears to be formed from the H+C+ population ( FIG. 4B ) is likely to consist of cells in which CXCR4 has been switched off and Hex is also being downregulated at the transcript level, but the RS protein is still present.
- the H ⁇ C+ cell population may contain cells in which Hex transcripts have begun to be produced but not the RS protein.
- Such a large difference between protein and transcript level was not observed for CXCR4 and may reflect the shorter maturity rate and half-life of the CXCR4 protein.
- the transcript level of both Hex and CXCR4 was highest in the H+C+ sorted population and allows us to be confident that the H+C+ sorted population is positive for both the Hex transcript and protein.
- the H+C+ cell population expressed the highest levels of E-cadherin, Cxcr4, Cerl and Hex transcript ( FIG. 5A ). All of these genes are expressed in the anterior definitive endoderm. Importantly, the expression of markers Tbra, Wnt3 and Mixl1 that are associated with the early primitive streak but not the anterior definitive endoderm, were lowest in the H+C+ population as was the paraxial mesoderm marker Meox1. Cdx2 is also expressed in the early primitive streak cell population (Beck et al. 1995) and is then restricted to the posterior endoderm. Both Cdx2 and the parietal endoderm marker Sox7 were only detected at very low levels during differentiation and were expressed at the lowest level in the H+C+ cell population ( FIG. 5A ).
- Microarray analysis was performed on Illumina Mouse-6-v1 Beadchip. Three chips were used for each of the four differentiated populations and Hex RS and wild type E14Tg2a ES cells. Initial inspection of the data suggested the differentiated samples cluster close to each other as do the two ES cell lines ( FIG. 6B ). The close proximity of the two ES cell lines indicates there is little difference in gene expression in Hex RS heterozygote and wild-type ES cells. Of the differentiated populations, the H+C+ population is most closely related to the H ⁇ C+ population, consistent with the view that the H+C+ ADE arises from the H ⁇ C+ mesendodermal population.
- ES Cell Derived ADE has Increased Potential to Form Pancreatic Progenitors and Hepatocytes.
- pancreatic and liver progenitors To examine the potential of the sorted cell populations to differentiate further down the endodermal lineage, we cultured the cell fractions in conditions conducive for the formation of foregut, pancreatic and liver progenitors.
- the ADE loops around and migrates in a posterior direction to form the ventral foregut.
- the anterior most component of the definitive endoderm ends up in a more posterior location that gives rise to liver and pancreas.
- the pancreas is formed by two budding outgrowths from this region of foregut and their induction and the subsequent specification of pancreatic progenitors is dependent on interactions with the surrounding tissues.
- Undifferentiated ES cells did not generate any Pdx1 positive cells (data not shown).
- Hex expression does persist in the ventral foregut that will give rise to the liver primoidium and thyroid (Thomas et al. 1998) and it is possible that these cells have progressed further towards one of these lineages and can no longer generate Pdx1 positive pancreatic progenitors.
- RS positive cells were present at day 9 of the total culture period in aggregates formed from the H+C+ and H+C ⁇ sorted cells only ( FIG. 6B ). While some AFP positive hepatocytes were observed at day 12 in the H ⁇ C+ and H ⁇ C ⁇ cell populations the efficiency of differentiation was always lower. No AFP positive hepatocytes were formed from non-induced ES cells cultured in the same conditions (data not shown). At day 12, AFP positive hepatocytes could be detected in all four cultured cell fractions, however the number of positive cells was highest in the H+C+ cell fraction ( FIG. 6C ). By day 20, AFP expression was reduced and the number of albumen positive cells had increased significantly in the H+C+ population ( FIG. 6D ).
- the cultures were sorted into the four RS/CXCR4 fractions following 7 days of differentiation, and immediately transplanted under the kidney capsule of adult 129 mice. Eight weeks after transplantation the mice were sacrificed and the grafts analysed. From the nine H+C+ transplants performed only one small growth was observed. In contrast 5 large teratomas were observed from the transplanted H ⁇ C ⁇ cells, most likely due to the presence of low numbers of ES cells within this cell fraction (see FIG. 4B ). The H+C ⁇ and H ⁇ C+ transplants resulted in 3 and 4 growths respectively (Table 4).
- the small H+C+ growth contained endodermal derivatives indicated by the presence of ductal epithelial structures containing PAS positive secretory granules ( FIG. 6E ). Similar epithelial structures were observed in the H+C ⁇ and H ⁇ C+ grafts. Interestingly, the H ⁇ C+ transplants were the only ones (excluding the H ⁇ C ⁇ teratomas) that contained cartilage ( FIG. 6E ). The appearance of both mesoderm and endoderm in these grafts suggest that H ⁇ C+ fraction contains non-committed mesendodermal progenitors.
- H+C+ fraction contains lineage restricted endodermal progenitors.
- H+C+ sorted cells generated clusters expressing markers of the emerging pancreatic buds, Pdx1 and Hnf4 ⁇ with the highest efficiency, indicating their pancreatic differentiation potential in vitro ( FIG. 11 ).
- H+C ⁇ fractions did not give rise to co-expressing clusters. Limited activity (2 and 9-fold reduced cluster number respectively and reduced staining intensity) was detected from the H ⁇ C+ and H ⁇ C ⁇ fractions ( FIG.
- FGF2, BMP4 and VEGF FGF2, BMP4 and VEGF.
- FACS purified fractions in defined media incorporating these cytokines Initially all four population were able to grow, but only the H+C+ fraction contained significant numbers of Hex positive cells ( FIG. 12A ). While, these cultures were not homogenous, the H+C+ fractions were able to give rise to new Hex positive colonies upon repeated passaging ( FIG. 12B ). The remaining three fractions were unable to survive four passages. The percentage of Hex positive cells in these cultures expanded over time, reacting as high as 96%.
- H+C+ ADE ability of H+C+ ADE to recapitulate foregut development in vivo and in vitro encouraged us to define the conditions required for the specification of this ADE population in vitro.
- H+C+ cells can only be derived in a multicellular aggregation suspension system (embryoid body).
- An adherent monolayer culture system would greatly improve our ability to investigate lineage specification in vitro. We therefore investigated whether it was possible to differentiate Hex RS ES cells to ADE under defined conditions in both multicellular aggregation and a monolayer culture system.
- CHIR99021 had either no or only very minor effects on the total number of H+C+ cells produced.
- Bmp4 increased the H+C+ percentage in monolayer culture during differentiation.
- the addition of Bmp4 and activin during the initial stage of differentiation gave the overall highest yield of H+C+ cells in both suspension and monolayer (Table 7).
- Fgf4 was required for the entire differentiation protocol ( FIG. 8 , Table 8).
- the number of CXCR4 expressing cells did not increase with the addition of Fgf4 indicating that the effect of Fgf4 appears to be specific to the induction of H+C+ double positive ADE, and not a general effect on mesendoderm induction ( FIG. 8 ).
- FGF signalling has been shown to mediate mesoderm, but not endoderm induction (reviewed in (Bottcher and Niehrs 2005)).
- PD17304 a highly specific inhibitor of the FGF receptor (Mohammadi et al. 1998).
- PD17304 was added to cultures either from day 0-2, day 3-7 or for the entire differentiation protocol. The presence of PD17304 in our cultures appears to inhibit both C+ single positives and H+C+ double positives.
- PD17304 was present for the first two days of differentiation, but then removed, we were able to generate a reduced number of both C+ and H+C+ cells ( FIG. 8 ). However, when PD17304 was present for the entire protocol, we were unable to generate either population.
- the activin buturate protocol (panel A) produces an abundance of Cxcr4 positive, mesendoderm (see discussion) and only isolated clumps of CER1 expressing ADE.
- the activin/Wnt3a protocol while more efficient, was highly also highly heterogenous.
- CXCR could be used to enrich for endoderm in Human ES cell differentiation (D'Amour et al., 2005), it appears to mark a heterogenous population of cells that contains a small proportion of ADE.
- the marker Cxcr4 is an early primitive streak marker that is expressed by both mesoderm and endoderm precursors.
- Panel C shows data from the differentiation protocol described herein.
- the defined monolayer differentiation protocol lasted 7 days, as Human ES cells are thought to potentially be related to a different state of embryonic development, we have done a carefully time course and analyzed differentiation by immuno-histochemistry for CXCR4, FOXA2, CLIC6.
- Human ES cells are thought to be a more mature epiblast like cell (slightly later stage of development (Brons et al., 2007; Tesar et al., 2007)) and the first stage of our protocol includes two factors, BMP4 and activin/Nodal recently shown to be involved in epiblast development (see discussion). As a result we thought this phase might promote synchronous growth and differentiation in HES cultures.
- RN was prepared from Hex RS ES cells, E14Tg2a ES cells and the four H/C sorted populations of differentiated Hex RS ES cells from three independent experiments. 2 ⁇ g was used to prepare a probe for hybridsation to the Illumina Mouse-6-v1 Beadchip. The data was filtered so that any probe with a detection score ⁇ 0.95 across all samples was removed from the analysis prior to log transformation (base2) and quantile normalisation. Initial inspection of the data suggested the samples clustered loosely according to when they were processed, therefore a model based analysis was used. Differentially expressed probes were identified using LIMMA (Smyth, 2004) modeling the sample effect and the date when the samples were processed once grouped.
- markers contains the following markers which includes those already implicated as being involved in endoderm differentiation, but which may now used to identify and/or generate ADE: Sst, Pyy, Ghrl, Slc38a5, Chga, Exph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4sf2, 0610040B21Rik (aka txndc12), Apoa1, 2410021P16Rik (aka acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (aka Cmtm8), Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7, Sfrp5, Pga5,
- cell surface markers which may be particularly useful in identifying and/or generating ADE cells.
- the 5′ and 3′ targeting arms used for homologous recombination were described by Martinez Barbera et al., (2000) with an Asc1 and Pac1 site engineered downstream of the Hex ATG (a gift from Shankarshrinivas).
- the RedStar gene was linked via an internal ribosome entry site (IRES) to the gene encoding blasticidin resistance (BSD) followed by a cytomegalovirus promoter-driven hygromycinR-thymidine kinase dual selection cassette flanked by loxP sites. This cassette was fused in frame with the ATG of Hex. Following electroporation into E14Tg2a ES cells correctly targeted clones were expanded and characterized by Southern Blot.
- the selection cassette was excised from three clones and two of them, Hex RS 1-2, were selected for further analysis.
- the ES cell line Hex RS 1 was injected into blastocysts to generate the Hex RS mouse line. Mice were maintained on a mixed 129Ola ⁇ C57Bl/6 background.
- ES cells were cultured according to Li et al., (1995). ADE was induced under serum-containing conditions using a 2-step protocol. ES cells were seeded onto non-coated 10 cm petri dishes (Sterilin) at a density of 5 ⁇ 10 3 cells/ml in GMEM supplemented as described in Li et al., (1995) except in the absence of LIF. EBs were harvested after two days by centrifugation and replated in N2B27 medium (StemCellSciences) supplemented with 20 ng/ml activin A (R&D) and 20 ng/ml EGF (R&D). This media was replaced again two days later. 10 ng/ml BMP4, 20 ng/ml activin A (R&D) and 1 ⁇ 10 ⁇ 5 M all-trans retinoic acid (Sigma) were added where indicated.
- Steilin non-coated 10 cm petri dishes
- GMEM GMEM supplemented as described in Li et al.,
- ES cells were seeded as above in N2B27 medium supplemented with 10 ng/ml BMP4 and 20 ng/ml activin A.
- EBs were harvested and cultured as above in SF03 medium (Iwai Chemicals Company) supplemented with 0.1 mM 2-mercaptoethanol (2ME), 0.1% BSA (Invitrogen), 20 ng/ml activin A and 20 ng/ml EGF.
- 10 ng/ml FGF4 (R&D) 10 ng/ml Bmp4, 20 ng/ml activin A, 10 ⁇ M all-trans retinoic acid were added as indicated.
- ES cells were seeded onto gelatin coated 6 well dishes (Iwaki) at a density of 1 ⁇ 10 4 cells/ml in N2B27 medium (StemCellSciences) supplemented with 10 ng/ml Bmp4, 20 ng/ml activin A and, where indicated, 10 ng/ml FGF4.
- N2B27 medium StemCellSciences
- 10 ng/ml Bmp4 20 ng/ml activin A
- FGF4 ng/ml FGF4
- EGF4 ng/ml EGF.
- the media was replaced every 2 days for the duration of the experiment.
- 100 ng/ml PD173074 (Sigma) or 25 ⁇ M SU5402 (Calbiochem) were added to the culture as indicated.
- FGF2, 5, 8b and 10 (R&D) were used at 10 ng/ml.
- pancreatic progenitor cells For the induction of pancreatic progenitor cells, sorted cell fractions were seeded onto gelatin coated 3 cm 6 well dishes (Iwaki) at 2.5 ⁇ 10 5 cells/ml in N2B27 media supplemented with 10 ng/ml FGF4, 2 ⁇ M all trans retinoic acid and 0.25 ⁇ M KAAD-cyclopamine (Toronto Research Chemicals). Hepatocyte differentiation was as described in Gouon-Evans et al., (2006) except N2B27 was used as the base media at all stages and activin was not included, while BMP4, FGF2 and VEGF were. Induction of haematopoietic precursors was described by Kennedy and Keller, (2003).
- day 7 purified fractions were plated on gelatin in 24 well plates (Iwaki) in N2B27 medium supplemented with 0.5 mM ascorbic acid, 450 monothioglycerol (MTG), 50 ng/ml BMP4, 10 ng/ml FGF2 (R&D) and 10 ng/ml VEGF.
- MMG monothioglycerol
- R&D 10 ng/ml FGF2
- VEGF 10 ng/ml VEGF.
- 2.5 ⁇ 10 5 cells were plated into each well of which 10% appeared to be viable and adherent after 24 hours.
- These cultures were expanded until confluence (approximately 14 days) and all subsequent passaging was done approximately every 7 days using Trypsin-EDTA (Sigma), splitting either 1:2 or 1:3. RedStar fluorescence was observed daily by microscopy.
- Quantitation of Hex RS expressing and antibody positive cells was done using fluorescent, phase and in the case of antibodies, DAPI overlays using Velocity 4.32 software (Improvision). Quantitation of the fold expansion was based on a 10-fold increase in cell number during the first passage multiplied by the split achieved at each passage to P7, a total of 216-fold. Cells were further differentiated as described above, except they were pre-treated for 24 hours in the above media supplemented with 20 ng/ml activin A.
- FITC-conjugated rat anti-CD184 Cxcr4
- FITC-conjugated rat anti-CD31 FITC conjugated rat anti-CD45
- FITC conjugated rat anti-CD45 purchased from BD Pharmingen.
- Cells were stained with Topro3-iodide (Invitrogen) to exclude dead cells from the analysis. Cells were analysed using a FACS Calibur (BD Biosciences) or sorted using a MoFlo MLS flow cytometer (DakoCytomation).
- Sorted cells were seeded onto gelatin coated 24 well dishes (Iwaki). Adherence of cells was enhanced by centrifugation at 1200 rpm for 3 min. Sorted cells, monolayer differentiated cells and ES cells were washed in PBS, fixed in 4% paraformaldehyde for 10 min and permeabilised by washing in PBS supplemented with 0.1% Triton X (PBST).
- PBST Triton X
- anti-mouse anti-Oct3/4, anti-Foxa2, anti-HNF-4a (Santa Cruz), anti-Cerl (R&D), anti-Gsc (Santa Cruz), anti Sox17 (Santa Cruz), anti-E-cadherin (Takara Bio Inc) anti-alpha fetoprotein (NeoMarkers), anti-Albumin (Bethyl laboratories inc), anti-Nkx 2.2 (Santa Cruz).
- Anti-Pdx1 was a gift from P. Serup or purchased from Santa Cruz. Alexa 488 and 568 (Molecular Probes) secondary antibodies were used.
- Hex RS 1 ES cells were used to generate a Hex RS mouse line. Embryos from Hex RS /+ intercrosses are shown in FIG. 1C . Red fluorescence was detected in the anterior definitive endoderm, foregut as well as the liver and thyroid primordia, reflecting the expression of endogenous Hex protein as reported by Thomas et al., (1998). Weak expression was also observed in the inter-somitic vessels, endocardium of the heart and aspects of the dorsal aorta reflecting endogenous Hex expression in haematopoietic/endothelial precursors.
- TGF ⁇ ligand activin has previously been shown to induce mesendoderm in Xenopus animal cap assays (reviewed in Okabayashi and Asashima, (2003)) and ES cells in culture (Kubo et al., 2004; Tada et al., 2005).
- ES cells were differentiated in a two-step aggregation culture system in serum containing media for 48 hr followed by serum-free media supplemented with activin for 5 days. Under these conditions, 6.8-8.6% of cells were RS positive (RS+) at day 7 ( FIG. 17A ).
- RT-PCR analysis on purified RS+ cell populations revealed they expressed Sox17, Cerl, E-cadherin and Gata4, indicating these cells have an endoderm identity ( FIG. 17B ).
- Hex is also expressed in mesodermal cell populations during early development including haemangioblast, angioblastic and endothelial precursor populations (Kubo et al., 2005; Rodriguez et al., 2001; Thomas et al., 1998).
- Flow cytometry analysis for the haematopoietic marker CD45 and endothelial marker CD31 showed that our activin treated cultures do not contain significant numbers of these cells ( FIG. 23A ), although the HRS cells can support haematopoetic differentiation ( FIG. 17C ).
- Using a Sox-1 GFP reporter ES cell line we also confirmed that our cultures do not contain neuroectodermal cells ( FIG. 23B ).
- Hex is also expressed in the AVE.
- Cxcr4 chemokine receptor Cxcr4 that is expressed in definitive mesoderm and endoderm populations, but excluded from all yolk sac visceral endoderm.
- Optimisation of media, additives and cell density identified a regimen in which ES cells cultured in suspension for two days and then five days serum-free in the presence of activin and EGF yielded significant numbers of RS/Cxcr4 double positive (H+C+) cells as assessed by flow cytometry ( FIG. 17D ).
- antagonists of ADE specification in vivo, Bmp4 and retinoic acid blocked the induction of the RS positive population (table 2), without effecting Cxcr4 induction (data not shown).
- FIG. 3A To assess whether our differentiating ES cell cultures display a gene expression pattern similar to that observed during ADE induction we examined a range of markers during a timecourse ( FIG. 3A ).
- Mixer-like 1 (Mixl1), Goosecoid (Gsc) and Foxa2 which define the streak region and prospective axial mesendoderm (notochord, prechordal plate and ADE), began to be expressed at day 3, and peaked at day 5-6.
- the H+C+ cell population expressed the highest levels of E-cadherin, Cxcr4, Cer1 and Hex transcript ( FIG. 19A ), all of which are expressed in the ADE. Importantly, the expression of markers Tbra, Wnt3 and Mixl1 that are associated with the early primitive streak but not the ADE, were low in the H+C+ population. Markers of posterior endoderm (Cdx2), paraxial mesoderm (Meox1) and parietal endoderm (Sox7) were only detected at very low levels during differentiation and barely detectable in the H+C+ cell population ( FIG. 19A ).
- H+C+ fraction contains lineage restricted endodermal progenitors.
- H+C+ sorted cells generated clusters expressing markers of the emerging pancreatic buds, Pdx1 and Hnf4 ⁇ with the highest efficiency, indicating their pancreatic differentiation potential in vitro ( FIG. 20F ). In contrast H+C ⁇ fractions did not give rise to co-expressing clusters.
- H ⁇ C+ transplants were the only ones (excluding the H ⁇ C ⁇ teratomas) that contained cartilage ( FIG. 5G ), consistent with the notion that this fraction still contains cells competent to generate both mesoderm and endoderm.
- FGF2, BMP4 and VEGF the four H/C FACS purified fractions were plated in defined media incorporating these cytokines. All four populations were seeded at approximately 10% confluence and the growth of the red population observed over time. Initially all four population were able to grow, but only the H+C+ fraction contained significant numbers of Hex positive cells ( FIG. 21A ). While these cultures were not homogeneous, the H+C+ fractions were able to give rise to Hex positive colonies upon repeated passaging ( FIG.
- pancreatic differentiation produced clusters of Nkx2.2 and Pdx1 expressing cells ( FIG. 21D ), whereas hepatic differentiation resulted in fields of cells with the morphology of immature hepatocytes expressing both AFP and Albumin ( FIG. 21D ).
- FIG. 22E shows that when FGF4 is added solely during the second phase of differentiation we obtain up to 20% H+C+ ADE.
- exogenous FGF4 was added only between days 3-4, the time window in which these cultures have neither mesodermal or endodermal identity, there was a significant effect on the production of ADE ( FIG. 22E , F).
- FGF2, 5, 8b, and 10 for activity in this protocol and found that only FGF2 had a similar ability to promote H+C+ ADE ( FIG. 25 ).
- This cell fraction appears to be ADE as judged by the following criteria: First, the sequence of gene expression in our ES cell cultures mirrors that which occurs during definitive endoderm differentiation in vivo. Second, the H+C+ cells express high levels of ADE markers and very low levels of markers of the primitive streak, mesoderm and ES cells and third these cells have the greatest capacity to differentiate further towards derivatives of the ADE, liver and pancreas. Thus, the ability to identify and purify ES cell derived ADE is an important platform for accurate recapitulation of in vivo differentiation.
- FGF signalling promoted ADE production from ES cells since FGF signalling is typically associated with mesoderm induction and cell migration during gastrulation (Casey et al., 1998; Ciruna and Rossant, 2001; Mizoguchi et al., 2006; Poulain et al., 2006; Rodaway et al., 1999).
- FGF signalling has also been shown to enhance mesoderm differentiation while suppressing endoderm and this view has also been supported by analysis of the FGFR1 mutant mouse embryos (Deng et al., 1994; Yamaguchi et al., 1994).
- Kidney capsule grafts cell explants no. growths recovered germ layers present fraction performed small medium large ecto meso endo H+C+ 9 1 ⁇ ⁇ ⁇ ⁇ + H+C ⁇ 9 ⁇ 3 ⁇ ⁇ ⁇ + H ⁇ C+ 9 1 1 2 ⁇ + + H ⁇ C ⁇ 9 ⁇ ⁇ 5 + + + +
- Activin A and BMP4 were included during the first two days for all conditions, as well as activin A and EGF for the following five days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cell markers and the like and their potential uses in a variety of applications.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/645,934, filed Mar. 12, 2015, which is a division of U.S. patent application Ser. No. 12/674,890 filed Feb. 23, 2010, which is a 35 U.S.C. §371 National Stage application of International Application PCT/GB2008/002875, filed Aug. 25, 2008, which claims priority to United Kingdom Application 0716515.2, filed Aug. 24, 2007 and United Kingdom Application 0809852.7, filed May 30, 2008, the contents thereof which are incorporated by reference in their entirety.
- The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cell markers and the like and their potential uses in a variety of applications.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 12, 2015 and modified Jan. 30, 2017, is named 8601US02_Seq_List_ST25.txt and is 8,753 bytes in size.
- Embryonic stem (ES) cells hold tremendous promise as a source of functional differentiated cell types for regenerative medicine. In addition, ES have great potential as an in vitro system for the study of developmental biology, allowing the effective isolation of distinct populations of cells that normal exist very close together in both space and time during embryonic development. Both the efficient directed differentiation of ES cells to specific lineages and studies of developmental mechanism require the in vitro recapitulation of the appropriate intermediate cell types formed in embryonic development. Thus, the successful differentiation of ES cells to neural, haematopoetic and epidermal cell types involve a progression through intermediate progenitor states prior to terminal differentiation (Bagutti et al. 1996; Nishikawa et al. 1998; Conti et al. 2005) [Conti 2005, Nishikawa 1998, Bagutti 1996]. It is likely that successful differentiation of endodermal lineages from ES cells will also depend on efficiently recapitulating the step-wise progression that occurs during normal embryogenesis.
- The anterior definitive endoderm (ADE) is one the first defined lineages to emerge from the primitive streak during gastrulation. It originates in the node, the mammalian equivalent of the Spemman Organiser (also referred to as axial mesendoderm) and these cells migrate anteriorly during embryogenesis and have an important role in patterning the anterior neural axis (Lu et al. 2001). Later during gut tube formation they migrate ventrally to form the ventral foregut, a unique population of bipotent precursors of the liver and pancreas (Deutsch et al. 2001). Thus the ADE not only represents an essential signalling centre for embryogenesis, but an important intermediate in the production of liver and pancreas.
- In vertebrate developmental contexts mesendoderm is often used to refer to the derivatives of the node or Spemman Organiser (here referred to as axial mesendoderm), structures that can be associated with both the mesoderm and endoderm. However, mesendoderm can also be used to refer globally to the migrating lineages at gastrulation, mesoderm and endoderm. These lineages may have evolved from a common ancestor and are induced by the same signalling pathways (Rodaway and Patient 2001), suggesting that in some instances the mesoderm and endoderm may develop from a common precursor population during embryonic development. In C. elegans, sea urchin and zebrafish, individual progenitor cells have been shown to be capable of differentiating into both mesoderm and endoderm have been identified (Rodaway et al. 1999; Angerer and Angerer 2000; Maduro et al. 2001; Davidson et al. 2002). In mouse, recent data from in vitro differentiation of ES cells provides evidence for the existence of a bi-potential mesendodermal cell in culture (Tada et al. 2005), however, whether individual epiblast derived mesendodermal progenitor exists in mouse in vivo remains to be demonstrated.
- Loss of function studies in the mouse suggest that mesendoderm induction is dependent on nodal related TGF-β and canonical Wnt signalling, with the ADE being most sensitive to a reduction in the activity of these pathways (Vincent et al. 2003). This is consistent with experiments in lower vertebrates and implies that the highest activity of these two pathways is required to induce the most anterior endoderm (Green and Smith 1990; Dyson and Gurdon 1998; Chen and Schier 2001; Vincent et al. 2003). However, the identity of mesendodermal cell populations in the embryo is intricately linked to the migration of these cells during gastrulation. Thus, perturbation of these signalling pathways in the embryo may disrupt cell movements and produce a phenotype in the mesendoderm, without being directly involved in mesendoderm induction. Studying the induction of endoderm using an in vitro cell system would avoid this complication.
- Several recent studies have described the generation of mesendodermal cell populations in vitro from ES cells as a starting point for the production of definitive endoderm and ventral foregut derivatives (Kubo et al. 2004; Tada et al. 2005; Yasunaga et al. 2005; D'Amour et al. 2006; Gadue et al. 2006). In mouse this work has relied on the use reporter cell lines that contain a marker under the control of a mesendodermal promoter. However, these reporter lines have been designed to identify mesendoderm precursors or all axial mesendoderm derivatives and cannot identify positionally specified populations such as the ADE. Without enrichment for ADE, the efficiency of generating foregut derivatives will be reduced. The inability to enrich for regionally specified axial mesendoderm also limits the usefulness of ES cells as an experimental system to address mechanisms of lineage specification in vitro.
- It is desired to be able to provide ADE cells and then differentiate these cells into other cells, such as pancreatic and liver cells, but this is hitherto not possible in significant numbers. It is also desired to provide differentiated cells such as pancreatic or liver cells for transplantation but the persistence of ES and other non-pancreatic/non-liver cells in ES-derived cell populations can give rise to tumours in recipient animals.
- A complete understanding of the molecular and cellular events controlling the behaviour of ADE cells is essential, not only as a route for understanding embryogenesis, but also as a framework upon which ADE cells can be isolated, expanded and controlled for future therapeutic and research applications. It is desirable to develop methods and conditions for culturing large quantities of ADE cells that allow the cells to be differentiated into, for example, pancreatic or liver cells. It is particularly desirable to have defined culture media, which enable this as the use of defined media is highly desirable in a clinical or research setting.
- The present invention seeks to solve one or more of the above described disadvantages.
- It is an object of the present invention to circumvent one or more of these problems by attempting to purify populations enriched for ADE and use these as a source of material for further differentiation.
- The failure of ES differentiation protocols to efficiently generate functional liver and pancreatic cells may be due to a failure to enrich for the appropriate developmental intermediate, anterior definitive endoderm (ADE). Described herein is the first demonstration that defined ADE can be produced, purified and expanded from ES cells. Thus purified or sub-cultured ES cell-derived ADE can be used as a platform for differentiation toward liver and pancreatic progenitors. Furthermore our ability to deconstruct ADE specification in vitro revealed an unsuspected requirement for FGF signalling that had been obscured because of this pathways role regulating gastrulation movements in vivo.
- The present invention is based on a novel strategy to isolate ADE from ES cells by detecting Hex expression in conjunction with the cell surface marker CXCR4. CXCR4 is expressed in the embryonic definitive endoderm but not anterior visceral endoderm (AVE) and thus, when coupled to Hex, defines prospective ADE. Hex is a homeobox transcriptional repressor that is one of the earliest markers of ADE and has also been shown to suppress more posterior, pan-mesodermal identities (Thomas et al. 1998; Brickman et al. 2000; Zamparini et al. 2006). Unlike a number of the marker genes previously employed, Hex is neither a marker of the earlier transient mesendoderm cell population (Brachyury (Kubo et al. 2004), Goosecoid (Tada et al. 2005), of all axial mesendoderm (Foxa2 (Gadue et al. 2006)) or of all endoderm at particular time points (Sox17 (Yasunaga et al. 2005)). In addition to its expression in the ADE, Hex is expressed in the extra-embryonic visceral endoderm, in an early patterning centre known as the anterior visceral endoderm (AVE) (Thomas et al. 1998). It is not hitherto been suggested that the detection of Hex and CXCR4 expression could be used as a marker of ADE cell generation.
- The inventors show that significant numbers of cells in differentiating ES cell cultures can be induced to express Hex and CXCR4 and present extensive expression analysis of these in vitro derived populations allowing further ADE markers to be identified. They further disclose culture conditions and present a serum free cell culture regime for the differentiation of ES cells towards ADE.
- Thus, in a first aspect there is provided a method of identifying anterior definitive endoderm (ADE) cells derived from a population of ES cells, said method comprising the step of detecting two or more ADE cell markers, in a cell population derived from said ES cell population, in order to identify said ADE cells. In accordance with one embodiment of the present invention, the method of identifying ADE comprises the step of detecting expression of Hex and CXCR4, in a cell population derived from said ES cell population, in order to identify said ADE cells. However, following identification of further markers and in particular cell surface markers other combinations of makers can be used to identify and/or isolate ADE cells. ADE markers which have been identified by the inventors include. Sst, Pyy, Ghrl, Slc38a5, Chga, Exph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4sf2, 0610040B21Rik (aka txndc12), Apoa1, 2410021P16Rik (aka acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (aka Cmtm8), Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7, Sfrp5, Pga5, foxa1, foxa2, foxa3, Cer1, Hhex, Otx2, Gatn3 and Cxcr4
- Preferred cell surface markers which have been identified and may be used to identified and/or isolate ADE cells include Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4sf2, Fzd5, Cklfsf8 (aka Cmtm8), Rarres1, Sic7a8, Sfrp5 and Cxcr4.
- Using methods described herein, the present inventors have been able to generate cell populations comprising greater than 5%, 10%, 15%, 20%, 30% or 40% ADE cells from a cell population substantially initially consisting essentially of ES cells.
- Thus, in a further aspect there is provided a mixed cell population obtained directly from an ES cell culture, said mixed cell population comprising at least 5%, 10%, 15%, 20%, 30% or 40% ADE cells. The ADE cells in said mixed population may be subsequently enriched or purified in order to provide substantially pure ADE cell populations.
- In a further aspect, there is provided a substantially pure population of ADE cells which i) will proliferate in an in vitro culture without further differentiation for at least 8 passages and/or over 2 months; and ii) maintains the potential to differentiate into derivatives of ADE cells. Conveniently, the cell line comprises cells which are not genetically modified.
- Following enrichment/purification of the ADE cells from the mixed population of cells by cell sorting techniques, e.g. flow cytometry, well known to those skilled in the art, the present inventors were able to further differentiate the ADE cells into cells of pancreatic or liver lineage, using appropriate differentiating factors. The inventors were able to generate a differentiated cell culture from a cell culture comprising ADE cells obtained using the methods described herein in which >40%, such or 50%, 60%, 70% or even 80% or 90% of the cells differentiated in the cell culture were pancreatic cells, or separately, in which >10%, such as 15% or 20%, 30%, 40%, 50% or 60% were liver cells. Such cell populations can be essentially free of ES cells and/or other progenitor cells, such as mesendoderm progenitor cells.
- In preferred embodiments, cells are cultured in the absence of serum, e.g. in medium that is free of serum and/or free of serum extract. It is preferred in some embodiments that cells are cultured attached to a substrate, otherwise referred to as in an adherent culture.
- The invention further provides methods of obtaining ADE cells or cells differentiated therefrom, and specifically as set out in the protocols herein, and additionally provides cells obtained by such methods.
- ADE cells of the invention and cells derived therefrom can be derived from, inter alia, humans, primates, rodents and birds. Preferably, the ADE cells are derived from mammals, especially mice, rats and humans. ES cells from which the ADE cells are derived may be either wild-type or genetically modified ES cells.
- Embryonic stem cells have been reported from a number of mammalian sources include mouse (Bradley et al (1984) Nature 309: 255-56), human (Thomson et al (1998), Science 202, p 1145-1147), American mink (Mol Reprod Dev (1992) December; 33(4): 418-31), pig and sheep (J Reprod Fertil Suppl (1991); 43: 255-60), hamster (Dev Biol (1988) May; 127(1): 224-7) and cow (Roux Arch Dev Biol (1992); 201: 1340141). Specific examples herein use mouse and ES cells. It will be appreciated that the methods and compositions of the present invention are suitable for adaptation to culturing of other mammalian pluripotent cell cultures, thus including primate, especially human, rodent, especially mouse and rat, and avian pluripotent stem cells, especially ES cells.
- The present inventors have generated a genetically modified mouse ES cell line which may be of use in the present invention. The mouse ES cell line comprises a nucleic acid construct comprising a marker gene which has been inserted within the Hex locus such that the marker gene is under control of the Hex promoter. The marker gene is preferably inserted into the first exon of the Hex locus by homologous recombination. A suitable marker is the RedStar (RS) marker gene and this may be introduced by use of an appropriate selection cassette which may be excised from the genome following marker gene insertion. This may be achieved for example using the Cre-LoxP system, or the Flp recombinase system, or other recombinase system.
- Suitable ES cells may be used to generate a HexRS mouse cell line which is heterozygous for the RS gene. Thus, the present inventors also provide a Hexmarker gene/+ embryo or a mouse especially a HexRS/+ embryo or a mouse for use in obtaining ADE cells.
- By using ES cells derived by using the above described mouse, the present inventors were able to obtain ADE cells by detecting for HexRS expression and CXCR4 expression. However, the skilled addressee can easily adapt this, using homologous genes, such that the technique can be carried out in order to obtain ADE cells from other organisms, especially other mammals including human.
- The cells of the present invention, whether grown in suspension or as adherent cell cultures, are grown in contact with culture media.
- Culture media used in the present invention preferably comprise a basal medium, optionally supplemented with additional components.
- Basal medium is a medium that supplies essential sources of carbon and/or vitamins and/or minerals for ES cells. The basal medium is generally free of protein and incapable on its own of supporting self-renewal/symmetrical division of ES cells. Examples of such media include GMEM, and DMEM.
- In certain embodiments, culture media used in the invention do not contain any components which are undefined (e.g. serum and/or feeder cells), that is to say components whose content is unknown or which may contain undefined or varying factors that are unspecified. An advantage of using fully defined media, free of serum and free of serum extracts, is that efficient and consistent protocols for culture and subsequent manipulation of ADE cells and cells derived therefrom can be obtained.
- Typical substrates for culture of the cells in all aspects of the invention are culture surfaces recognized in this field as useful for cell culture, and these include surfaces of plastics, metal, composites, though commonly a surface such as a plastic tissue culture plate, widely commercially available, is used. Such plates are often a few centimetres in diameter. For scale up, this type of plate can be used at much larger diameters and many repeat plate units used.
- The culture surface may further comprise a cell adhesion protein, usually coated onto the surface. Receptors or other molecules present on the stem cells bind to the protein or other cell culture substrate and this promotes adhesion to the surface and promotes growth. Gelatin coated plates are particularly preferred.
- In certain embodiments, the cultures of the invention are preferably adherent cultures, i.e. the cells are attached to a substrate.
- Methods of the invention can be used for stimulating differentiation of ES cells to ADE cells in medium which is free of serum and free of serum extract. Preferably, such methods are also carried out in the absence of feeder cells and/or feeder cell extracts.
- For example, differentiation of ES cells to ADE cells can be carried out comprising the steps of:—
- maintaining ES cells in a first culture medium for a period of time, optionally on feeders, in the presence of serum or an extract of serum or in a serum free/serum extract free medium;
- replacing the first medium with a second serum free medium comprising activin or removing the serum or the serum extract from the first medium and withdrawing the feeders (if present) and adding activin, so that the first medium is free of feeders, serum and serum extract; and
- subsequently propogating the ES cells in the medium comprising activin in order to obtain cells comprising ADE cells, with the proviso that the first and second medium are not SF03 medium.
- SF03 medium has been described previously by Tada et al 2005 and is available from Iwai Chemicals Company, Japan.
- Suitable culture media includes GMEM, DMEM, F12 and N2B27. N2B27 is preferred and is available from Invitrogen, Paisley, UK.
- Further agents may be included in the first or second medium such as EGF and/or an agonist of a receptor of the TGF-β superfamily.
- An agonist of a receptor of the TGF-β superfamily is suitably a member of the TGF-β superfamily of signalling factors, and is preferably a bone morphogenetic protein (BMP) such as BMP-4. Known homologues of BMP4, such as BMP2 and BMP7, may also be suitable, as are homologues from non-mammalian species such as decapentaplegic (dpp) from Drosophila melanogaster. The term “agonist” is also intended to embrace mimetics, fusion proteins or chimaeras of TGF-β superfamily signalling polypeptides, and fragments, variants and derivatives thereof, capable of activating receptors of the TGF-β superfamily.
- For cells grown in suspension a preferred protocol comprises maintaining cells in a medium comprising serum such as, fetal calf serum, following by maintaining the cells in a serum free medium comprising activin in order to obtain ADE cells. Typically, the cells are grown in serum comprising medium for 1-3 days, e.g. 2 days followed by culture in serum free medium for 3-6 days such as 5 days.
- Preferably the medium comprising serum is GMEM. Preferably the medium comprising activin is N2B27.
- Preferably the initial cell density in medium containing serum or serum extract is less than 1×105 cells/ml, typically between 1×103 cells/ml to 7×104 cells/ml, such as 3×103 cells/ml to 5×104 cells/ml especially 5×103 cells/ml.
- For cells grown in serum free solution, the cells may be grown as adherent monolayer cultures, or may be allowed to form embryoid bodies in suspension.
- Cells grown in monolayer may initially be grown for 1-3 days, e.g. 2 days in a first medium which may comprise one or more of activin, Fgf4, Bmp4 or CHIR99021. Thereafter, the cells may be grown for 3-6 days e.g. 5 days, in a second medium supplemented with activin and further optionally comprising EGF and/or Fgf4.
- Preferably the first medium comprises activin and Bmp4 and optionally Fgf4. Preferably the second medium comprises EGF and optionally Fgf4. Preferably the first medium is N2B7. Preferably the second medium is SF03.
- Cells grown in serum free solution and which are allowed to form embroid bodies may be initially grown for 1-3 days such as 2 days in a medium which may optionally comprise activin and may further comprise Bmp4. A preferred medium is N2B27. Thereafter cells may be grown for 3-6 days especially 5 days in a second medium comprising activin and preferably further comprising Egf4, and optionally Bmp4 and/or GI. Preferably the first medium is N2B7. Preferably the second medium is SF03.
- Using appropriate cell sorting techniques to detect Hex and
CXCR 4 expression, the present inventors have been able to further purify the ADE cells obtained, in order to obtain ADE cells substantially free of other cells, such as ES cells. - Such ADE cells have been observed to display a number of genes which can serve as unique markers of ADE cells or may be used to reprogramme cells using iPS techniques known in the art. The genes which have been observed to be upregulated in ADE cells may therefore be of use as unique ADE cell markers or used to generate ADE cells are Sst, Pyy, Ghrl, Slc38a5, Chga, Exph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4sf2, 0610040B21Rik (aka txndc12), Apoa1, 2410021P16Rik (aka acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (aka Cmtm8), Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7, Sfrp5, Pga5, foxa1, foxa2, foxa3, Cer1, Hhex, Otx2, Gatn3 and Cxcr4. Desirably at least 2, 3, 4, 5, 10, 15 or 20 of these genes may be used to identify/generate such ADE cells.
- In order to facilitate purification of ADE cells from mixed populations of cells, proteins, from the list above, which are cell surface expressed, may be used to identify and/or purify ADE cells. The genes/proteins which are cell surface expressed include Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4sf2, Fzd5, Cklfsf8 (aka Cmtm8), Rarres1, Sic7a8, Sfrp5 and Cxcr4 The ADE cells may be identified an/or purify using such cell surface expressed proteins using, for example, protein specific antibodies, using techniques well known to those of skill in the art.
- The ADE cells of the present invention may be allowed to differentiate and the present inventors have been able to obtain, through use of appropriate differentiation factors, pancreatic and liver cells.
- There is much interest in the use of pancreatic cells and liver cells in the treatment of pancreatic and liver diseases; in particular in the treatment of diseases such as diabetes, hepatitis and cirrhosis. The methods, compositions, cell populations, cell lines and single cells of the present invention are all capable of being used in such treatment, as well as in the manufacture of preparations for such treatment.
- In a further aspect, therefore, the invention provides for the use of cell lines, cell populations, single cells and compositions described above for cell therapy and for the manufacture of a preparation for the treatment of pancreatic and liver disease and injury. Such preparations may be formulated in phosphate buffered saline (PBS).
- Methods of treatment of the diseases listed above can comprise the transplantation of single cells, cell lines, compositions, or cell populations of the invention into a patient. Preferably, the patient is mammalian, more preferably the patient is human.
- The cells of the invention, and in particular the cell lines, can be used to assay the effective of inductive or blocking factors on the differentiation of ADE cells. Such an assay may comprise contacting an ADE cell of the invention (i.e. as present in the compositions, cell lines, and populations, or a single ADE cell) with the factor to be tested. The effect of the factor on the differentiation of the ADE cell can be suitably assessed by determining the marker profile of the resultant cells, i.e. to show whether the cells have a similar marker profile to the cells of the invention, or whether these markers have been lost. The cells of the invention are also suitable for assaying pharmaceuticals for, for example, the treatment of pancreatic or liver disease.
- The present invention will now be further described by way of Example and with reference to the following figures which show:
-
FIG. 1 shows that RS protein recapitulates endogenous Hex expression. - (A) Schematic representation of the strategy used for the insertion of the RS coding sequence into the Hex locus. (B) Southern blot indicating the correct insertion of the RedStar cassette into the Hex allele (9 kb band). Targeting frequency=40%. (C) The HexRS mouse line was generated by blastocyst injection. 4 male chimeras were produced from HRS1 ES cells, all gave germline transmission. Top panel, HexRS/+ and HexRS/HexRS embryos at E9.5 and E8. RS expression is visible in the thryoid and liver primordial (white arrowheads) and the ventral foregut (black arrow). Lower panel, HexRS homozygous mutant embryos and HexRS/+ littermates at E9.5 and E15.
-
FIG. 2 shows In vitro expression of RS is specific to Hex expressing cell lineages. - HRS and E14Tg2a (parental) ES cells cultured in serum containing media for 2 days followed by N2B27 plus or minus activin for 5 days. Percentages of RS expressing cells are indicated. (B) HRS ES cells cultured in endoderm inducing conditions for 7 days and sorted for CD45 (haematopoietic) and CD31 (endothelial) expression. (C) Sox1GFP/+ES cells cultured in endoderm inducing conditions for 7 days. The presence of
sox 1 positive cells in the ES cell culture is typically encountered when culturing the cells in serum containing media (ref or personal communication?) (D) HRS and E14Tg2a (parental) ES cells cultured in early haematopoietic progenitor inducing conditions. Percentages of RS expressing cells are indicated. (E) Semi-quantitative RT-PCR for a range of markers associated with endoderm (Sox17, Cerl1, Ecadherin, Gata4), mesoderm (Tbra, Mixl1, Meox1, Gata1), ectoderm (Zic1) and parietal endoderm (Sox7) on RS positive and RS negative cell fractions sorted by flow cytometry. Samples were first analysed by quantitative RT-PCR for B-actin expression and normalised accordingly. -
FIG. 3 shows that Activin and EGF induce H+C+ cells following culture in serum containing media. - Analysis of
day 7 differentiated cells by flow cytometry. Cells were cultured in serum containing media for 2 days followed by 5 days in N2B27 plus activin and EGF. The percentage of H+C+ cells induced after 7 days varied between 11.4 and 22.0. -
FIG. 4 shows In vitro differentiating cell cultures produce a gene expression dynamic similar to that observed during ADE induction in vivo. - Analysis of gene expression from
day 0 today 7 of differentiation by quantitative real-time RT-PCR. The x axis represents the time in days at which the RNA was collected (timepoint 0=ES cells) and the y axis represents relative expression calculated by normalising the transcript number by the b-actin transcript number. The relative expression value represents the mean of 2 experimental replicates. Error bars represent the standard deviation. (B) Analysis of RS and CXCR4 expression by flow cyctometry fromday 0 today 7 of differentiation. The percentage of the four cell fractions are indicated. (C) RS expression in differentiating cell aggregates. RS expression was first detected by fluorescent microscopy atday 6, peaked at day 7-8 and was undetectable byday 10. -
FIG. 5 shows Hex and CXCR4 marks the emerging ADE cell population. (A) Quantitative real-time RT-PCR. - RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in
FIG. 4 . The y axis represents relative expression calculated by normalising the transcript number to the b-actin transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations. (B) Immunocytochemistry on ADE differentiated cells. The four cell fractions were sorted by flow cytometry following 7 days of differentiation as described inFIG. 4 . Cells were immunostained by anti-Cerl1, anti-Foxa2, anti-Oct4 and anti-Ecad. Nuclei were stained with DAPI. Green Cerl1, Oct4 and Ecad positive cells were detected using an Alexa-488 secondary antibody and red Foxa2 positive cells were detected using an Alexa-568 secondary antibody. -
FIG. 6 shows Gene expression profiling of RS and CXCR4 cell populations. - (A) Heat map. (B) Cluster dendrogram (C) Quantitative real-time RT-PCR of genes differentially expressed in the microarray analysis. RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in
FIG. 4 . The y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean relative expression value from 3 independent experiments. Error bars represent standard deviations. -
FIG. 7 shows ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo. - (A) Induction of pancreatic progenitors.
Day 7 ADE cultures were sorted into 4 cell fractions and plated in pancreatic progenitor inducing conditions for 5 days. Cells were immunostained with anti-Pdx1 and nuclei stained with DAPI. Pdx1 positive cells were detected using an Alexa-488 secondary antibody and shown in green. All clusters of Pdx staining were similar for each condition. We obtained 9 from H+C+ cultures, 4 from H−C+ cultures and 1 from H−C− cultures. (B) Induction of hepatocytes.Day 7 ADE cultures were sorted into 4 cell fractions and plated into hepatocyte inducing conditions as aggregates for 2 days. At this timepoint RS protein was only observed in the H+C+ and H+C− cell aggregates. (C) 2 day hepatocyte cell aggregates were plated on gelatin for a further 3 days. Cells were immunostained with anti-albumen, anti-AFP and nuclei stained with DAPI. Green albumen positive cells were detected using an Alexa-488 secondary antibody and red AFP positive cells were detected using an Alexa-568 secondary antibody. A few albumen positive cells were observed in the H+C+ and H+C− samples and these samples contained the highest percentage of AFP positive cells. (D) Byday 13 of the hepatocyte culture (day 20 of the total culture period) many albumen positive cells were present in the H+C+ cultures. (E) Analysis of sorted cell populations in kidney capsule explants. Hematoxylin and Eosin and PAS staining of sections from the four sorted cell fractions. Gut-like epithelial structures containing PAS positive secretory granules (deep red, black arrowheads) were present in H+C+ and H+C− growths. Cartilage (black arrow) was observed in the H−C+ growths. -
FIG. 8 shows Defining the requirements for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling. - (A) Flow cytometry showing the proportion of H+C+ cells induced under a series of conditions. All differentiation was done in N2B27 for two days, followed by five days in SF03. The minimum set of cytokines is indicated on top of each panel. The presence or absence of the FGF antagonist, PD173074 is indicated. (B) Fluorescence images of cell morphology. Cells were cultured with indicated cytokines or the FGF receptor antagonist, PD173074.
-
FIG. 9 shows Verification of microarray gene expression profiles by quantitative real-time RT-PCR. - Quantitative real-time RT-PCR. RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in Figure. 4. The y axis represents relative expression calculated by normalising the transcript number to the TBP transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations.
-
FIG. 10 . Hex and Cxcr4 marks the emerging ADE cell population - (A) Quantitative real-time RT-PCR. RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described in
FIG. 2d . The y axis represents relative expression calculated by normalising the transcript number to the β-actin transcript number. Values represent the mean relative expression value from 2 independent experiments. Error bars represent standard deviations. Purity checks on these populations were typically greater than 96% for the H+C+ and H−C+ populations and 91-93% for the H+C− and H−C− populations. (B) immunocytochemistry on ADE differentiated cells. The four cell fractions were sorted by flow cytometry following 7 days off differentiation as described inFIG. 2d . Cells were immunostained by anti-Cerl, anti-Coxa2, anti-Oct4 and Anti-Ecad. Nucleic were stained with DAPI. Green Cerl, Oct4 and Ecad positive cells were detected using an Alexa-488 secondary antibody and red FoxA2 positive cells were detected using an Alexa-568 secondary antibody. (C) Gene expression profiling of Hex (RS) and CXCR4 sorted cell populations. Cluster dendagram showing the relationship between the different cell populations and ES cells. Clustered normalised data using the 1-Perason's correlation coefficient as a measure of similarity. A=H+C+, C=H−C+, D=H−C−, ES=HexRS ES cells, E14=H14Tg2a wild-type ES cells. The figure indicates that the H+C+ fraction is most closely related to the H−C+ and all four fractions are closer to each other, than any fraction is to ES cells. (D) Hierarchical clustering of the differentially expressed genes identified in a pairwise analysis of populations A, B, C and D (see methods). Based on the observations in C, this comparison is made in the absence of these cell dataset. Red bars indicate expression cluster. (E) Quantitative real-time RT-PCR of genes differentially expressed in the ADE-like fraction by microarray analysis. RNA was prepared from the four Hex/Cxcr4 cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were as described inFIG. 2d . The y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean relative expression value from 3 independent experiments. Error bars represent standard derivations. -
FIG. 11 . ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo - (A) Induction of hepatocytes.
Day 7 ADE cultures were sorted into 4 cell fractions and plated into hepatocyte inducing conditions as aggregates for 2 days. At this timepoint RS protein was only observed in the H+C+ and H+C− cell aggregates. (B) Quantitative real time RT-PCR for genes expressed in hepatic differentiation. Expression levels are represent as a percentage of that achieved in cells derived from the H+C+ fraction. Values are based on relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. (C) 2 day hepatocyte cell aggregates were plated on gelatine for a further 3 days. Cells were immunostained with anti-albumin, anti-AFP and nucleic stained with DAPI. Green albumin positive cells were detected using an Alexa-488 secondary antibody and red AFP positive cells were detected using an Alexa-568 secondary antibody. A few albumin positive cells were observed in the H+C+ and H+C− samples and these samples contained the highest percentage of AFP positive cells. (D) Byday 13 of the hepatocyte culture (day 20 of the total culture period) many albumen positive cells were present in the H+C+ cultures. (E) Quantitation of cardiomyocyte induction based on scoring of beating foci. Data represents the average of four independent cultures. Cells were differentiated as in C and D. (F) Induction of pancreatic progenitors.Day 7 differentiated cultures were sorted into 4 cell fractions and plated in pancreatic progenitor inducting conditions for 5 days (see methods). Cells were immunostained with anti-Pdx1 and anti-HNF4α and nucleic stained with DAPI. The H+C+ fraction was both quantitatively and qualitatively more efficient at generating Pdx1/HNF4α clusters. Typical clusters for the H+C+(n=9) and H−C+(n=4) fractions. The H−C− fraction produced a single Pdx1/HNF4α positive cluster, while the H+C− fraction did not produce any. Green Pdx1 positive cells were detected using an Alexa-488 secondary antibody and red Hnf4α positive cells were detected using an Alexa-568 secondary antibody. We obtained 9 Pdx1/Hnf4α positive clusters from H+C+ cultures, 4 from H−C+ cultures and 1 from H−C− cultures. (G) Analysis of sorted cell populations in kidney capsule explants. Growths arising from the four sorted cells fractions were sectioned, stained with PAS and counterstained with Hematoxylin and Eoisin. Gut-like epithelial structures containing PAS positive secretory granules (deep red, black arrowheads) were present in H+C+ and H+C− growths. Cartilage (black arrow) was observed in the H−C+ growths. -
FIG. 12 . Expansion of ADE progenitors derived from differentiating ES cell culture - (A) FACS purified fractions from differentiating ES cell cultures plated and grown in culture for 12 days. The images are overlays of phase contrast and red fluorescence. Images captured with 10× objective (B) Images of colonies and cells in culture from the double positive H+C+ fraction. Top left 20×, bottom left 10×, top right 40×, bottom right 40×.
2, 4 and 5 are indicated on the figure. (C) Antibody staining of H+C+ cells in culture for six passages compared to ES cell controls. Cells were immunostained with anti-FoxA2, anti-Cerl, anti-Oct4 and anti-E-cadherin and nucleic stained with DAPI, FoxA2 andPassage numbers Oct 4 red were detected using Alexa-568 secondary antibody and Cerl and E-cadherin green were detected using Alexa 488 secondary antibody. (D) Antibody staining of passage 7 H+C+ cultures challenged to further differentiate towards pancreatic or hepatic fates. Top panel: cells were immunostained with anti-Nkx2.2, anti-Pdx1 and nucleic stained with DAPI. Nkx2.2 red was detected using Alexa-568 secondary antibody and Pdx1 green was detected using Alexa-488 secondary antibody. Bottom panel: cells were immunostained with anti-albumin, anti-AFP and nucleic stained with DAPI. Green albumin positive cells were detected using an Alexa-488 secondary antibody and red AFP positive cells were detected using an Alexa-568 secondary antibody. -
FIG. 13 . Defining the requirement for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling - (A) Flow cytometry of HexRS and E14Tg2a ES cells differentiated in monolayer culture. All differentiation was carried out in N2B27 plus activin and Bmp4 for two days, followed by five days in SF03 plus activin and EGF or the FGF antagonist, PD173074 as indicated. (B) Fluorescence images of cell morphology. Cells were cultured as above with FGF4 or the Fgf antagonist PD173074 as indicated. (C) Immunohistochemistry showing the expression of anterior mesendoderm markers in response to FGF4 in defined monolayer culture. Nucleic were stained with DAPI. Green Ger1 and Oct4 positive cells were detected using Alexa-488 secondary antibody and red Sox17, Foxa2 and Gsc positive cells were detected using Alexa-568 secondary antibody. (D) Real time quantitative PCR from
day 0 today 7 of serum-free differentiation showing gene expression changes in respect to FGF4. The x axis represents the time in days at which the RNA was collected (timepoint 0−ES cells) and the y axis represents relative expression calculated by normalising the transcript number by to the Tata box-binding protein (TBp) transcript number. (E) Time course for FGF addition. Left panel, bright field and fluorescent images of cultures differentiated in monolayer with FGF added for the indicated times. Right panel, bar graph indicating the percentage H+C+ obtained in these experiments as determined by flow cytometry. (F) Optimal levels of H+C+ correlates with optimal levels of ADE marker expression. Real time quantitative PCR indicating the relative level of transcription of a representative set of markers in response to different periods of exposure to FGF4 in monolayer culture. The x axis represents the time in days at which the RNA was collected (timepoint 0=ES cells) and the y axis represents relative expression calculated by normalising the transcript number by to the Tata box-binding protein (TBP) transcript number. -
FIG. 14 shows the differentiation of human ES cells to anterior definitive endoderm - Top panel (A) was differentiation with sodium burate and active as described in (Hay et al., 2008b) and the image in (B) is of cells differentiated with activin A and Wnt3a (Hay et al., 2008a). Cells were stained with anti-CER1 (Santa Cruz) in green and anti-Cxcr4 (BD Biosystems, APC conjugate) red. The figure shows that both protocols produce heterogeneous endodermal differentiation, with the activin and Wnt protocol producing higher numbers of CER1 positive cells. Flow cytometry is also shown in (B). Here the cells at the same stage of differentiation as those depicted in the image were analyzed by flow cytometry for FRZD5, one of the new markers identified and described in (Morrison et al., 2008). A similar proportion of these cells appear to FRZD5 positive as express CER1 by immuno-histochemistry.
Panel C shows data of cell staining following cells which have undergone differentiation in accordance with the present invention. -
FIG. 15 shows an illustration of ADE staining by new cell surface markers identified in this work. Embryiod bodies were differentiated to make ADE and either stained with individual markers (top panel) or disassociated and stained with a combination of two antibodies (bottom panel). EBs differentiated under conditions used to generate ADE show an abundance of cells staining at their membrane (green) for either Frzd5 or Clic6. Nuclei are in blue and stained with Dapi. In the bottom panel, clumps of cells express both the ADE marker Cerl (red or purple in the overlay) and either Frzd5 or Clic6. -
FIG. 16 . RS protein recapitulates endogenous Hex expression - (A) Schematic representation of the strategy used for the insertion of the redstar (RS) coding sequence into the Hex locus. (B) Southern blot indicating the correct insertion of the RedStar cassette into the Hex allele (9 kb band). Targeting frequency=40%. (C) The HexRS mouse line recapitulates Hex expression and phenotype. Top panel, HexRS/+ embryos at E8, E8.5 and E9.5. RS expression is visible at E8 in the anterior definitive endoderm, at E8.5 in the ventral foregut (black arrow) and at E9.5 in the thryoid and liver primordial (white arrowheads). Lower panel, HexRS homozygous mutant embryos and HexRS/+ littermates at E9.5 and E15.
-
FIG. 17 . In vitro expression of RS is specific to Hex expressing cell lineages. - (A) HRS and E14Tg2a (parental) ES cells cultured in serum containing media for 2 days followed by N2B27 plus or minus activin for 5 days. Percentages of RS expressing cells are indicated. (B) Semi-quantitative RT-PCR for a range of markers associated with endoderm (Sox17, Cerl, Ecadherin, Gata4), mesoderm (Tbra, Mixl1, Meox1, Gata1), ectoderm (Zic1) and parietal endoderm (Sox7) on RS positive and RS negative cell fractions sorted by flow cytometry. Samples were first analysed by quantitative RT-PCR for β-actin expression and normalised accordingly. (C) HRS and E14Tg2a ES cells cultured in early haematopoietic progenitor inducing conditions. Percentages of RS expressing cells are indicated. (D) Induction of H+C+ cells. Flow cytometry for RS and Cxcr4 (FITC) on
day 7 cells differentiated as in 2A with the addition of activin and EGF. -
FIG. 18 . In vitro differentiating cell cultures produce a gene expression dynamic similar to that observed during ADE induction in vivo - (A) Gene expression analysis during differentiation by quantitative real-time RT-PCR. The x axis represents the time in days when RNA was collected (
timepoint 0=ES cells). The y axis represents relative expression calculated by normalising the transcript number by the β-actin transcript number. Values represent the mean of 2 independent experiments. Error bars represent the standard deviation. (B) Analysis of RS and CXCR4 expression by flow cytometry fromday 0 today 7 of differentiation. The percentages of the four cell fractions are indicated. (C) RS expression in differentiating cell aggregates. Images captured using a 10× objective. -
FIG. 19 . Hex and Cxcr4 marks the emerging ADE cell population - (A) Quantitative real-time RT-PCR. RNA was prepared from the four cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were the same as
FIG. 2D . The y axis represents relative expression calculated by normalising the transcript number to the β-actin transcript number. Values represent the mean from 2 independent experiments. Error bars represent standard deviations. Purity checks on these populations were typically greater than 96% for the H+C+ and H−C+ populations and 91-93% for the H+C− and H−C− populations. RT-PCR values for cells prior to sorting (PS) and ES cells (ES) are included for reference. (B) Immunostaining on ADE differentiated cells. The four cell fractions were sorted by flow cytometry following 7 days of differentiation. Cells were immunostained by anti-Cerl (green), anti-Foxa2 (red), anti-Oct4 (green) and anti-Ecadherin (green). Nuclei were stained with DAPI (blue). Images captured using a 20× objective. (C) Gene expression profiling of Hex (RS) and CXCR4 sorted cell populations. Cluster dendrogram showing the relationships between the different cell populations and ES cells. Clustered normalised data using the 1-Pearson's correlation coefficient as a measure of similarity. A=H+C+, B=H+C−, C=H−C+, D=H−C−, ES=HexRS ES cells, E14=E14Tg2a wild-type ES cells. The figure indicates that the H+C+ fraction is most closely related to the H−C+ and all four fractions are closer to each other, than any fraction is to ES cells. (D) Hierarchical clustering of the differentially expressed genes identified in a pairwise analysis of populations A, B, C and D (see methods). Based on the observations in C, this comparison is made in the absence of the ES cell dataset. Red bars indicate expression cluster. (E) Quantitative real-time RT-PCR of genes differentially expressed in the ADE-like fraction by micorarray analysis. RNA was prepared from the four Hex/Cxcr4 cell fractions sorted by flow cytometry following 7 days of differentiation. The differentiation conditions were the same asFIG. 2D . RT-PCR values for cells prior to sorting (PS) and ES cells (ES) are included for reference. The y axis represents relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. Values represent the mean from 3 independent experiments. Error bars represent standard deviations. -
FIG. 20 . ADE cell cultures can be further differentiated towards mature endodermal lineages in vitro and in vivo - (A) Induction of hepatocytes.
Day 7 ADE cultures were sorted into 4 cell fractions and plated into hepatocyte inducing conditions as aggregates for 2 days. At this timepoint RS protein was only observed in the H+C+ and H+C− cell aggregates. White numbers shown on panels represent the percentage of Hex positive cells present in these cultures as measured by flow cytometry. Images captured using a 10× objective. (B) Quantitative real time RT-PCR for genes expressed atday 9 of hepatic differentiation. Expression levels are represented as a percentage of that achieved in cells derived from the H+C+ fraction. Values are based on relative expression calculated by normalising the transcript number to the Tata box-binding protein (TBP) transcript number. (C) Hepatocyte cell outgrowths onday 12 of total culture period. Cells were immunostained with anti-Albumin (green), anti-AFP (red) and nuclei stained with DAPI (blue). A few Albumin positive cells were observed in the H+C+ and H+C− samples and these samples contained the highest percentage of AFP positive cells. Images captured using a 10× objective. (D) Hepatocyte cultures onday 20 of the total culture period. Many Albumin positive cells can be observed in the H+C+ cultures. Images captured using a 10× objective. (E) Capacity for cardiomyocyte induction. Quantification of beating foci. Data represents the average of four independent wells and error bars the standard deviation. Cells were differentiated as in C and D. (F) Induction of pancreatic progenitors.Day 7 differentiated cultures were sorted into 4 cell fractions and plated in pancreatic progenitor inducing conditions for 5 days (see methods). Cells were immunostained with anti-Pdx1 (green) and anti-HNF4α (red) and nuclei stained with DAPI (blue). The H+C+ fraction was both quantitatively and qualitatively more efficient at generating Pdx1/HNF4α clusters. Nine Pdx1/HNF4α were obtained from the H+C+ cultures, four from H−C+ cultures, one from H−C− cultures and none from the H−C+ cultures. Images captured using a 20× objective. (G) Analysis of sorted cell populations in kidney capsule explants. Sections of growths were stained with PAS and counterstained with Hematoxylin and Eosin. Gut-like epithelial structures containing PAS positive secretory granules (deep red, black arrowheads) were present in H+C+ and H+C− growths. Cartilage (black arrow) was observed in the H−C+ growths. Images captured using a 20× objective. -
FIG. 21 . Expansion of ADE-like progenitors purified from differentiating ES cell culture. (A) Flow cytometry purified fractions from differentiating ES cell cultures plated and grown on gelatin for 12 days. The images are overlays of phase contrast and red fluorescence. Images captured with 10× objective (B) Images of colonies and cells growing in culture from the double positive H+C+ fraction. Images captured using the following objectives: top left 20×, bottom left 10×, top right 20×, bottom right 40×. Passage numbers (P) are as indicated. (C) Immunostaining of H+C+ cells in culture for five passages compared to ES cell controls. Cells were immunostained with anti-Foxa2 (red), anti-Cerl (green), anti-Oct4 (red) and anti-E-cadherin (green) and nuclei stained with DAPI (blue). (D) Immunostaining of passage 7 H+C+ cultures challenged to further differentiate towards pancreatic or hepatic fates compared to ES cell controls. Top panel; cells were immunostained with anti-Nkx2.2 (red), anti-Pdx1 (green) and nuclei stained with DAPI (blue). Bottom panel; cells were immunostained with anti-Albumin (green), anti-AFP (red) and nuclei stained with DAPI (blue). All images C-D captured using a 10× objective. -
FIG. 22 . Defining the requirements for ADE induction in chemically defined serum-free culture conditions reveals a novel requirement for FGF signalling - (A) Flow cytometry of HexRS and E14Tg2a ES cells differentiated in monolayer culture. All differentiation was carried out in N2B27 plus activin and Bmp4 for two days, followed by four to five days in SF03 plus activin and EGF. FGF4 or the FGF antagonist, PD173074 were added as indicated. Flow cytometry was used to quantitate the size of the H+C+ fraction on
day 6. (B) Fluorescence images of cell morphology. Cells were cultured as above with FGF4 or the FGF antagonist PD173074 as indicated. Images captured using a 20× objective onday 6. (C) Immunostaining showing the expression of anterior mesendoderm markers in response to FGF4 in defined monolayer culture. Differentiation was carried out in the presence or absence of FGF4 as indicated by +FGF. Nuclei were stained with DAPI (blue), Cerl and Oct4 are green, Sox17, Foxa2 and Gsc are red. Images captured using a 10× objective on cultures stained onday 5. (D) Real time quantitative PCR fromday 0 today 7 of serum-free differentiation showing gene expression changes in response to FGF4. The x axis represents the time in days at which the RNA was collected (timepoint 0=ES cells) and the y axis represents relative expression calculated by normalising the transcript number by to the Tata box-binding protein (TBP) transcript number. (E) Time course for FGF addition. Left panel, bright field and fluorescent images of cultures differentiated in monolayer with FGF added for the indicated times. Images captured with a 10× objective onday 6. Right panel, bar graph indicating the percentage H+C+ obtained in these experiments as determined by flow cytometry for the same day. Error bars represent the standard deviation in two independent experiments. (F) Optimal levels of H+C+ induction correlates with peak levels of ADE gene expression (Cer1) and reduced mesodermal gene expression (Meox). Real time quantitative PCR indicating the relative level of transcription of a representative set of markers in response to different periods of exposure to FGF4 in monolayer culture. The x axis represents the time window during differentiation over which cells were exposed to FGF4 and the y axis represents relative expression calculated by normalising the transcript number by to the Tata box-binding protein (TBP) transcript number. RNA was collected atday 6. -
FIG. 23 . Activin treated ES cell cultures do not produce haematopoeitic, endothelial or neurectodermal cells. (A) HexRS ES cells cultured in endoderm inducing conditions for 7 days and sorted for CD45 (haematopoietic) and CD31 (endothelial) expression. (B) Sox1GFP/+ES cells cultured in endoderm inducing conditions for 7 days. The presence of Sox1 positive cells in the ES cell culture is typically encountered when culturing the cells in serum containing media (Stavridis et al., 2007). -
FIG. 24 . Quantitation of the number of Hex positive cells, derived from the H+C+ ADE fraction, maintained in culture over multiple passages. The number of HexRS positive cells was assessed at each passage using fluorescent microscopy and expressed as a percentage of the total number of cells in the culture. The passage number and time point (days) is indicated on the X axis of the graph. Three or four representative fields were counted and the error bars represent the standard deviation between the measurements. -
FIG. 25 . Treatment of monolayer cultures with FGF2 and FGFR inhibitor SU5402 provide additional evidence that FGF signalling promotes ADE production. Treatment of cultures with different FGFs, suggest that FGF2 and FGF4 but not FGF5, 8b and 10 have the ability to promote ADE formation. Inhibition of ADE by a second FGF receptor inhibitor, SU5402 further supports a requirement for FGF signalling during ADE differentiation. Both PD173074 and SU5402 were added to cultures for days 3-4 or days 3-7 and found to inhibit ADE differentiation. Inhibitors and FGFs are indicated above each graph. In this figure we have not quoted percentages because these inhibitors have induced morphological changes with high levels of autofluorescence indicated by an abundance of cells fluorescing equivalently in both the green and red. Altered morphologies in response to FGF inhibitors can also be observed microscopically (seeFIG. 7B ) and low (FIG. 7A ) to modest (this figure) levels of autofluorescence can be observed when the inhibitors are included from day three of the differentiation protocol. - Sequences of the oligonucleotides used herein are disclosed in Table 9.
- Gene Targeting and Production of HexRedStar (HexRS) Mouse Line.
- The 5′ and 3′ targeting arms of the targeting construct homologous to the Hex genomic sequence were as described previously (Martinez Barbera et al. 2000) with an Asc1 and Pac1 site engineered downstream of the ATG at the Hex translation initiation site (a gift from Shankar Shrinivas). The RedStar gene was linked via an internal ribosome entry site (IRES) to the gene encoding blasticidin resistance (BSD) followed by a cytomegalovirus promoter-driven hygromycinR-thymidine kinase dual selection cassette flanked by loxP sites. This cassette was fused in frame with the ATG at the Hex translation initiation site via the engineered Asc1 and Pac1 restriction enzyme sites (
FIG. 1A ). Following electroporation into E14Tg2a ES cells and seven days of selection with hygromycin, resistant clones were selected and expanded. Correctly targeted clones were identified by Southern analysis with aflanking 5′probe (FIG. 1B ). Three clones were selected for transient transfection with a Cre recombinase expression vector to remove the selection cassette. Clones that had undergone excision were selected for in the presence of ganciclovir and screened by Southern analysis. Two clones, HRS1-2, were selected for further analysis. The ES cell line HRS1 was injected into blastocysts and passed through the germ line of chimeras to generate the HexRS mouse line. Mice were maintained on a mixed 129Ola×C57Bl/6 background. - Mouse ES cells were cultured in serum according to (Li et al. 1995) or serum-free according to (Ying et al. 2003). All ES cells and differentiated cultures were maintained in a 7% CO2-air mixture at 37° C.
- ADE was induced under serum-containing conditions using a 2-step protocol. ES cells were seeded onto non-coated 10 cm petri dishes (sterilin) at a density of 5×103 cells/ml in Glasgow minimum essential medium (G-MEM; GIBCO-BRL) supplemented with 10% fetal calf serum (FCS), 0.1 mM nonessential amino acids (GIBCO-BRL), 1 mM sodium pyruvate, 2 mM glutamine and 0.1 mM 2-mercaptoethanol (2ME). Following 2 days of culture the resulting embryoid bodies (EBs) were harvested by centrifugation at 500 rpm for 1 min and replated on 10 cm non-coated petri dishes at the same density in N2B27 culture medium (StemCellSciences) supplemented with 20 ng/ml activin A (R&D). The media was replaced 2 days later and then every 3 days for the duration of the experiment. For some
experiments 20 ng/ml EGF, 10 ng/ml Bmp4, 20 ng/ml activin A (R&D), 1×10−5M all-trans retinoic acid (Sigma) and 3 μM CHIR99021 (a gift from StemCellSciences) were added to the culture at the indicated timepoints. - For ADE induction under serum-free conditions in suspension culture, ES cells were seeded onto non-coated 10 cm Petri dishes at 5×103 cells/ml in N2B27 culture medium supplemented with 10 ng/ml Bmp4 and 20 ng/ml activin A. Following 2 days of culture the resulting EBs were harvested as above and replated on non-coated Petri dishes at the same density in SF03 culture medium (ref Tada 2005) supplemented with 20 ng/ml activin A and 20 ng/ml EGF. The media was replaced 2 days later and then every 3 days for the duration of the experiment. For some
experiments 10 ng/ml Fgf4 (R&D), 10 ng/ml Bmp4, 20 ng/ml Activin A, 1×10−5M all-trans retinoic acid, 100 ng/ml PD173074 (Sigma), 20 ng/ml EGF and 3 μM CHIR99021 were added to the culture at the indicated timepoints. - For ADE induction under serum-free conditions in adherent monolayer culture, ES cells were seeded onto gelatin coated 3
cm 6 well dishes (Iwaki) at a density of 1×104 cells/ml in N2B27 medium (StemCellSciences) supplemented with 10 ng/ml Bmp4, 20 ng/ml activin A and 10 ng/ml Fgf4. Following 2 days of culture the media was replaced with SF03 culture medium (Tada 2005) supplemented with 20 ng/ml activin A, 10 ng/ml Fgf4 and 20 ng/ml EGF. The media was replaced 2 days later and then every 3 days for the duration of the experiment. For someexperiments 1×10−5M all-trans retinoic acid, 100 ng/ml PD173074 and 3 μM CHIR99021 were added to the culture at the indicated timepoints. - For the induction of pancreatic progenitor cells, sorted cell fractions were seeded onto gelatin coated 3
cm 6 well dishes (Iwaki) at 2.5×105 cells/ml in N2B27 media supplemented with 10 ng/ml Fgf4, 2 μM all trans retinoic acid and 0.25 μM KAAD-cyclopamine (Toronto Research Chemicals). Similar results were obtained with 1×105 cells in the absence of KAAK-cyclopmaine. Pdx positive cells appear within 3-5 days of plating onto Gelatin. - For the induction of hepatocytes, we adapted a protocol recently described by Gouon-Evans et al. (Gouon-Evans et al. 2006).
Day 7 sorted cell fractions were re-aggregated in N2B27 medium supplemented with 0.5 mM ascorbic acid, 4.5×10−4 M monothioglycerol (MTG), 50 ng/ml BMP4, 10 ng/ml bFGF (R&D) and 10 ng/ml VEGF (AMS Biotechnology Ltd) at a density of 2.5×105 cells/ml in ultralow cluster 24 well plates (Costar). Aggregates were harvested at 48 hr and replated in N2B27 medium supplemented with 10 ng/ml EGF, 10 ng/ml bFGF, 20 ng/ml HGF (Autogen Bioclear), 20 ng/ml TGF-β (AMS Biotechnology Ltd), 10 ng/ml VEGF and 10−7M dexamethasone (Sigma) on gelatin-coated 3 cm tissue culture coated dishes (Nunc). The media was replaced every 3 days for the duration of the experiment. - For the induction of haematopoietic precursors we used a similar protocol to that described by Kennedy and Keller (Kennedy and Keller 2003). Briefly, ES cells were seeded onto non-coated 10 cm petri dishes at a density of 1×104 cells/ml in IMDM (GIBCO-BRL) supplemented with 15% FCS, 2 mM glutamine, 300 μg/ml transferrin (Roche), 4×10−4 M MTG (Sigma), 50 μg/ml ascorbic acid (Sigma) and the cells analysed at 48 hr and 72 hr.
- FITC-conjugated rat anti-CD184 (CXCR4), FITC-conjugated rat anti-CD31 and FITC conjugated rat anti-CD45 were purchased from BD Pharmingen. EBs generated under various different differentiation conditions were dissociated by treatment with cell dissociation buffer (PBS based) (GIBCO-BRL). Cells were washed in PBS supplemented with 10% FCS (FB) and resuspended at a maximum density of 5×106 cells/ml. For surface staining 200 μl of cells were plated in a V shape 96 well polystyrene plate (Sterilin) in PBS supplemented with 1% serum of the species in which the antibody was manufactured. The FITC-conjugated antibody or a FITC-conjugated isotype control was added at a 1:100 dilution. Cells were incubated in the dark for 20 mins, washed 3 times with FB and resuspended in FB supplemented with Topro3-iodide (Invitrogen) to exclude dead cell from the analysis. Cells were analysed using a FACS Calibur (BD Biosciences) or sorted using a MoFlo MLS flow cytometer (DakoCytomation).
- Total RNA was prepared from a minimum of 1×104 cells from sorted cell fractions, EBs, monolayer differentiated cells or ES cells using Trizol reagent (Invitrogen). 1 μg of RNA was used as a template for cDNA synthesis using Superscript III (Invitrogen). Real-time RT-PCR was performed using a LightCycler 480 (Roche) and LightCycler 480
SYBR Green 1 Master (Roche). The following cycling conditions were used: denaturation: 95° C. 5 sec, amplification: 95° C. 5 sec, 58° C. 10 sec, 72° C. 20 sec (45 cycles), 81° C. 1 sec, melt: 95° C. 1 sec, 65° C. 10 sec, 95° C.-ramp 5 C per sec continuous, cool: −40° C. 10 sec. Standard curves were generated from plasmid. Samples were normalized to β-actin or TATA-box binding protein (TBP) expression levels. PCR primers and conditions are listed in Table 9. - Sorted cells were seeded onto gelatin coated 24 well dishes (Iwaki). Adherence of cells to the substrate was enhanced by centrifugation at 1200 rpm for 3 mins. Sorted cells, monolayer differentiated cells and ES cells were washed in PBS, fixed in 4% paraformaldehyde for 10 mins and permeabilised by washing in PBS supplemented with 0.1% Triton X (PBST). Cells were treated with a blocking reagent (3% serum of same species as secondary antibody, 1% BSA in PBST) for 15 min before incubation with the primary antibody at 4° C. overnight. The cells were washed with PBST and incubated with the appropriate fluorescence-tagged secondary antibody for 2 hr at room temperature. The cells were washed with PBST and DAPI added during the final wash. The following primary antibodies were used, all are anti-mouse: anti-Oct3/4, anti-HNF-3β (Foxa2), anti-HNF-4α (Santa Cruz), anti-Cerl1 (R&D), anti-E-cadherin (Takara Bio Inc) anti-alpha fetoprotein (NeoMarkers), anti-albumin (Bethyl laboratories inc). Anti-Pdx1 was a gift from P. Serup.
- Cells were sorted at
day 7 and approximately 5-10×104 cells of each population were transplanted under the kidney capsule of adult 129 mice. Four to eight weeks after transplantation any live mice were sacrificed and the kidneys removed and fixed in 4% paraformaldehyde (PFA). Following fixation the kidneys were embedded in paraffin wax, sectioned and stained with hematoxylin and eosin and PAS reagent (Sigma). - RNA was prepared from HexRS ES cells, E14Tg2a ES cells and the four RS/CXCR4 sorted populations of differentiated HexRS ES cells from three independent experiments. 2 μg was used to prepare a probe for hybridsation to the Illumina Mouse-6-v1 Beadchip. The data was filtered so that any probe with a detection score <0.95 across all samples was removed from the analysis prior to log transformation (base2) and quantile normalisation. Initial inspection of the data suggested the samples clustered loosely according to when they were processed, therefore a model based analysis was used. Differentially expressed probes were identified using LIMMA (Smyth 2004) modeling the sample effect and the date when the samples were processed once grouped. Those with an adjusted B-value>1.0 were deemed differential. Data was also analyzed in a pairwise fashion to determine significant differentiatials between each of the four populations. This was used to produce a molecular signature for the H+C+ double positive population.
- During embryonic development Hex is expressed in the newly specified ADE cells and therefore represents an ideal early marker for anterior endoderm formation. We created an ES cell line containing the marker gene, RedStar (RS) (Knop et al. 2002) under the control of the Hex locus (
FIG. 1A ). These cells allowed us to monitor the emergence of newly formed ADE cells during in vitro differentiation. The RS coding sequence was introduced into the first exon of the Hex locus by homologuous recombination in ES cells. The insertion of the RS targeting cassette into this exon terminates the endogenous Hex transcript and should produce a null Hex allele. Correctly targeted clones (FIG. 1B ) were transfected with Cre recombinase to remove the selection cassette and two independent clones with normal karotype, HexRedStar (HexRS) 1-2, were selected for further analysis. - To confirm that the RS protein accurately reflects endogenous Hex expression,
Hex RS1 ES cells were used to generate a HexRS mouse line. Embryos from HexRS/+ intercrosses are shown inFIG. 1C . At E8.5 red fluorescence was detected in the foregut and by E9.5 was present in the liver and thyroid primordia and weakly expressed in the intersomitic blood vessels. Thus, RS protein reflects the expression of endogenous Hex protein as reported by Thomas et al, (Thomas et al. 1998). No live HexRS/HexRS mice were born (Table 1) and HexRS/HexRS embryos exhibited anterior defects and reduced hepatic tissue mass (FIG. 1C ). This phenotype is consistent with the Hex null phenotype (Martinez Barbera et al. 2000) and confirms the loss of the endogenous Hex transcript from the targeted HexRS allele. Moreover, no phenotype was detected in HexRS/+ embryos or mice (FIG. 1C , Table 1), indicating that any reduced Hex dosage in heterozygous cells will not impact on the ability of the cells to form ADE in vitro. - The secreted TGFβ ligand activin, has previously been shown to induce markers of endoderm in Xenopus animal cap assays (reviewed by (Okabayashi and Asashima 2003)) and to induce a mesendodermal cell population from ES cells in culture (Kubo et al. 2004; Tada et al. 2005). In these early embryonic tissues, activin can induce the same spectrum of mesendodermal gene expression as the endogenous inducer, Nodal. To test the ability of activin to induce HexRS expression, ES cells were differentiated in a two-step aggregation culture system in serum containing media for 48 hr followed by serum free media supplemented with activin for 5 days. Under these conditions, 6.8-8.6% of cells were RS positive at day 7 (
FIG. 2A ). This induction was shown to be dependent upon activin treatment and was consistent in two independently derived HexRS ES cell lines (FIG. 2A ). - Hex expression in the developing embryo is not exclusive to endodermally derived cells since it is also expressed in a specific mesodermal cell population that may represent a bipotent haematopoietic and endothelial precursor often termed a haemangioblast (Kubo et al. 2005). In developing embryos Hex is also expressed in angioblastic and endothelial precursor populations in the dorsal aorta, in intersomitic vessels and the visceral yolk sac and later in the endocaridium of the heart (Thomas et al. 1998; Rodriguez et al. 2001). To ensure that the activin induced HexRS positive cells do not represent these cell populations we analysed the differentiated cells by flow cytometry for the presence of endothelial and haematopoietic markers.
FIG. 2B shows that our activin treated cell cultures do not contain significant numbers of endothelial (CD31 positive) or haematopoietic (CD45 positive) cells. In addition, a Sox-1 GFP reporter ES cell line was used to demonstrate the absence of neurectodermal cell types during our activin induced differentiation protocol (FIG. 2C ). - Despite the absence of haematopoetic precursors in these activin treated cultures, it was important to confirm that HexRS ES cells could give a reliable read out of haematopoetic differentiation in vitro. Using culture conditions tailored towards the specific induction of early haematopoietic cell populations (Kubo et al. 2005) we see a modest but significant induction of RS positive cells at day 3 (
FIG. 2D ) whereas under our endodermal differentiation conditions, significant numbers of RS+ cells were not detected until day 6 (seeFIG. 3A ). - In summary, our analysis of multiple cell lineages indicates that activin induced HexRS positive cells represents endoderm. This was confirmed by profiling the flow cytometry purified RS positive cell population by RT-PCR (
FIG. 2E ). - Purification of ADE from Differentiating ES Cells
- In addition to being a marker of early ADE specification, Hex is also expressed in the extra-embryonic primitive and visceral endoderm lineages. In particular, Hex is expressed in a visceral endoderm population known to have similar signalling properties to the ADE, the anterior visceral endoderm (AVE) (Thomas and Beddington 1996; Beddington and Robertson 1998). Unlike ADE which contributes to the foregut, AVE will contribute predominately to the visceral yolk sac (Lawson and Pedersen 1987). At the level of marker gene expression, the AVE is very difficult to distinguish from the ADE. While expression levels of the visceral endoderm associated gene Sox7, was low during our differentiation protocol (FIG. 2E), this marker is not expressed in the AVE region of the visceral endoderm in vivo. To confirm that the HexRS positive population was ADE rather than AVE, we used expression of a second marker, the chemokine receptor Cxcr4. Cxcr4 is expressed in definitive mesoderm and endoderm populations, but excluded from all yolk sac visceral endoderm (McGrath et al. 1999; Yusuf et al. 2005). We used flow cytometry to analyze a Cxcr4, RS double positive cell population we believed was putative ADE (
FIG. 3 ). Quantification of this population enabled us to determine media conditions optimal for the production of this putative ADE population of RS/Cxcr4 double positive (H+C+) cells. Table 2 summarises the different culture conditions tested. Optimal H+C+ induction was obtained with ES cells in suspension culture for two days in the presence of serum and then an additional five days serum free in the presence of activin and EGF. This culture condition was the one used for the induction of ADE with the exception of the serum-free experiments. Optimal induction conditions were also sensitive to cell density (Table 3). - During the ADE optimisation process we also observed that the addition of Bmp4 and retinoic acid (either at
day 0 or day 3) completely blocked the induction of the RS positive population (Table 2), without effecting CXCR4 induction (data not shown). This suggests that the induction of ADE from non-committed precursors is particularly sensitive to manipulation of these signalling pathways. Thus these pathways either block the progression of mesendodermal progenitors toward ADE or shift the differentiation of these progenitors towards more posterior or mesodermal lineages. Interestingly, both BMPs and retinoic acid have been shown to posteriorize anterior endoderm (Kumar et al. 2003) and thus may be acting during differentiation to modify the regional identity of these cultures. - We were surprised by the inability of a Wnt agonist, CHIR99021 (Bennett et al. 2002) to stimulate the induction of significant H+C+ populations. To the contrary, addition of CHIR99021 at day 0-2 completely blocked the induction of the H+C+ cell population. While these observations may be relevant to lineage specification in the anterior endoderm, it is hard to resolve the effects of specific signalling angonists and antagonists in the presence of serum.
- Molecular Analysis of ADE Derived from ES Cells
- To date, no markers have been identified that are exclusively expressed in the ADE. Therefore, in order to be confident that our cultures were producing ADE we characterised differentiating populations of HexRS ES cells using a comprehensive range of markers and techniques.
- To assess whether our cell cultures produce a gene expression dynamic similar to that observed during ADE induction in the gastrulating embryo we examined the kinetics of gene expression from day 0-7 of the differentiation process. Markers associated with ES cells, early epiblast, the primitive streak, ectoderm, mesoderm and endoderm were examined by quantitative real-time PCR (
FIG. 4A ). As in the mouse epiblast, Oct4 (Pou5f1), Nodal and E-cadherin are expressed at high levels in ES cells. Significant levels of all three of these markers are maintained during the early phase of ES cell differentiation and they are then rapidly down regulated. Both Nodal (Norris et al. 2002) and Oct4 (Perea-Gomez et al. 1999) expression are maintained during epiblast development and become restricted to the posterior epiblast region surrounding the primitive streak. Interestingly the expression of these early markers was maintained alongside the peak expression of early primitive streak markers (Wnt3a, Brachyury (reviewed in (Beddington and Robertson 1999)). Early during primitive streak formation node-associated markers such as Mixer like 1 (Mixl1) Goosecoid (Gsc) and FoxA2 are expressed, first through out the streak region and then in the prospective axial mesendoderm (notochord, prechordal plate and ADE) (Robb et al. 2000; Kinder et al. 2001). Similarly, our cultures expressed these markers and Cxcr4 beginning atday 3, the peak of Wnt3a and Brachyury (Tbra) expression, and peaking from day 5-6. During gastrulation, the first discrete ADE markers appear in cells at the anterior end of the primitive streak and are then are maintained in those cells as they migrate forward along the midline (Kinder et al. 2001). These region or lineage specific genes, such asCerberus 1 homologue (Cer1), Hex and Sox17 appeared between days 5-7 in our cultures. - Although Mixl1 and Wnt signalling, are required for endoderm induction, (Hart et al. 2002) ((Lickert et al. 2002) Wnt3 and Mixl1 are not expressed in definitive endoderm. In our culture conditions these markers are significantly expressed from day 3-5 and are then down regulated concordant with the emergence of markers of endoderm such as Sox17, Cerl and Hex.
- Based on the expression of these gastrulation stage markers, the dynamic pattern of expression evident in our differentiating ES cell cultures reflects the progression of markers during ADE specification in embryos. Similarly,
FIGS. 4B and C show that both RS fluoresence and CXCR4 protein were produced several days after activin treatment and that CXCR4 production precedes Hex. This is consistent with the expression of these markers in vivo (McGrath et al. 1999; Yasunaga et al. 2005; Yusuf et al. 2005) and suggests that the Cxcr4 single positive population may represent non-committed mesendoderm, whereas the H+C+ population is committed ADE. - The sequential expression of a number of markers observed in
FIG. 4A appears inconsistent with differentiation towards the visceral endoderm population that expresses Hex, AVE. During embryogenesis Hex expression in the AVE proceeds Brachyury by at least one day (Thomas et al. 1998) and this is the opposite of what we observe. While Gsc and Cerl are expressed in the AVE, Hex expression throughout the primitive endoderm precedes the induction of these markers ((Thomas et al. 1997; Thomas et al. 1998) and Brickman and Beddington, unpublished observations). Finally, while Sox17 is expressed in the visceral endoderm, it is not expressed alongside Hex in the AVE (Kanai-Azuma et al. 2002), whereas Sox17 is expressed during ADE induction and is expressed with similar kinetics to Hex during differentiation. ADE identity is therefore also consistent with the expression of Sox17 in the H+C+ population (seeFIG. 5A ). The parietal endoderm marker, Sox7 was barely detectable by Q-PCR during the differentiation process and therefore not considered to be significantly expressed (seeFIG. 9 ). We conclude that our H+C+ populations represent ADE. - We found the majority of committed cells generated using our protocol appear to be endoderm rather than mesoderm. E-cadherin is expressed in ES cells and in the preimplantation stage embryo. Cells destined to become mesoderm lose E-cadherin expression at the gastrulation stage whereas cells destined to become endoderm remain E-cadherin positive. E-cadherin expression can therefore be used to distinguish mesoderm cells from ectoderm and endoderm (Huber et al. 1996). We found E-cadherin to be expressed at significant levels during the late stages of the differentiation protocol, indicating that this protocol did not favour the production of mesoderm. Immunostaining confirmed that the majority of cells in the
day 7 cultures were E-cadherin positive (seeFIG. 5B ). - To better understand the spectrum of cell types produced in our ES cell differentiation protocol and gain a more comprehensive picture of the H+C+ cells, HexRS cultures were sorted into four populations based on RS and CXCR4 protein levels and profiled by quantitative RT-PCR, immunostaining and microarray. Surprisingly we found that the transcript level of Hex in the RShigh/CXCR4low (H+C−) and RSlow/CXCR4high (H−C+) populations were very similar and significantly less than the RShigh/CXCR4high (H+C+) population (
FIG. 5A ). This may reflect the time lag between the production of Hex transcript and mature RS protein. Thus the H+C− cell population which appears to be formed from the H+C+ population (FIG. 4B ) is likely to consist of cells in which CXCR4 has been switched off and Hex is also being downregulated at the transcript level, but the RS protein is still present. Similarly, the H−C+ cell population may contain cells in which Hex transcripts have begun to be produced but not the RS protein. Such a large difference between protein and transcript level was not observed for CXCR4 and may reflect the shorter maturity rate and half-life of the CXCR4 protein. The transcript level of both Hex and CXCR4 was highest in the H+C+ sorted population and allows us to be confident that the H+C+ sorted population is positive for both the Hex transcript and protein. - The H+C+ cell population expressed the highest levels of E-cadherin, Cxcr4, Cerl and Hex transcript (
FIG. 5A ). All of these genes are expressed in the anterior definitive endoderm. Importantly, the expression of markers Tbra, Wnt3 and Mixl1 that are associated with the early primitive streak but not the anterior definitive endoderm, were lowest in the H+C+ population as was the paraxial mesoderm marker Meox1. Cdx2 is also expressed in the early primitive streak cell population (Beck et al. 1995) and is then restricted to the posterior endoderm. Both Cdx2 and the parietal endoderm marker Sox7 were only detected at very low levels during differentiation and were expressed at the lowest level in the H+C+ cell population (FIG. 5A ). - We performed immunostaining to analyse marker expression at the single cell level. In accordance with the PCR data we found almost all of the H+C+ cells to express the anterior definitive endoderm marker Cerl, and the definitive endoderm markers Foxa2 and E-cadherin but not the ES cell marker Oct4 (
FIG. 5B ). - Microarray analysis was performed on Illumina Mouse-6-v1 Beadchip. Three chips were used for each of the four differentiated populations and HexRS and wild type E14Tg2a ES cells. Initial inspection of the data suggested the differentiated samples cluster close to each other as do the two ES cell lines (
FIG. 6B ). The close proximity of the two ES cell lines indicates there is little difference in gene expression in HexRS heterozygote and wild-type ES cells. Of the differentiated populations, the H+C+ population is most closely related to the H−C+ population, consistent with the view that the H+C+ ADE arises from the H−C+ mesendodermal population. Differentially expressed genes were identified using LIMMA (Smyth 2004) modeling the sample effect and the date when the samples were processed once grouped. Those with an adjusted B-value>1.0 were deemed differential. Clustering of these differentials is shown inFIG. 6A . Interestingly, the H+C+ population is enriched for a number of anterior endoderm markers such as Frizled 5 (Finley et al. 2003), Cerl (confirming the data inFIG. 5 ), Lim1 (Shawlot and Behringer 1995) and FoxA2/FoxA3 (Friedman and Kaestner 2006). We conclude from this data that the H+C+ population is axial mesodendoderm that is enriched for the expression of anterior markers, normally expressed in the ADE.FIG. 6C shows qRT-PCR validation on the expression of these genes and a number of novel transcripts and potential new ADE markers. - To examine the potential of the sorted cell populations to differentiate further down the endodermal lineage, we cultured the cell fractions in conditions conducive for the formation of foregut, pancreatic and liver progenitors. During gut tube formation, the ADE loops around and migrates in a posterior direction to form the ventral foregut. Thus the anterior most component of the definitive endoderm ends up in a more posterior location that gives rise to liver and pancreas. The pancreas is formed by two budding outgrowths from this region of foregut and their induction and the subsequent specification of pancreatic progenitors is dependent on interactions with the surrounding tissues. In explants and grafting experiments, posterior mesoderm and signalling molecules associated with it (BMP, FGF and RA) can induce more posterior, pancreatic identity, on the anterior end of the gut tube (Wells and Melton 2000; Kumar et al. 2003). One of the earliest markers of emerging pancreatic buds is the transcription factor Pdx1 (Offield et al. 1996). Induction of Pdx1 and formation of the dorsal pancreatic bud also requires inhibition of sonic hedgehog (Hebrok et al. 1998).
- We attempted to differentiate our ES cell derived ADE to pancreatic progenitors using retinoic acid, FGF4 and the sonic hedgehog inhibitor cyclopamine. After 5 days in culture we could detect Pdx1 positive cells in the H+C+ sorted cell fraction (
FIG. 6A ). Pdx1 positive cells were also present in the H−C+ and H−C− cells, however both the intensity of Pdx1 staining and the number of positive cell clusters was lower than for the H+C+ cells (FIG. 6A and Figure legend). The ability of H−C+ populations to form Pdx1 positive pancreatic progenitors with reduced efficiency may reflect the ability of putative non-committed mesendoderm to generate ADE upon further culture. Undifferentiated ES cells did not generate any Pdx1 positive cells (data not shown). We were unable to culture H+C− cells in this culture condition and it is possible that these cells have become more restricted in their differentiation potential. Interestingly Hex expression does persist in the ventral foregut that will give rise to the liver primoidium and thyroid (Thomas et al. 1998) and it is possible that these cells have progressed further towards one of these lineages and can no longer generate Pdx1 positive pancreatic progenitors. - Since both the pancreas and the liver are derived from ADE we would predict that our H+C+ ADE cells would also be capable of generating hepatocytes. Using a method adapted from Gouon-Evans et al (Gouon-Evans et al. 2006), day 7 H/C sorted cell fractions were cultured in hepatocyte differentiation conditions for 5-13 days (total culture period 12-20 days). Hex is expressed in the liver primordial at E9 ((Thomas et al. 1998) and
FIG. 1B ) therefore we would expect to see RS protein in cells forming hepatocytes. RS positive cells were present atday 9 of the total culture period in aggregates formed from the H+C+ and H+C− sorted cells only (FIG. 6B ). While some AFP positive hepatocytes were observed atday 12 in the H−C+ and H−C− cell populations the efficiency of differentiation was always lower. No AFP positive hepatocytes were formed from non-induced ES cells cultured in the same conditions (data not shown). Atday 12, AFP positive hepatocytes could be detected in all four cultured cell fractions, however the number of positive cells was highest in the H+C+ cell fraction (FIG. 6C ). Byday 20, AFP expression was reduced and the number of albumen positive cells had increased significantly in the H+C+ population (FIG. 6D ). - To evaluate the level of commitment established by cells in each fraction, the cultures were sorted into the four RS/CXCR4 fractions following 7 days of differentiation, and immediately transplanted under the kidney capsule of adult 129 mice. Eight weeks after transplantation the mice were sacrificed and the grafts analysed. From the nine H+C+ transplants performed only one small growth was observed. In
contrast 5 large teratomas were observed from the transplanted H−C− cells, most likely due to the presence of low numbers of ES cells within this cell fraction (seeFIG. 4B ). The H+C− and H−C+ transplants resulted in 3 and 4 growths respectively (Table 4). The small H+C+ growth contained endodermal derivatives indicated by the presence of ductal epithelial structures containing PAS positive secretory granules (FIG. 6E ). Similar epithelial structures were observed in the H+C− and H−C+ grafts. Interestingly, the H−C+ transplants were the only ones (excluding the H−C− teratomas) that contained cartilage (FIG. 6E ). The appearance of both mesoderm and endoderm in these grafts suggest that H−C+ fraction contains non-committed mesendodermal progenitors. - Since both pancreas and liver arise from ADE, we tested the hepatic potential of the H+C+ population using a method adapted from Gouon-Evans et al., (2006), which involves up to 13 additional days of hepatocyte differentiation (
total culture period 20 days). Byday 12, AFP positive hepatoblasts were apparent in the H+C+ cell fraction and while some AFP expression was observed in all four fractions, it was significantly higher in the double positive fraction (FIG. 11C ). No AFP positive cells were formed from non-induced ES cells cultured in the same conditions (data not shown). This trend was already apparent at the RNA level fromday 9, where the H+C+ fraction expressed at least 3-4 fold higher levels of Krt19, Albumin, AFP, Hnf6 and Foxa2 transcript than any of the other fractions (FIG. 11B ). The pattern of Hex expression during the differentiation period is also consistent with its later expression in the liver primordia (Thomas et al., (1998) andFIG. 1C ) with RS protein detected atday 9 in forming hepatocytes but only in the H+C+ and weakly in H+C− sorted cells (FIG. 11B ). Flow cytometry at this stage of differentiation also supports the quantitative capacity of the H+C+ fraction to differentiate towards liver, as 62% of the H+C+ cess are Hex positive forming hepatocytes, whereas only 11% of the H−C+ population were weakly fluorescent (FIG. 11A ). Byday 20, AFP expression was reduced and the number of albumin positive cells had increased significantly in the H+C+ population reflecting the maturation of hepatoblasts to hepatocytes (FIG. 11D ). At this stage, Albumin expression was not detected in the other fractions (data not shown). On the contrary, under these conditions large numbers of cardiomyocytes were observed in H−C+ and double negative fractions (FIG. 11E ). Taken together these results suggest H+C+ fraction contains lineage restricted endodermal progenitors. - To examine the pancreatic potential of the sorted cell populations we cultured them with cytokines implicated in pancreatic specification (Hebrok et al., 1998; Kumar et al., 2003); retinoic acid, FGF4 and the sonic hedgehog inhibitor cyclopamine. H+C+ sorted cells generated clusters expressing markers of the emerging pancreatic buds, Pdx1 and Hnf4α with the highest efficiency, indicating their pancreatic differentiation potential in vitro (
FIG. 11 ). In contrast H+C− fractions did not give rise to co-expressing clusters. Limited activity (2 and 9-fold reduced cluster number respectively and reduced staining intensity) was detected from the H−C+ and H−C− fractions (FIG. 11F ), presumable reflecting the ability of non-committed cells to generate ADE upon further culture. Using undifferentiated ES cells as a starting population from this 5 day protocol did not generate any Pdx1 or Hnf4α positive cells (data not shown). When this was repeated with FGF10 (D'Amour et al., 2006) in place of FGF4, we obtained a similar (3-fold) quantitative enhancement in cluster formation in the H+C+ fraction (data not shown). - To evaluate the in vivo potency exhibited by cells in each H/C fraction following 7 days of differentiation they were sorted and immediately transplanted under the kidney capsule of adult mice. Nine transplants were performed for each sorted fraction. The H−C− transplants gave rise to large teratomas (5 out of 9) indicating this fraction still contains ES cells. In contrast, no teratomas were generated from the H+C+ transplants. The H+C+ cells in one animal gave rise to a small growth that contained endodermal derivatives indicated by the presence of ductal epithelial structures containing PAS positive secretory granules (
FIG. 11E ) Similar epithelial structures were observed in the growths from the H−C+ grafts (4 out of 9) and H+C− grafts (3 out of 9). The H−C+ transplants were the only ones (excluding the H−C− teratomas) that contained cartilage (FIG. 11E ), consistent with the notion that this fraction still contains cells competent to generate both mesoderm and endoderm. - During the early phase of further ADE differentiation we noticed that purified H+C+ ADE proliferated in the presence of FGF2, BMP4 and VEGF. To test whether these conditions could be used to expand H+C+ ADE progenitors we plated FACS purified fractions in defined media incorporating these cytokines. Initially all four population were able to grow, but only the H+C+ fraction contained significant numbers of Hex positive cells (
FIG. 12A ). While, these cultures were not homogenous, the H+C+ fractions were able to give rise to new Hex positive colonies upon repeated passaging (FIG. 12B ). The remaining three fractions were unable to survive four passages. The percentage of Hex positive cells in these cultures expanded over time, reacting as high as 96%. All four populations were seeded at approximately 10% confluence and the growth of the red population observed over time. Initially all four population were able to grow, but only the H+C+ fraction contained significant numbers of Hex positive cells (FIG. 6A ). While these cultures were not homogeneous, the H+C+ fractions were able to give rise to Hex positive colonies upon repeated passaging (FIG. 6B ) and the percentage of Hex positive cells in these cultures expanded over time, reaching as high as 96%. - To confirm the identity of cultures H+C+ cells, we examined the expression of the endoderm markers FoxA2, and E-cadherin, the ADE marker Cerberus and ES cell marker Oct4 at
passage 6. Indeed the vast majority of these cultures expressed Cerberus, FoxA2 and E cadherin, but not Oct4 (FIG. 12C ), indicating these cells represent a form of proliferating ADE progenitor. We also tested the ability of these cultures to further differentiate towards hepatic and pancreatic cell types.Passage 7 ADE cultures were differentiated as described above. Pancreatic differentiation produced clusters of Nkx2.2 and Pdx1 expression cells (FIG. 12D ) whereas hepatic differentiation resulted in field of cells with the morphology of immature hepatocytes expressing both AFP and albumin (FIG. 12D ). - The ability of H+C+ ADE to recapitulate foregut development in vivo and in vitro encouraged us to define the conditions required for the specification of this ADE population in vitro. In the presence of serum, H+C+ cells can only be derived in a multicellular aggregation suspension system (embryoid body). An adherent monolayer culture system would greatly improve our ability to investigate lineage specification in vitro. We therefore investigated whether it was possible to differentiate HexRS ES cells to ADE under defined conditions in both multicellular aggregation and a monolayer culture system.
- As anterior endoderm specification in vivo occurs during a series of complex morphogenetic movements, it is possible that differentiation cannot be uncoupled from the multicellular interactions present within an embryoid body. Mesendoderm induction has been reported using the serum-free media SF03 in an adherent monolayer culture system (Tada et al. 2005). However, these cultures appear to express significant levels of mesodermal marker genes and have no established positional identity. Moreover, the extent to which these cultures can be differentiated further towards specific endodermal lineages is not clear.
- Our attempts to culture HexRS cells in SF03 and activin, both as aggregates and in monolayer, resulted in cell death (Table 5,6). A very low percentage of live cells could be obtained in monolayer with SF03 by increasing the plating density and adding Bmp4 and EGF to the media, however, the very low cell yield obtained with this adapted SF03 protocol did not make it a viable option for in vitro culture of ADE (data not shown).
- Our previous experiments showed that switching to N2B27 serum-free media following serum induced the highest percentage of ADE (Table 2,
FIG. 3A ). We therefore tried N2B27 media, in combination with various growth factors, for the entire differentiation process. In both suspension and monolayer systems, culturing with N2B27 resulted in no induction of Hex at day 7 (Table 5,6). Changing the insulin content of the N2B27 media and the plating density of the starting culture did not alter this result (data not shown). - Following extensive optimisation, we found that a significant H+C+ cell population could be induced in both suspension culture and monolayer following a two-step serum-free differentiation protocol. Cells cultured in N2B27 plus Bmp4 for 2 days and then switched to SF03 plus activin and EGF for 5 days resulted in an average H+C+ induction of 13.3% and 5.7% in suspension and monolayer culture respectively. Interestingly, we found that adding either BMP4 or the Wnt signalling agonist, CHIR99021 during the first two days of differentiation significantly increased the total number of surviving cells at the end of the 7 day differentiation process (Table 7). Activin had a similar effect but only in aggregation culture. Surprisingly the addition of CHIR99021 had either no or only very minor effects on the total number of H+C+ cells produced. Conversely, Bmp4 increased the H+C+ percentage in monolayer culture during differentiation. The addition of Bmp4 and activin during the initial stage of differentiation gave the overall highest yield of H+C+ cells in both suspension and monolayer (Table 7).
- While we were able to obtain H+C+ positive populations in adherent monolayer culture, it was still significantly less efficient than aggregation differentiation. Since FGF signalling was recently shown to be required for transitions between ES cells and early states of differentiation in multiple lineages (Kunath et al. 2007; Stavridis et al. 2007), we tested whether the addition of FGF4 would improve our monolayer differentiation protocol. Inclusion of FGF4 in our differentiation protocol doubled the H+C+ cell number in monolayer cultures (Table 8). The HexRS expressing cells form colony-like growths as illustrated in
FIG. 8 . The ability to consistently obtain high levels of H+C+ cells in adherent monolayer cultures allows for the production of significant quantities of ADE from ES cells. This protocol was repeated on wild-type E14Tg2a ES cells and resulted in the same percentage of Cxcr4 single positive cells, indicating its potential for producing ADE from genetically unmodified ES cells (FIG. 8 ). - To obtain optimal levels of H+C+ induction, Fgf4 was required for the entire differentiation protocol (
FIG. 8 , Table 8). Interestingly, the number of CXCR4 expressing cells did not increase with the addition of Fgf4 indicating that the effect of Fgf4 appears to be specific to the induction of H+C+ double positive ADE, and not a general effect on mesendoderm induction (FIG. 8 ). We were initially surprised by this observation, as FGF signalling has been shown to mediate mesoderm, but not endoderm induction (reviewed in (Bottcher and Niehrs 2005)). To confirm a role for FGF signalling in H+C+ induction, we blocked FGF signalling using PD17304, a highly specific inhibitor of the FGF receptor (Mohammadi et al. 1998). PD17304 was added to cultures either from day 0-2, day 3-7 or for the entire differentiation protocol. The presence of PD17304 in our cultures appears to inhibit both C+ single positives and H+C+ double positives. When PD17304 was present for the first two days of differentiation, but then removed, we were able to generate a reduced number of both C+ and H+C+ cells (FIG. 8 ). However, when PD17304 was present for the entire protocol, we were unable to generate either population. Interestingly, when Fgf signalling is blocked for days 3-7, it resulted in a complete loss of both H+C+ and C+ populations and also dramatically compromised cell survival such that any cells that did survive were morphologically distinct from those obtained in the presence of activin and FGF4 (FIG. 8 ). Thus in the presence of FGF signalling, Activin and Bmp4, ES cells may progress towards mesendoderm, but when FGF signalling is blocked they shift towards a lineage that is unable to survive in these conditions. - We have also differentiated Human ES cells using the adherant monolayer protocol described herein and compared these cells to Human ES cells differentiated as described in two different established protocols for endoderm differentiation in the human ES cell line SHEF4. Similar results have been obtained with a second human ES cell line, SHEF6 (not shown). Cells were grown on mtesr (Stem Cell Technologies) and passaged with EDTA at a split ratio of 1:3. Cells were plated in mtesr and allowed to adhere overnight onto Matrigel (BD) and in the morning, media was changed to N2B27 and cells were differentiated as we have described for mouse ES cells (Morrison et al., 2008). The only exception being that cells were initially plated on Matrigel instead of gelatin. Cells were fixed at
0, 3, 5, 7 and 9 in 4% PFA. Results are shown inday FIG. 14 . - Interestingly, the activin buturate protocol (panel A) produces an abundance of Cxcr4 positive, mesendoderm (see discussion) and only isolated clumps of CER1 expressing ADE. The activin/Wnt3a protocol, while more efficient, was highly also highly heterogenous. Thus, while it has been proposed that CXCR could be used to enrich for endoderm in Human ES cell differentiation (D'Amour et al., 2005), it appears to mark a heterogenous population of cells that contains a small proportion of ADE. Based on this new human data and our previous work in the mouse, the marker Cxcr4 is an early primitive streak marker that is expressed by both mesoderm and endoderm precursors. Even in conjuction with c-kit (Gouon-Evans et al., 2006), Sox17 or Goosecoid (Yasunaga et al., 2005), these enrichments will at best produce the equivalent of anterior primitive streak mesendoderm, a population that has not yet fixed its positional identity and still contains mesodermal as well as endodermal progenitors, and array data contained herein indicates these markers will at best produce a mixed population of H−C+, and H+C+ cells).
- Panel C shows data from the differentiation protocol described herein. In mouse the defined monolayer differentiation protocol lasted 7 days, as Human ES cells are thought to potentially be related to a different state of embryonic development, we have done a carefully time course and analyzed differentiation by immuno-histochemistry for CXCR4, FOXA2, CLIC6. Human ES cells are thought to be a more mature epiblast like cell (slightly later stage of development (Brons et al., 2007; Tesar et al., 2007)) and the first stage of our protocol includes two factors, BMP4 and activin/Nodal recently shown to be involved in epiblast development (see discussion). As a result we thought this phase might promote synchronous growth and differentiation in HES cultures. This appears to be the case, as we are able to initiate this protocol at a relatively low density (left hand panel in C) and by
day 3, obtain a relatively homogenous population of CXCR4 expressing mesendoderm. Moreover, this population of cells appears to convert to a culture consisting predominantly of FoxA2, CER1 and CLIC6 positive cells. Taken together this data shows that our conditions, defined initially for mouse, are extremely effective at driving HES cells towards ADE. This represents the first demonstration of the generation of positionally defined endoderm from HES. - RN was prepared from HexRS ES cells, E14Tg2a ES cells and the four H/C sorted populations of differentiated HexRS ES cells from three independent experiments. 2 μg was used to prepare a probe for hybridsation to the Illumina Mouse-6-v1 Beadchip. The data was filtered so that any probe with a detection score <0.95 across all samples was removed from the analysis prior to log transformation (base2) and quantile normalisation. Initial inspection of the data suggested the samples clustered loosely according to when they were processed, therefore a model based analysis was used. Differentially expressed probes were identified using LIMMA (Smyth, 2004) modeling the sample effect and the date when the samples were processed once grouped. Data was also analyzed in a pairwise fashion to determine significant differentials between each of the four populations. This was used to produce a molecular signature for the H+C+ double positive population. This list contained 54 genes. We then refined this analysis by setting a fold filter on the list of H+C+ specific genes of 1.4 fold compared to H−C+ and 2.0 fold compared to H−C−. These filters were selected based on the behavior of the known ADE markers, Cerl HHex and Foxa1, 2 and 3. When we include this analysis, the list of A specific probe sets now numbers, 73. Primers were designed to the genes represented by these 73 probes and RT-PCR used to validate their expression in both the A population, and through out differentiation in response to activin. Based on this analysis, we were able to reduce this gene list to 47 genes that behave in a similar manner to either Hex or Cerl during in vitro differentiation. A number of genes are already known based on their appearance in the literature or their well defined roles in endoderm differentiation (e.g. HHex, Foxa3, Cerl). Our resulting markers contains the following markers which includes those already implicated as being involved in endoderm differentiation, but which may now used to identify and/or generate ADE: Sst, Pyy, Ghrl, Slc38a5, Chga, Exph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4sf2, 0610040B21Rik (aka txndc12), Apoa1, 2410021P16Rik (aka acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (aka Cmtm8), Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7, Sfrp5, Pga5, foxa1, foxa2, foxa3, Cerl, Hhex, Otx2, Gatn3. From this list, the following are cell surface markers, which may be particularly useful in identifying and/or generating ADE cells. We have gone on to analyze these markers and two commercially available antibodies of these markers (Clic6 and Frzd5) when used to shown their applicability as specific markers of ADE cells (see
FIG. 15 ). - The 5′ and 3′ targeting arms used for homologous recombination were described by Martinez Barbera et al., (2000) with an Asc1 and Pac1 site engineered downstream of the Hex ATG (a gift from Shankar Shrinivas). The RedStar gene was linked via an internal ribosome entry site (IRES) to the gene encoding blasticidin resistance (BSD) followed by a cytomegalovirus promoter-driven hygromycinR-thymidine kinase dual selection cassette flanked by loxP sites. This cassette was fused in frame with the ATG of Hex. Following electroporation into E14Tg2a ES cells correctly targeted clones were expanded and characterized by Southern Blot. The selection cassette was excised from three clones and two of them, HexRS1-2, were selected for further analysis. The ES
cell line Hex RS1 was injected into blastocysts to generate the HexRS mouse line. Mice were maintained on a mixed 129Ola×C57Bl/6 background. - Mouse ES cells were cultured according to Li et al., (1995). ADE was induced under serum-containing conditions using a 2-step protocol. ES cells were seeded onto non-coated 10 cm petri dishes (Sterilin) at a density of 5×103 cells/ml in GMEM supplemented as described in Li et al., (1995) except in the absence of LIF. EBs were harvested after two days by centrifugation and replated in N2B27 medium (StemCellSciences) supplemented with 20 ng/ml activin A (R&D) and 20 ng/ml EGF (R&D). This media was replaced again two days later. 10 ng/ml BMP4, 20 ng/ml activin A (R&D) and 1×10−5M all-trans retinoic acid (Sigma) were added where indicated.
- For ADE induction under serum-free conditions in suspension culture, ES cells were seeded as above in N2B27 medium supplemented with 10 ng/ml BMP4 and 20 ng/ml activin A. Following 2 days of culture, EBs were harvested and cultured as above in SF03 medium (Iwai Chemicals Company) supplemented with 0.1 mM 2-mercaptoethanol (2ME), 0.1% BSA (Invitrogen), 20 ng/ml activin A and 20 ng/ml EGF. 10 ng/ml FGF4 (R&D), 10 ng/ml Bmp4, 20 ng/ml activin A, 10 μM all-trans retinoic acid were added as indicated. For ADE induction in adherent monolayer culture, ES cells were seeded onto gelatin coated 6 well dishes (Iwaki) at a density of 1×104 cells/ml in N2B27 medium (StemCellSciences) supplemented with 10 ng/ml Bmp4, 20 ng/ml activin A and, where indicated, 10 ng/ml FGF4. Following 2 days of culture the media was replaced with SF03 medium supplemented with 0.1 mM 2-mercaptoethanol (2ME), 0.1% BSA (Invitrogen), 20 ng/ml activin A, 10 ng/ml FGF4 and 20 ng/ml EGF. The media was replaced every 2 days for the duration of the experiment. 100 ng/ml PD173074 (Sigma) or 25 μM SU5402 (Calbiochem) were added to the culture as indicated. FGF2, 5, 8b and 10 (R&D) were used at 10 ng/ml.
- For the induction of pancreatic progenitor cells, sorted cell fractions were seeded onto gelatin coated 3
cm 6 well dishes (Iwaki) at 2.5×105 cells/ml in N2B27 media supplemented with 10 ng/ml FGF4, 2 μM all trans retinoic acid and 0.25 μM KAAD-cyclopamine (Toronto Research Chemicals). Hepatocyte differentiation was as described in Gouon-Evans et al., (2006) except N2B27 was used as the base media at all stages and activin was not included, while BMP4, FGF2 and VEGF were. Induction of haematopoietic precursors was described by Kennedy and Keller, (2003). - For expansion of sorted cell fractions,
day 7 purified fractions were plated on gelatin in 24 well plates (Iwaki) in N2B27 medium supplemented with 0.5 mM ascorbic acid, 450 monothioglycerol (MTG), 50 ng/ml BMP4, 10 ng/ml FGF2 (R&D) and 10 ng/ml VEGF. 2.5×105 cells were plated into each well of which 10% appeared to be viable and adherent after 24 hours. These cultures were expanded until confluence (approximately 14 days) and all subsequent passaging was done approximately every 7 days using Trypsin-EDTA (Sigma), splitting either 1:2 or 1:3. RedStar fluorescence was observed daily by microscopy. Quantitation of HexRS expressing and antibody positive cells was done using fluorescent, phase and in the case of antibodies, DAPI overlays using Velocity 4.32 software (Improvision). Quantitation of the fold expansion was based on a 10-fold increase in cell number during the first passage multiplied by the split achieved at each passage to P7, a total of 216-fold. Cells were further differentiated as described above, except they were pre-treated for 24 hours in the above media supplemented with 20 ng/ml activin A. - FITC-conjugated rat anti-CD184 (Cxcr4), FITC-conjugated rat anti-CD31 and FITC conjugated rat anti-CD45 were purchased from BD Pharmingen. Cells were stained with Topro3-iodide (Invitrogen) to exclude dead cells from the analysis. Cells were analysed using a FACS Calibur (BD Biosciences) or sorted using a MoFlo MLS flow cytometer (DakoCytomation).
- Total RNA was prepared from a minimum of 1×104 cells using Trizol reagent (Invitrogen). 1 μg of RNA was used as a template for cDNA synthesis using Superscript III (Invitrogen). Real-time RT-PCR was performed using a LightCycler 480 (Roche) and LightCycler 480
SYBR Green 1 Master (Roche). Primers and PCR conditions are listed in supplementary table 7. - Sorted cells were seeded onto gelatin coated 24 well dishes (Iwaki). Adherence of cells was enhanced by centrifugation at 1200 rpm for 3 min. Sorted cells, monolayer differentiated cells and ES cells were washed in PBS, fixed in 4% paraformaldehyde for 10 min and permeabilised by washing in PBS supplemented with 0.1% Triton X (PBST). The following primary antibodies were used, all are anti-mouse: anti-Oct3/4, anti-Foxa2, anti-HNF-4a (Santa Cruz), anti-Cerl (R&D), anti-Gsc (Santa Cruz), anti Sox17 (Santa Cruz), anti-E-cadherin (Takara Bio Inc) anti-alpha fetoprotein (NeoMarkers), anti-Albumin (Bethyl laboratories inc), anti-Nkx 2.2 (Santa Cruz). Anti-Pdx1 was a gift from P. Serup or purchased from Santa Cruz. Alexa 488 and 568 (Molecular Probes) secondary antibodies were used.
- Cells were sorted at
day 7 and approximately 5-10×104 cells of each population were transplanted under the kidney capsule of adult 129 mice. Four to eight weeks after transplantation surviving mice were sacrificed and the kidneys removed and fixed in 4% paraformaldehyde (PFA). Following fixation the kidneys were embedded in paraffin wax, sectioned and stained with hematoxylin and eosin and PAS reagent (Sigma). - RNA was prepared from three independent experiments. 2 μg was used to prepare a probe for hybridsation to the Illumina Mouse-6-v1 Beadchip and the data deposited at Array Express (accession number E-TABM-515). The data was filtered so that any probe with a detection score <0.95 across all samples was removed from the analysis prior to log transformation (base2) and quantile normalisation. Initial inspection of the data suggested the samples clustered loosely according to when they were processed, therefore a model based analysis was used. Differentially expressed probes were identified using LIMMA (Smyth, 2004) modeling the sample effect and the date when the samples were processed once grouped. Data was also analyzed in a pairwise fashion to determine significant differentials between each of the four populations. This was used to produce a molecular signature for the H+C+ double positive population.
- We created ES cell lines containing the marker gene, RedStar (RS) (Knop et al., 2002) under the control of the Hex locus (
FIG. 16A , B). These cells allowed us to monitor the emergence of newly formed ADE cells during in vitro differentiation. Two independent clones with normal karotype, HexRedStar (HexRS) 1 and 2, were selected for further analysis. - To confirm that expression of RS protein accurately reflects endogenous Hex expression,
Hex RS1 ES cells were used to generate a HexRS mouse line. Embryos from HexRS/+ intercrosses are shown inFIG. 1C . Red fluorescence was detected in the anterior definitive endoderm, foregut as well as the liver and thyroid primordia, reflecting the expression of endogenous Hex protein as reported by Thomas et al., (1998). Weak expression was also observed in the inter-somitic vessels, endocardium of the heart and aspects of the dorsal aorta reflecting endogenous Hex expression in haematopoietic/endothelial precursors. Consistent with the previously described phenotype (Martinez Barbera et al., 2000) no live HexRS/HexRS mice were born (table 1) and HexRS/HexRS embryos appear to recapitulate the Hex null phenotype (FIG. 16C ). Importantly, no phenotype was detected in HexRS embryos or mice (FIG. 16C , table 1), indicating that any reduced Hex dosage in heterozygous cells will not impact on the ability of the cells to form ADE cells in vitro. - The secreted TGFβ ligand activin, has previously been shown to induce mesendoderm in Xenopus animal cap assays (reviewed in Okabayashi and Asashima, (2003)) and ES cells in culture (Kubo et al., 2004; Tada et al., 2005). To test the ability of activin to induce HexRS expression, ES cells were differentiated in a two-step aggregation culture system in serum containing media for 48 hr followed by serum-free media supplemented with activin for 5 days. Under these conditions, 6.8-8.6% of cells were RS positive (RS+) at day 7 (
FIG. 17A ). RT-PCR analysis on purified RS+ cell populations revealed they expressed Sox17, Cerl, E-cadherin and Gata4, indicating these cells have an endoderm identity (FIG. 17B ). - Hex is also expressed in mesodermal cell populations during early development including haemangioblast, angioblastic and endothelial precursor populations (Kubo et al., 2005; Rodriguez et al., 2001; Thomas et al., 1998). Flow cytometry analysis for the haematopoietic marker CD45 and endothelial marker CD31 showed that our activin treated cultures do not contain significant numbers of these cells (
FIG. 23A ), although the HRS cells can support haematopoetic differentiation (FIG. 17C ). Using a Sox-1 GFP reporter ES cell line we also confirmed that our cultures do not contain neuroectodermal cells (FIG. 23B ). - Isolation of Putative ADE Cells from Differentiating ES Cells
- In addition to marking early ADE specification, Hex is also expressed in the AVE. To distinguish ADE from AVE we used the chemokine receptor Cxcr4 that is expressed in definitive mesoderm and endoderm populations, but excluded from all yolk sac visceral endoderm (McGrath et al., 1999; Yasunaga et al., 2005). Optimisation of media, additives and cell density (summarised in table 2 and table 3) identified a regimen in which ES cells cultured in suspension for two days and then five days serum-free in the presence of activin and EGF yielded significant numbers of RS/Cxcr4 double positive (H+C+) cells as assessed by flow cytometry (
FIG. 17D ). As might be expected, antagonists of ADE specification in vivo, Bmp4 and retinoic acid, blocked the induction of the RS positive population (table 2), without effecting Cxcr4 induction (data not shown). - Differentiating ES Cell Cultures have a Gene Expression Profile Similar to ADE.
- To assess whether our differentiating ES cell cultures display a gene expression pattern similar to that observed during ADE induction we examined a range of markers during a timecourse (
FIG. 3A ). Epiblast markers, Oct4 (Pou5f1), Nodal and E-cadherin were expressed during the early phase of in vitro differentiation and then down-regulated concurrent with the expression of the early primitive streak markers Wnt3 and Brachyury (Tbra). Mixer-like 1 (Mixl1), Goosecoid (Gsc) and Foxa2, which define the streak region and prospective axial mesendoderm (notochord, prechordal plate and ADE), began to be expressed atday 3, and peaked at day 5-6. Importantly, genes expressed in the ADE,Cerberus 1 homologue (Cer1), Hex and Sox17, appeared between days 5-7 in our cultures. Although Mixl1 and Wnts have been implicated in endoderm induction (Hart et al., 2002) (Lickert et al., 2002), they are not expressed in definitive endoderm. In our culture conditions these markers are significantly expressed from day 3-5 and are then down regulated concordant with the emergence of markers of ADE. Thus, the dynamic pattern of expression evident in our differentiating ES cell cultures is similar to that during ADE specification in vivo. Furthermore, Cxcr4 and Hex protein is present from 4 and 5 respectively (day FIG. 18A , B), consistent with the expression of these markers in vivo (McGrath et al., 1999; Yasunaga et al., 2005; Yusuf et al., 2005). This suggests that the Cxcr4 single positive population may represent non-committed mesendoderm or a mixture of mesoderm and endoderm precursors, whereas the H+C+ population is committed ADE. The sequential expression of a number of markers observed inFIG. 18A is also consistent with differentiation towards anterior definitive endoderm rather than anterior visceral endoderm. - Isolation and Analysis of Hex+Cxcr4+ Cells Confirm their Similarity to ADE
- Differentiating cultures were sorted into four populations based on RS (H) and Cxcr4 (C) protein levels and profiled by quantitative RT-PCR, microarrays and immunomarkers.
- Levels of both Hex and Cxcr4 mRNA were highest in the H+C+ cell fraction confirming the success of cell sorting. Surprisingly, we found that the transcript level of Hex in the H+C− and H−C+ populations were very similar and significantly less than the H+C+ population (
FIG. 19A ). This may reflect the time lag between the production of Hex transcript and the presence of RS protein. - The H+C+ cell population expressed the highest levels of E-cadherin, Cxcr4, Cer1 and Hex transcript (
FIG. 19A ), all of which are expressed in the ADE. Importantly, the expression of markers Tbra, Wnt3 and Mixl1 that are associated with the early primitive streak but not the ADE, were low in the H+C+ population. Markers of posterior endoderm (Cdx2), paraxial mesoderm (Meox1) and parietal endoderm (Sox7) were only detected at very low levels during differentiation and barely detectable in the H+C+ cell population (FIG. 19A ). In accordance with the PCR data, immunostaining showed almost all of the H+C+ cells to express the ADE marker Cerl, and the definitive endoderm markers Foxa2 and E-cadherin, but not the ES cell marker Oct4 (FIG. 19B ). - Microarray analysis of the four Hex/Cxcr4 cell fractions sorted from
day 7 differentiated cultures showed that these fractions cluster close to each other and not to the samples derived from undifferentiated ES cell cultures (FIG. 19C ). The close clustering of the two ES cell lines to each other indicates there is little difference in gene expression in HexRS heterozygote and wild-type ES cells. Of the differentiated populations, the H+C+ population is most closely related to the H−C+ population, consistent with the view that the H+C+ ADE cells arises from the H−C+ mesendodermal cell population. Hierarchical clustering of the differentially expressed genes identified in a pairwise analysis of all four populations is shown inFIG. 4D . This analysis supports the expression analysis inFIG. 4A and gives a clear indication of the unique signature of the H+C+ fraction, which expresses a significant number of ADE markers such as Cerl,Frizzled 5, Lhx1 (Lim1), Otx2 and a number of novel gene products. Quantitative RT-PCR validation supports the identity of this expression cluster as unique to the H+C+ fraction (FIG. 19E ). We conclude from this data that the H+C+ population is enriched for the expression of anterior markers, normally expressed in the ADE. - Since both pancreas and liver arise from ADE, we tested the hepatic potential of the H+C+ population using a method adapted from Gouon-Evans et al., (2006), which involves up to 13 additional days of hepatocyte differentiation (
total culture period 20 days). Byday 12, AFP positive hepatoblasts were apparent in the H+C+ cell fraction and while some AFP expression was observed in all four fractions, it was significantly higher in the double positive fraction (FIG. 20C ). No AFP positive cells were formed from non-induced ES cells cultured in the same conditions (data not shown). This trend was already apparent at the RNA level fromday 9, where the H+C+ fraction expressed at least 3-4 fold higher levels of Krt19, Albumin, AFP, Hnf6 and Foxa2 transcript than any of the other fractions (FIG. 20B ). The pattern of Hex expression during the differentiation period is also consistent with its later expression in the liver primordia (Thomas et al., (1998) andFIG. 16C ) with RS protein detected atday 9 in forming hepatocytes but only in the H+C+ and weakly in H+C− sorted cells (FIG. 20A ). Flow cytometry at this stage of differentiation also supports the quantitative capacity of the H+C+ fraction to differentiate towards liver, as 62% of the early hepatocyte cultures resulting from H+C+ sorted cells were Hex positive, whereas only 11% of the H−C+ population were weakly fluorescent (FIG. 20A ). Byday 20, AFP expression was reduced and the number of Albumin positive cells had increased significantly in the H+C+ population reflecting the maturation of hepatoblasts to hepatocytes (FIG. 20D ). At this stage, Albumin expression was not detected in the other fractions (data not shown). On the contrary, under these conditions large numbers of cardiomyocytes were observed in H−C+ and double negative fractions (FIG. 20E ). Taken together these results suggest H+C+ fraction contains lineage restricted endodermal progenitors. - To examine the pancreatic potential of the sorted cell populations we cultured them with cytokines implicated in pancreatic specification (Hebrok et al., 1998; Kumar et al., 2003); retinoic acid, FGF4 and the sonic hedgehog inhibitor cyclopamine. H+C+ sorted cells generated clusters expressing markers of the emerging pancreatic buds, Pdx1 and Hnf4α with the highest efficiency, indicating their pancreatic differentiation potential in vitro (
FIG. 20F ). In contrast H+C− fractions did not give rise to co-expressing clusters. Limited potential was detected from the H−C+ and H−C− fractions with 2 and 9-fold reduced cluster number respectively and reduced Pdx1 and Hnf4α immunostaining intensity for both (FIG. 20F , H−C− data not shown), presumable reflecting some ability of non-committed cells to generate ADE upon further culture. Using undifferentiated ES cells as a starting population for this 5-day protocol did not generate any Pdx1 or Hnf4α positive cells (data not shown). When this protocol was repeated substituting FGF10 for FGF4 based on a human ES cell differentiation protocol described by D'Amour et al., (2006), a similar (3-fold) quantitative enhancement in cluster formation in the H+C+ fraction was obtained (data not shown). - To evaluate the in vivo potency exhibited by cells in each H/C fraction they were sorted at
day 7 of differentiation and immediately transplanted under the kidney capsule of adult mice. Nine transplants were performed for each sorted fraction. The H−C− transplants gave rise to large teratomas (5 out of 9) indicating these fractions still contained some ES cells. In contrast, no teratomas were generated from the H+C+ transplants. The H+C+ cells in one animal (1 out of 9) gave rise to a small growth that contained endodermal derivatives indicated by the presence of ductal epithelial structures containing PAS positive secretory granules (FIG. 20G ). Similar epithelial structures were observed in the growths from the H−C+ grafts (4 out of 9) and H+C− grafts (3 out of 9). The H−C+ transplants were the only ones (excluding the H−C− teratomas) that contained cartilage (FIG. 5G ), consistent with the notion that this fraction still contains cells competent to generate both mesoderm and endoderm. - During the early phase of further ADE differentiation we noticed that purified H+C+ ADE proliferated in the presence of FGF2, BMP4 and VEGF. To test whether these conditions could be used to expand H+C+ ADE progenitors the four H/C FACS purified fractions were plated in defined media incorporating these cytokines. All four populations were seeded at approximately 10% confluence and the growth of the red population observed over time. Initially all four population were able to grow, but only the H+C+ fraction contained significant numbers of Hex positive cells (
FIG. 21A ). While these cultures were not homogeneous, the H+C+ fractions were able to give rise to Hex positive colonies upon repeated passaging (FIG. 21B ) and the percentage of Hex positive cells in these cultures expanded over time, reaching as high as 96% (FIG. 24 ). Cultures were routinely split 1:2 or 1:3 (see methods) for 8 passages to generate cultures that were a minimum of 90% Hex positive bypassage 7. Based on these figures, this constituted a 1944-fold expansion of putative ADE. In contrast, cells from the other three fractions (H+C−, H−C+ and H−C−) were unable to survive multiple passages. To confirm the identity of cultured H+C+ cells, we examined the expression of the endoderm markers Foxa2 and E-cadherin, the ADE marker Cerl and ES cell marker Oct4 atpassage 5. The majority of cells within these cultures expressed Cerl, Foxa2 and E-cadherin, but not Oct4 (FIG. 21C ), indicating these cells represent a form of ADE progenitor. To confirm that these cultures were predominantly ADE we quantitated the percentage of cells expressing these markers and found that 79% (+/−1.4) expressed Cerl, 71% (+/−14) expressed Hex and 54% (+/−2.8%) expressed E-cadherin. Moreover, quantitation of the DAPI staining shown inFIG. 6 and similar images indicated that the E-cadherin expressing fraction contained greater than 3-fold more mitotic nuclei than E-cadherin negative fraction, supporting the notion that the endodermal progenitors in these cultures are the major proliferating cell type. - The ability of these cultures at
passage 7 to further differentiate towards hepatic and pancreatic cell types was tested as described above. Pancreatic differentiation produced clusters of Nkx2.2 and Pdx1 expressing cells (FIG. 21D ), whereas hepatic differentiation resulted in fields of cells with the morphology of immature hepatocytes expressing both AFP and Albumin (FIG. 21D ). - Taken together these results indicate that while the overall differentiation efficiency of ES cells to ADE using our strategy may not exceed the 20% of the total culture, the ability to sort these ADE cells, expand and maintain them as progenitors, greatly enhances the utility of our approach.
- Mechanistic studies on lineage specification in the mesendoderm require defined serum-free conditions and would benefit from an adherent monolayer culture system. As ADE specification in vivo occurs during a series of complex morphogenetic movements, it is possible that differentiation cannot be uncoupled from the multi-cellular interactions present within an embryoid body. Mesendoderm induction in the absence of positional specification has been reported using the serum-free media SF03 in an adherent monolayer culture system (Tada et al., 2005). Initial attempts to culture HexRS cells in SF03 and activin, both as aggregates and in monolayer, did not yield sufficient number of viable cells for in vitro culture of ADE (table 5).
- Given our results with N2B27 media (
FIGS. 2A and D) we tried various permutations of N2B27, SF03 and growth factors (table 5). Following extensive optimisation, we found that a significant H+C+ cell population could be induced in both suspension culture and monolayer following a two-step serum-free differentiation protocol. Cells cultured in N2B27 with activin and Bmp4 for 2 days and then switched to SF03 with activin and EGF for 5 days gave the overall highest yield of H+C+ cells in both suspension and monolayer (table 5, 10). - As we were able to obtain H+C+ positive populations in adherent monolayer culture under defined conditions, albeit at lower efficiency than aggregation differentiation (6% versus 13%), this afforded the possibility of identifying additional determinants. A requirement for FGF signalling for transitions between ES cells and early states of differentiation in multiple lineages has recently been shown (Kunath et al., 2007; Stavridis et al., 2007). We tested whether the addition of FGF4 would improve our monolayer differentiation protocol. Inclusion of FGF4 doubled the H+C+ cell number in monolayer cultures (
FIG. 22A and table 11). The HexRS expressing cells appeared to cluster, forming colony-like growths as shown inFIG. 22B . This protocol was repeated on wild-type E14Tg2a ES cells and resulted in colonies with similar morphology that contained the same percentages of Cxcr4 single positive cells, indicating its potential for producing ADE from genetically unmodified ES cells (FIG. 22A ). - A requirement for FGF signalling during ADE specification was surprising, as FGF signalling has been shown to mediate mesoderm, but not endoderm induction (reviewed in Bottcher and Niehrs, (2005)). To determine whether signalling downstream of FGF was required for the differentiation of ES cells to ADE, we used a selective inhibitor of the FGF receptor, PD173074 (Mohammadi et al., 1998). When PD173074 was present for the first two days of differentiation, but then removed, we observed a reduced number of both C+ and H+C+ cells (
FIG. 22A and table 11). However, when PD173074 was present for the entire protocol, we were unable to generate either population. Interestingly, when FGF signalling is blocked for days 3-7, it resulted in a complete loss of both H+C+ and C+ populations, altered morphologies and also dramatically compromised cell viability (FIG. 7B ). Similar results were obtained with a second FGF inhibitor, SU5402 (Mohammadi et al., 1997) (FIG. 25 ). - Despite an overall requirement for FGF signalling in differentiation towards mesoderm and endoderm, the addition of FGF4 appeared to promote specifically H+C+ double positive ADE (
FIG. 22A ). Thus, rather than promoting overall levels of differentiation towards both mesoderm and endoderm lineages, the addition of exogenous FGF4 to these cultures led to the induction of anterior markers Cer1 and Gsc and increased the expression of Foxa2 and Sox17 (FIG. 22C , D), while suppressing levels of both mesodermal and primitive streak gene expression (FIG. 22D ). - The action of FGF on the initial formation of ES cell derived ADE is also reflected in the optimal timing of FGF addition.
FIG. 22E shows that when FGF4 is added solely during the second phase of differentiation we obtain up to 20% H+C+ ADE. Interestingly, when exogenous FGF4 was added only between days 3-4, the time window in which these cultures have neither mesodermal or endodermal identity, there was a significant effect on the production of ADE (FIG. 22E , F). We also tested FGF2, 5, 8b, and 10 for activity in this protocol and found that only FGF2 had a similar ability to promote H+C+ ADE (FIG. 25 ). - We have described the production of a defined population of ADE cells from embryonic stem cells. This represents the first derivation and purification of endoderm with specific anterior-posterior (A-P) properties in vitro. We have demonstrated increased potency of these cells to differentiate towards liver and pancreas and identified a condition in which Hex expressing ADE-like progenitors can be propagated in culture. Through our efforts to establish defined conditions for ADE specification we have uncovered a novel role for FGF signalling in endoderm differentiation.
- Previously reported mesendoderm induction protocols employed markers normally expressed in either the node (Gsc) or primitive streak (Tbra). Refinements to these approaches have involved a second marker believed to represent a more defined lineage such as Foxa2, a pan axial mesendoderm marker or Sox17, a transient marker of all endoderm (Kanai-Azuma et al., 2002). Despite these refinements, the resulting population still lack any A-P identity. By using the HexRS reporter cell line in conjunction with Cxcr4 we have been able to purify an in vitro equivalent to ADE. This cell fraction appears to be ADE as judged by the following criteria: First, the sequence of gene expression in our ES cell cultures mirrors that which occurs during definitive endoderm differentiation in vivo. Second, the H+C+ cells express high levels of ADE markers and very low levels of markers of the primitive streak, mesoderm and ES cells and third these cells have the greatest capacity to differentiate further towards derivatives of the ADE, liver and pancreas. Thus, the ability to identify and purify ES cell derived ADE is an important platform for accurate recapitulation of in vivo differentiation.
- We have also managed to couple the ability to generate ES cell derived ADE with the capacity to expand this population in vitro. While this population is not entirely homogeneous it appears to contain very high levels of anterior endoderm in the form of Hex and Cer1 expressing populations (between 70-90%) indicating the exciting possibility that our culture system may ultimately afford the generation of self-renewing lineage restricted anterior endoderm progenitor cell lines. Nonetheless the ability to grow and expand sorted ADE cells as an endodermal progenitor population greatly enhances the utility of ES derived ADE as a platform for further differentiation.
- During the development of monolayer differentiation towards ADE we observed an interesting dependence on BMP4 and activin for cell survival and/or proliferation in the serum-free differentiating cultures (Supplementary Table 5). As this particular requirement appears limited to the early phase of differentiation, we believe this activity to be related to the requirement for these pathways in epiblast growth. Both Nodal (Camus et al., 2006; Mesnard et al., 2006) and BMP (Di-Gregorio et al., 2007) signalling have recently been shown to be required for the development and growth of the primitive ectoderm.
- We were initially surprised to discover that FGF signalling promoted ADE production from ES cells since FGF signalling is typically associated with mesoderm induction and cell migration during gastrulation (Casey et al., 1998; Ciruna and Rossant, 2001; Mizoguchi et al., 2006; Poulain et al., 2006; Rodaway et al., 1999). In lower vertebrates FGF signalling has also been shown to enhance mesoderm differentiation while suppressing endoderm and this view has also been supported by analysis of the FGFR1 mutant mouse embryos (Deng et al., 1994; Yamaguchi et al., 1994). However, there is also evidence to support a role for FGF signalling in the specification of anterior mesendoderm, as FGFR1(−/−) ES cells are unable to contribute to the endoderm (Ciruna et al., 1997). Previously this defect had been attributed to an inability of the FGFR1(−/−) ES cells to traverse the primitive streak and participate in gastrulation movements. However, our demonstration that FGF signalling can potentiate anterior endoderm differentiation in defined monolayer culture suggest these observations reflect a more fundamental requirement for FGF signalling in the specification of the anterior most gastrulating tissue in embryogenesis. This role might be mediated through direct induction of ADE target genes or alternatively through selective cell survival and/or proliferation.
- Our ability to produce ADE cells in a chemically-defined, monolayer culture system represents a significant step towards the uncoupling of lineage specification from the complex morphogenetic movements and context dependent positional cues that occur in vivo during gastrulation. It also represents an important intermediate step in the in vitro generation of mature cell lineages from foregut endoderm.
-
- Angerer L M, Angerer R C (2000) Animal-vegetal axis patterning mechanisms in the early sea urchin embryo. Dev Biol 218(1): 1-12.
- Bagutti C, Wobus A M, Fassler R, Watt F M (1996) Differentiation of embryonal stem cells into keratinocytes: comparison of wild-type and
beta 1 integrin-deficient cells. Dev Biol 179(1): 184-196. - Beck F, Erler T, Russell A, James R (1995) Expression of Cdx-2 in the mouse embryo and placenta: possible role in patterning of the extra-embryonic membranes. Dev Dyn 204(3): 219-227.
- Beddington R S P, Robertson E J (1998) Anterior patterning in mouse. Trends Genet 14(7): 277-284.
- Beddington R S P, Robertson E J (1999) Axis development and early asymmetry in mammals. Cell 96(2): 195-209.
- Bennett C N, Ross S E, Longo K A, Bajnok L, Hemati N et al. (2002) Regulation of Wnt signaling during adipogenesis. J Biol Chem 277(34): 30998-31004.
- Bottcher R T, Niehrs C (2005) Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26(1): 63-77.
- Brickman J M, Jones C M, Clements M, Smith J C, Beddington R S P (2000) Hex is a transcriptional repressor that contributes to anterior identity and suppresses Spemann organiser function. Development 127(11): 2303-2315.
- Brons, I. G., Smithers, L. E., Trotter, M. W., Rugg-Gunn, P., Sun, B., Chuva de Sousa Lopes, S., Howlett, S. K., Clarkson, A., Ahrlund-Richter, L., Pedersen, E. A., et al. (2007). Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature.
- Camus A, Perea-Gomez A, Moreau A, Collignon J (2006) Absence of Nodal signaling promotes precocious neural differentiation in the mouse embryo. Dev Biol 295(2): 743-755.
- Casey E S, O'Reilly M A, Conlon F L, Smith J C (1998) The T-box transcription factor Brachyury regulates expression of eFGF through binding to a non-palindromic response element. Development 125(19): 3887-3894.
- Chen Y, Schier A F (2001) The zebrafish Nodal signal Squint functions as a morphogen. Nature 411(6837): 607-610.
- Ciruna B, Rossant J (2001) FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev Cell 1(1): 37-49.
- Ciruna B G, Schwartz L, Harpal K, Yamaguchi T P, Rossant J (1997) Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. Development 124(14): 2829-2841.
- Conti L, Pollard S M, Gorba T, Reitano E, Toselli M et al. (2005) Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3(9): e283.
- Cornell R A, Musci T J, Kimelman D (1995) FGF is a prospective competence factor for early activin-type signals in Xenopus mesoderm induction. Development 121(8): 2429-2437.
- D'Amour K A, Bang A G, Eliazer S, Kelly O G, Agulnick A D et al. (2006) Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24(11): 1392-1401.
- D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., and Baetge, E. E. (2005). Efficient differentiation of human embryonic stem cells to definitive endoderm.
Nat Biotechnol 23, 1534-1541. - Davidson E H, Rast J P, Oliveri P, Ransick A, Calestani C et al. (2002) A genomic regulatory network for development. Science 295(5560): 1669-1678.
- Deng C X, Wynshaw-Boris A, Shen M M, Daugherty C, Ornitz D M et al. (1994) Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 8(24): 3045-3057.
- Deutsch G, Jung J, Zheng M, Lora J, Zaret K S (2001) A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 128(6): 871-881.
- Dyson S, Gurdon J B (1998) The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors. Cell 93(4): 557-568.
- Finley K R, Tennessen J, Shawlot W (2003) The mouse secreted frizzled-related
protein 5 gene is expressed in the anterior visceral endoderm and foregut endoderm during early post-implantation development. Gene Expr Patterns 3(5): 681-684. - Friedman J R, Kaestner K H (2006) The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci 63(19-20): 2317-2328.
- Gadue P, Huber T L, Paddison P J, Keller G M (2006) Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. Proc Natl Acad Sci USA 103(45): 16806-16811.
- Gouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler C I et al. (2006) BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nat Biotechnol 24(11): 1402-1411.
- Green J B, Smith J C (1990) Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate. Nature 347(6291): 391-394.
- Hart A H, Hartley L, Sourris K, Stadler E S, Li R et al. (2002) Mixl1 is required for axial mesendoderm morphogenesis and patterning in the murine embryo. Development 129(15): 3597-3608.
- Hay, D. C., Fletcher, J., Payne, C., Terrace, J. D., Gallagher, R. C. J., Snoeys, J., Black, J. R., Wojtacha, D., Samuel, K., Hannoun, Z., et al. (2008a). Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl
Acad Sci USA 105, doi10.1073pnas.0806522105. - Hay, D. C., Zhao, D., Fletcher, J., Hewitt, Z. A., McLean, D., Urruticoechea-Uriguen, A., Black, J. R., Elcombe, C., Ross, J. A., Wolf, R., et al. (2008b). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem cells 26, 894-902.
- Hebrok M, Kim S K, Melton D A (1998) Notochord repression of endodermal Sonic hedgehog permits pancreas development. Genes Dev 12(11): 1705-1713.
- Huber O, Bierkamp C, Kemler R (1996) Cadherins and catenins in development. Curr Opin Cell Biol 8(5): 685-691.
- Kanai-Azuma M, Kanai Y, Gad J M, Tajima Y, Taya C et al. (2002) Depletion of definitive gut endoderm in Sox17-null mutant mice. Development 129(10): 2367-2379.
- Kennedy M, Keller G M (2003) Hematopoietic commitment of ES cells in culture. Methods Enzymol 365: 39-59.
- Kinder S J, Tsang T E, Wakamiya M, Sasaki H, Behringer R R et al. (2001) The organizer of the mouse gastrula is composed of a dynamic population of progenitor cells for the axial mesoderm. Development 128(18): 3623-3634.
- Knop M, Barr F, Riedel C G, Heckel T, Reichel C (2002) Improved version of the red fluorescent protein (drFP583/DsRed/RFP). Biotechniques 33(3): 592, 594, 596-598 passim.
- Kubo A, Chen V, Kennedy M, Zahradka E, Daley G Q et al. (2005) The homeobox gene HEX regulates proliferation and differentiation of hemangioblasts and endothelial cells during ES cell differentiation. Blood 105(12): 4590-4597.
- Kubo A, Shinozaki K, Shannon J M, Kouskoff V, Kennedy M et al. (2004) Development of definitive endoderm from embryonic stem cells in culture. Development 131(7): 1651-1662.
- Kumar M, Jordan N, Melton D, Grapin-Botton A (2003) Signals from lateral plate mesoderm instruct endoderm toward a pancreatic fate. Dev Biol 259(1): 109-122.
- Kunath T, Saba-El-Leil M K, Almousailleakh M, Wray J, Meloche S et al. (2007) FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development 134(16): 2895-2902.
- LaBonne C, Whitman M (1994) Mesoderm induction by activin requires FGF-mediated intracellular signals. Development 120(2): 463-472.
- Lawson K A, Pedersen R A (1987) Cell fate, morphogenetic movement and population kinetics of embryonic endoderm at the time of germ layer formation in the mouse. Development 101(3): 627-652.
- Li M, Sendtner M, Smith A (1995) Essential function of LIF receptor in motor neurons. Nature 378(6558): 724-727.
- Lickert H, Kutsch S, Kanzler B, Tamai Y, Taketo M M et al. (2002) Formation of multiple hearts in mice following deletion of beta-catenin in the embryonic endoderm. Dev Cell 3(2): 171-181.
- Lu C C, Brennan J, Robertson E J (2001) From fertilization to gastrulation: axis formation in the mouse embryo. Curr Opin Genet Dev 11(4): 384-392.
- Maduro M F, Meneghini M D, Bowerman B, Broitman-Maduro G, Rothman J H (2001) Restriction of mesendoderm to a single blastomere by the combined action of SKN-1 and a GSK-3beta homolog is mediated by MED-1 and -2 in C. elegans. Mol Cell 7(3): 475-485.
- Martinez Barbera J P, Clements M, Thomas P, Rodriguez T, Meloy D et al. (2000) The homeobox gene Hex is required in definitive endodermal tissues for normal forebrain, liver and thyroid formation. Development 127(11): 2433-2445.
- McGrath K E, Koniski A D, Maltby K M, McGann J K, Palis J (1999) Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 213(2): 442-456.
- Mesnard D, Guzman-Ayala M, Constam D B (2006) Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. Development 133(13): 2497-2505.
- Mizoguchi T, Izawa T, Kuroiwa A, Kikuchi Y (2006) Fgf signaling negatively regulates Nodal-dependent endoderm induction in zebrafish. Dev Biol 300(2): 612-622.
- Mohammadi M, Froum S, Hamby J M, Schroeder M C, Panek R L et al. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J 17(20): 5896-5904.
- Morrison, G. M., Oikonomopoulou, I., Portero, R., and Brickman, J. M. (2008). Anterior Definitive Endoderm from ES cells reveals a novel role for FGF signaling. Cell Stem Cell In Press.
- Nishikawa S I, Nishikawa S, Hirashima M, Matsuyoshi N, Kodama H (1998) Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development 125(9): 1747-1757.
- Norris D P, Brennan J, Bikoff E K, Robertson E J (2002) The Foxh1-dependent autoregulatory enhancer controls the level of Nodal signals in the mouse embryo. Development 129(14): 3455-3468.
- Offield M F, Jetton T L, Labosky P A, Ray M, Stein R W et al. (1996) PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122(3): 983-995.
- Okabayashi K, Asashima M (2003) Tissue generation from amphibian animal caps. Curr Opin Genet Dev 13(5): 502-507.
- Perea-Gomez A, Shawlot W, Sasaki H, Behringer R R, Ang S (1999) HNF3beta and Lim1 interact in the visceral endoderm to regulate primitive streak formation and anterior-posterior polarity in the mouse embryo. Development 126(20): 4499-4511.
- Poulain M, Furthauer M, Thisse B, Thisse C, Lepage T (2006) Zebrafish endoderm formation is regulated by combinatorial Nodal, FGF and BMP signalling. Development 133(11): 2189-2200.
- Robb L, Hartley L, Begley C G, Brodnicki T C, Copeland N G et al. (2000) Cloning, expression analysis, and chromosomal localization of murine and human homologues of a Xenopus mix gene. Dev Dyn 219(4): 497-504.
- Rodaway A, Takeda H, Koshida S, Broadbent J, Price B et al. (1999) Induction of the mesendoderm in the zebrafish germ ring by yolk cell-derived TGF-beta family signals and discrimination of mesoderm and endoderm by FGF. Development 126(14): 3067-3078.
- Rodriguez T A, Casey E S, Harland R M, Smith J C, Beddington R S (2001) Distinct enhancer elements control Hex expression during gastrulation and early organogenesis. Dev Biol 234(2): 304-316.
- Tesar, P. J., Chenoweth, J. G., Brook, F. A., Davies, T. J., Evans, E. P., Mack, D. L., Gardner, R. L., and McKay, R. D. (2007). New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature.
- Shawlot W, Behringer R R (1995) Requirement for Lim1 in head-organizer function [see comments]. Nature 374(6521): 425-430.
- Smyth G K (2004) Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments. Statistical Applications in Genetics and Molecular Biology 3(1):
Article 3. - Stavridis M P, Lunn J S, Collins B J, Storey K G (2007) A discrete period of FGF-induced Erk1/2 signalling is required for vertebrate neural specification. Development 134(16): 2889-2894.
- Sun X, Meyers E N, Lewandoski M, Martin G R (1999) Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev 13(14): 1834-1846.
- Tada S, Era T, Furusawa C, Sakurai H, Nishikawa S et al. (2005) Characterization of mesendoderm: a diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture. Development 132(19): 4363-4374.
- Thomas P, Beddington R (1996) Anterior primitive endoderm may be responsible for patterning the anterior neural plate in the mouse embryo. Curr Biol 6(11): 1487-1496.
- Thomas P, Brickman J M, Popperl H, Krumlauf R, Beddington R S P (1997) Axis duplication and anterior identity in the mouse embryo. Cold Spring Harb Symp Quant Biol 62: 115-125.
- Thomas P Q, Brown A, Beddington R S P (1998) Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early transient marker of endothelial cell precursors. Development 125(1): 85-94.
- Vincent S D, Dunn N R, Hayashi S, Norris D P, Robertson E J (2003) Cell fate decisions within the mouse organizer are governed by graded Nodal signals. Genes Dev 17(13): 1646-1662.
- Wells J M, Melton D A (2000) Early mouse endoderm is patterned by soluble factors from adjacent germ layers. Development 127(8): 1563-1572.
- Yamaguchi T P, Harpal K, Henkemeyer M, Rossant J (1994) fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 8(24): 3032-3044.
- Yasunaga M, Tada S, Torikai-Nishikawa S, Nakano Y, Okada M et al. (2005) Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. Nat Biotechnol 23(12): 1542-1550.
- Ying Q L, Nichols J, Chambers I, Smith A (2003) BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115(3): 281-292.
- Yusuf F, Rehimi R, Dai F, Brand-Saberi B (2005) Expression of chemokine receptor CXCR4 during chick embryo development. Anat Embryol (Berl) 210(1): 35-41.
- Zamparini A L, Watts T, Gardner C E, Tomlinson S R, Johnston G I et al. (2006) Hex acts with beta-catenin to regulate anteroposterior patterning via a Groucho-related co-repressor and Nodal. Development 133(11): 3709-3722.
-
TABLE 1 HexRS mouse genotypes arising from HexRS/+ intercrosses. genotype number percentage expected percentage +/+ 114 39 33 +/− 176 61 66 −/− 0 0 0 -
TABLE 2 optimisation in serum day 0-2. Day 0-2 Day 3-7 media FCS A E B4 RA GI media FCS A E B4 RA GI H+C+ % GMEM + − − − − − GMEM + + − − − − 0.00 GMEM + − − − − − N2B27 − − − − − − 0.00 GMEM + − − − − − N2B27 − + − − − − 9.95 ± 4.62 GMEM + − − − − − N2B27 − + + − − − 18.72 ± 4.08 GMEM + − − + − − N2B27 − + + − − − 0.61 GMEM + − − + − − N2B27 − + + + − − 0.39 GMEM + − − − − − N2B27 − + + + − − 0.60 ± 0.61 GMEM + − − − − − N2B27 − + + − + − 0.73 GMEM + − − − − + N2B27 − + + − − − 0.05 ± 0.03 GMEM + − − − − + N2B27 − + + − − + 0.83 GMEM + − − − − − N2B27 − + + − − + 0.00 GMEM + − − − − − SF03 − + + − − − 4.51* GMEM + − − − − − SF03 − + − − − − Dead *= very low cell survival -
TABLE 3 Cell density Day 0-2 Day 3-7 Cell density H+C+ % GMEM + 10% FCS N2B27 + activin 1 × 105/ml 0.68 GMEM + 10% FCS N2B27 + activin 5 × 104/ml 1.32 GMEM + 10% FCS N2B27 + activin 5 × 103/ml 15.21 -
TABLE 4 Kidney capsule grafts. cell explants no. growths recovered germ layers present fraction performed small medium large ecto meso endo H+ C+ 9 1 − − − − + H+C− 9 − 3 − − − + H− C+ 9 1 1 2 − + + H−C− 9 − − 5 + + + -
TABLE 5 Optimisation of ADE production using chemically defined media in aggregation culture. Day 0-2 Day 3-7 media Act Bmp4 EGF GI media Act Bmp4 EGF GI H+C+ s.d. SF03 − − − − SF03 − − − − dead SF03 − − − − SF03 + − − − dead SF03 + + − − SF03 + − + − dead SF03 − + − − SF03 + − + − dead SF03 + − − − SF03 + − − − dead N2B27 − − − − N2B27 − − − − dead N2B27 − + − − N2B27 + − + − 1.18 N2B27 − + + − N2B27 + − − − 1.46 N2B27 − + + − N2B27 + − + − 1.15 N2B27 − + − − N2B27 + − − − 0.93 0.72 N2B27 + + + − N2B27 + − + − 0.91 N2B27 + + − − N2B27 + − + − 1.05 N2B27 + + + − N2B27 + − − − 0.77 N2B27 + + − − N2B27 + − − − 0.92 N2B27 − − − − SF03 + − + − 7.03* N2B27 − − − − SF03 + + + − 2.75* N2B27 + − − − SF03 + − + − 2.07* N2B27 − + − − SF03 + − − − 5.37 N2B27 − + − − SF03 + − + − 12.32 5.97 N2B27 − + − − SF03 + + + − 2.73 2.77 N2B27 + + − − SF03 + − + − 13.34 1.68 N2B27 − + − + SF03 + − + − 2.95 N2B27 − + − + SF03 + − + + 4.68 N2B27 − + − − SF03 + − + + 0.32 N2B27 − + − − SF03 − − + − dead N2B27 + + − − SF03 − − + − dead The optimal condition from these experiments is highlighted in bold. Abbreviations: Act; activin A, GI; GSK3 inhibitor CHIR99021, H+C+; percentage of RS/CXCR4 double positive cells, s.d.; standard deviation. -
TABLE 6 Optimisation of ADE production using chemically defined media in adherent monolayer culture. Day 0-2 Day 3-7 media Act Bmp4 GI media Act EGF H+C+ s.d. SF03 − − − SF03 − − dead SF03 − − − SF03 + − dead SF03 + + − SF03 + − dead SF03 + + − SF03 + + dead SF03 − + − SF03 + + dead SF03 + − − SF03 + − dead N2B27 − − − N2B27 − − dead N2B27 − + − N2B27 + + 0.3 N2B27 − + − N2B27 + − 0.2 N2B27 + + − N2B27 + + 0.1 N2B27 + + − N2B27 + − 0.3 N2B27 − − − SF03 + + 0 N/A N2B27 + − − SF03 + + 0 N/A N2B27 − + − SF03 + + 5.03 1.8 N2B27 + + − SF03 + + 5.7 1.9 N2B27 − − + SF03 + + 1.7 N2B27 + − + SF03 + + 2.0 N2B27 − + + SF03 + + 0.2 N2B27 + + + SF03 + + 4.2 The optimal condition from these experiments is highlighted in bold. Abbreviations: Act; activin A, GI; GSK3 inhibitor CHIR99021, H+C+; percentage of RS/CXCR4 double positive cells, s.d.; standard deviation, N/A; not applicable. -
TABLE 7 ADE percentage and total cell number following 7 days serum-free differentiation. aggregation monolayer Media (day 0-2) H+C+ total cells H+C+ total cells N2B27 13.49 0.75 × 106 0 0.3 × 106 N2B27 + GI 5.86 2.3 × 106 1.7 0.9 × 106 N2B27 + A 1.21 1.6 × 106 0 0.3 × 106 N2B27 + A + GI 7.81 1.7 × 106 2.0 0.8 × 106 N2B27 + B 2.68 2.2 × 106 3.0 1 × 106 N2B27 + B + GI 5.11 1.2 × 106 0.2 1 × 106 N2B27 + A + B 9.1 5.7 × 10 6 5.0 2 × 10 6 N2B27 + A + B + GI 7.68 2.6 × 106 4.2 1.5 × 106 The optimal condition in terms of H+C+ yield is highlighted in bold. -
TABLE 8 Addition of Fgf4 increases ADE production. Day 0-2 Day 3-7 media Act Bmp4 Fgf4 PD173074 media Act EGF Fgf4 PD173074 H+C+ s.d. N2B27 + + − − SF03 + + − − 5.7 1.9 N2B27 + + + − SF03 + + + − 11.5 4.6 N2B27 + + + + SF03 + + + + 0.08 N/A N2B27 + + − + SF03 + + − + 0.13 0.07 N2B27 + + − + SF03 + + − − 2.55 0.2 N2B27 + + − − SF03 + + − + 1.58 0.6 The optimal condition is highlighted in bold. Abbreviations: Act; activin A, H+C+; percentage of RS/CXCR4 positive cells, s.d.; standard deviation, N/A; data not available. -
TABLE 9 Primers used for real-time RT-PCR Amplicon Gene Forward Reverse size (bp) B-actin GGCCCAGAGCAAGAGAGGTATCC ACGCACGATTTCCCTCTCAGC 460 TBP GGGGAGCTGTGATGTGAAGT CCAGGAAATAATTCTGGCTCA 93 Hex GAGGTTCTCCAACGACCAGA GTCCAACGCATCCTTTTTGT 202 Cxcr4 TCAGTGGCTGACCTCCTCTT TTTCAGCCAGCAGTTTCCTT 220 Brachyury GTGACTGCCTACCAGAATGA ATTGTCCGCATAGGTTGGAG 336 Pou5f1 GGCGTTCTCTTTGGAAAGGTGTTC CTCGAACCACATCCTTCTC 314 Foxa2 CATCCGACTGGAGCAGCTA GCGCCCACATAGGATGAC 178 Sox17 GGTCTGAAGTGCGGTTGG TGTCTTCCCTGTCTTGGTTGA 182 Gsc GAGACGAAGTACCCAGACGTG GGCGGTTCTTAAACCAGACC 94 Cer1 AGGAGGAAGCCAAGAGGTTC CATTTGCCAAAGCAAAGGTT 189 Mixl1 AGTTGCTGGAGCTCGTCTTC AGGGCAATGGAGGAAAACTC 194 Nodal GGCGTACATGTTGAGCCTCT GCCTGGTGGAAAATGTCAAT 228 Cdx2 GGAAGCCAAGTGAAAACCAG CTTGGCTCTGCGGTTCTG 189 Wnt3 CGCTCAGCTATGAACAAGCA GGTGTTTCTCCACCACCATC 202 Meox1 GGAAGGAGAGGACAGCCTTC CCCTTCACACGTTTCCACTT 178 Ecad AGACTTTGGTGTGGGTCAGG CATGCTCAGCGTCTTCTCTG 176 Sox7 AGATGCTGGGAAAGTCATGG AGAGGGAGCTGAGGAGGAAG 186 Fhl2 AGAAAACCATCATGCCAGGT ACAGGTGAAGCAGGTCTCGT 74 Lhx1 CAGGAGACTGGCCTCAACAT GTTTCATCCTTCGCTCCTTG 76 Pdlim4 TTACGCTCTCGGTCAGCAG TCCTATGTGCTTGAGCCTTG 75 Foxa3 CCTCCTTCGTCCACACCTTA GAAGTTATAGGGCGCATCCA 64 Tle2 TATGGGGCCAGCATTTTTC CCTGAGCCTGTCACGATGTA 92 Tmprss2 GCCAAGAGCTCGGACAGA AGCAGCATGAGGAGGTCAGT 86 -
TABLE 10 Effect of BMP4 and activin A on ADE induction and final cell number following 7 days serum-free differentiation in adherent monolayer culture. Media (day 0-2) Percentage H+C+ Total cells in culture N2B27 0.0 0.3 × 106 N2B27 + A 0.0 0.3 × 106 N2B27 + B 3.0 1 × 106 N2B27 + A + B 5.0 2 × 10 6 The optimal culture condition in terms of H+C+ yield is highlighted in bold. All samples were cultured in SF03 plus activin and EGF from day 2-7. Abbreviations: A; activin, B; Bmp4, H+C+; RS/Cxcr4 double positive cells. -
TABLE 11 Addition of Fgf4 increases ADE production. Day 0-2 Day 3-7 media Fgf4 PD173074 media Fgf4 PD173074 H+C+ s.d. N2B27 − − SF03 − − 5.7 1.9 N2B27 + − SF03 + − 11.5 4.6 N2B27 + + SF03 + + 0.08 N/A N2B27 − + SF03 − − 2.55 0.2 N2B27 − − SF03 − + 1.58 0.6 N2B27 − + SF03 − + 0.13 0.07 N2B27 − − SF03 + − 21.5 0.8 The optimal conditions are highlighted in bold. Activin A and BMP4 were included during the first two days for all conditions, as well as activin A and EGF for the following five days. Abbreviations: N2B27; N2B27 media plus activin A and Bmp4, SF03; SF03 media plus activn and EGF, H+C+; mean percentage of RS/CXCR4 positive cells from a minimum of 3 independent experiments, s.d.; standard deviation, N/A; data not available.
Claims (29)
1. A method of identifying anterior definitive endoderm (ADE) cells derived from a population of ES cells, comprising detecting two or more ADE cell markers in a cell population derived from said ES cell population, in order to identify said ADE cells.
2. The method according to claim 1 , wherein said two or more markers are selected from and group consisting of Sst, Pyy, Ghrl, Slc38a5, Chga, xph5, Tmprss2, Clic6, 1110003E01Rik, Sstr2, 4732456N10Rik, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, 1700027A23Rik, Tm4st2, 0610040B21Rik (txndc12), Apoa1, 2410021P16Rik (acad10), 4832420M10, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8 (Cmtm8), Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7, Sfrp5, Pga5, foxa1, foxa2, foxa3, Cerl, Hhex, Otx2, and Gatn3.
3. The method according to claim 2 , wherein the cell markers are cell surface expressed.
4. The method according to claim 3 , wherein the cell surface markers are selected from the group consisting of Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4st2, Fzd5, Cklfsf8 (Cmtm8), Rarres1, Sic7a8, and Sfrp5.
5. The method according to claim 2 , further comprising detecting at least 3 of the makers.
6. The method according to claim 1 , further comprising obtaining a cell population comprising greater than 40% ADE cells.
7. The method according to claim 1 , further comprising differentiating said ADE cells in order to obtain differentiated cells in which greater than 40% of the cells differentiated in the cell culture are pancreatic cells.
8. The method according to claim 1 , further comprising differentiating said ADE cells in order to obtain differentiated cells in which greater than 10% are liver cells.
9. The method according to claim 7 , comprising purifying said differentiated cells such that the resulting differentiated cell population is essentially free of ES cells.
10. A mixed cell population obtained directly from an ES cell culture, comprising at least 40% ADE cells.
11. A mammalian ES cell line comprising a nucleic acid construct comprising a marker gene which has been inserted within an ADE specific gene locus of the genome such that the marker gene is under control of the ADE specific gene promoter.
12. A method of reprogramming a somatic cell or somatic cell progenitor in order to generate an ADE cell, comprising:
i) providing one or more ADE cell markers;
ii) providing a somatic cell or somatic cell progenitor; and
iii) transferring the ADE marker(s) or genes encoding said markers into the cell or cell progenitor, thereby reprogramming the cell or cell progenitor.
13. A method of differentiating ES cells to ADE cells, comprising:
(i) culturing the ES cells in a first culture medium, optionally on a feeder, in (a) the presence of serum or an extract thereof or (b) in a serum free or serum extract free medium;
(ii) replacing the first culture medium with a second serum free medium comprising activin or removing any serum or extract thereof and any feeder present in the first culture medium and adding activin; and
(iii) propagating the ES cells in the medium comprising activing, in order to obtain cells comprising ADE cells, with the proviso that the first and second medium are not SF03 medium.
14. The method according to claim 13 , wherein said first and/or second medium is N2B27.
15. The method according to claim 14 , wherein the first or second medium further comprises EGF and/or an agonist of a receptor of the TGF-β superfamily.
16. The method according to claim 14 , wherein the ES cells are grown in suspension.
17. The method according to claim 16 , wherein the first culture medium comprising serum is GMEM and the second medium comprising activin is N2B27.
18. The method according to claim 13 , wherein the initial cell density in first culture medium containing the serum or extract thereof is less than 1×105 cells/ml.
19. The method according to claim 13 , wherein the ES cells are grown in monolayer culture and the first medium comprises one or more of activin, Fgf4, Bmp4 and CHIR99021, and wherein the second medium optionally comprises EGF and/Fgf4.
20. The method according to claim 19 , wherein the second medium is SF03.
21. The method according to claim 13 , wherein the second medium comprises Bmp4 or EGF4.
22. The method according to claim 12 , wherein the one or more markers ADE cell markers is selected from the group consisting of Clic6, Sstr2, Rab15, Rnase4, Slc6a4, Fxyd3, Slc12a2, Tm4sf2, Apoa1, Fzd5, Gckr, Enpp5, Syt5, Cklfsf8, Robo1, Ctsh, Rarres1, Sec14l2, Ripk4, Slc7a8, Ng23, Krt2-7m, Sfrp5, Pga5, Foxa1, 2, 3, Cerl, Hhex, Otx2, Gata3, Cish, Pik3cb, and Rfxdc1.
23. The method according to claim 22 , wherein the cell markers are cell surface expressed.
24. The method according to claim 23 , wherein the cell markers are selected from the group consisting of Sic38a5, Tmprss2, Clic6, Sstr2, Sic6a4, Fxyd3, Sic12a2, Tm4sf2, Fzd5, Cklfsf8 (Cmtm8), Rarres1, Sic7a8, and Sfrp5.
25. The method according to claim 22 , wherein at least 2 of the cell markers are used to generate the ADE cells.
26. A method of treating a disease of the liver, pancreas, lung, thymus, thyroid or parathyroid, comprising administering ADE cells prepared according to claim 12 or claim 13 to a subject in need thereof.
27. The cell population according to claim 26 , wherein the ADE cells are derived from humans, primates, rodents or birds.
28. The cell population according to claim 26 , wherein the ADE cells are derived from mammals, especially mice, rats and humans.
29. The cell population according to claim 26 , wherein the ES cells from which the ADE cells are derived are either wild-type or genetically modified ES cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/423,126 US20170218332A1 (en) | 2007-08-24 | 2017-02-02 | Regionalised Endoderm Cells and Uses Thereof |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0716515.2 | 2007-08-24 | ||
| GB0716515A GB0716515D0 (en) | 2007-08-24 | 2007-08-24 | Regionalised endoderm cells and uses thereof |
| GB0809852.7 | 2008-05-30 | ||
| GB0809852A GB0809852D0 (en) | 2008-05-30 | 2008-05-30 | Regionalised endoderm cells and uses thereof |
| PCT/GB2008/002875 WO2009027654A1 (en) | 2007-08-24 | 2008-08-25 | Regionalised endoderm cells and uses thereof |
| US67489010A | 2010-02-23 | 2010-02-23 | |
| US14/645,934 US20150252323A1 (en) | 2007-08-24 | 2015-03-12 | Regionalised endoderm cells and uses thereof |
| US15/423,126 US20170218332A1 (en) | 2007-08-24 | 2017-02-02 | Regionalised Endoderm Cells and Uses Thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/645,934 Continuation US20150252323A1 (en) | 2007-08-24 | 2015-03-12 | Regionalised endoderm cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20170218332A1 true US20170218332A1 (en) | 2017-08-03 |
Family
ID=39951568
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/674,890 Expired - Fee Related US9005962B2 (en) | 2007-08-24 | 2008-08-25 | Regionalised endoderm cells and uses thereof |
| US14/645,934 Abandoned US20150252323A1 (en) | 2007-08-24 | 2015-03-12 | Regionalised endoderm cells and uses thereof |
| US15/423,126 Abandoned US20170218332A1 (en) | 2007-08-24 | 2017-02-02 | Regionalised Endoderm Cells and Uses Thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/674,890 Expired - Fee Related US9005962B2 (en) | 2007-08-24 | 2008-08-25 | Regionalised endoderm cells and uses thereof |
| US14/645,934 Abandoned US20150252323A1 (en) | 2007-08-24 | 2015-03-12 | Regionalised endoderm cells and uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US9005962B2 (en) |
| EP (1) | EP2195417A1 (en) |
| WO (1) | WO2009027654A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2563908B1 (en) * | 2010-04-25 | 2019-01-09 | Icahn School of Medicine at Mount Sinai | Generation of anterior foregut endoderm from pluripotent cells |
| CN102234627B (en) * | 2010-04-30 | 2015-06-03 | 中国科学院广州生物医药与健康研究院 | Culture medium additive and application thereof |
| GB201014169D0 (en) * | 2010-08-25 | 2010-10-06 | Cambridge Entpr Ltd | In vitro hepatic differentiation |
| ES2902650T3 (en) * | 2011-06-21 | 2022-03-29 | Novo Nordisk As | Efficient induction of definitive endoderm from pluripotent stem cells |
| ES3015228T3 (en) * | 2012-09-25 | 2025-04-30 | Univ Yale | Differentiation of human ips cells to human alveolar type ii via definitive endoderm |
| EP2925859B1 (en) * | 2012-11-29 | 2018-05-02 | Takara Bio Europe AB | Maturation of hepatocyte-like cells derived from human pluripotent stem cells |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| GB201317869D0 (en) * | 2013-10-09 | 2013-11-20 | Cambridge Entpr Ltd | In vitro production of foregut stem cells |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| EP4386081A3 (en) * | 2019-05-21 | 2024-10-16 | President and Fellows of Harvard College | Endocrine differentiation-inducing molecule |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3584311A1 (en) * | 2005-10-27 | 2019-12-25 | Viacyte, Inc. | Pdx-1 expressing dorsal and ventral foregut endoderm |
| CA2644468C (en) * | 2006-03-02 | 2022-02-01 | Cythera, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
-
2008
- 2008-08-25 EP EP08788434A patent/EP2195417A1/en not_active Withdrawn
- 2008-08-25 WO PCT/GB2008/002875 patent/WO2009027654A1/en not_active Ceased
- 2008-08-25 US US12/674,890 patent/US9005962B2/en not_active Expired - Fee Related
-
2015
- 2015-03-12 US US14/645,934 patent/US20150252323A1/en not_active Abandoned
-
2017
- 2017-02-02 US US15/423,126 patent/US20170218332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9005962B2 (en) | 2015-04-14 |
| EP2195417A1 (en) | 2010-06-16 |
| WO2009027654A8 (en) | 2009-07-16 |
| US20150252323A1 (en) | 2015-09-10 |
| WO2009027654A1 (en) | 2009-03-05 |
| US20120100115A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10428308B2 (en) | Mesoderm and definitive endoderm cell populations | |
| US20170218332A1 (en) | Regionalised Endoderm Cells and Uses Thereof | |
| CA2684022C (en) | Mesoderm and definitive endoderm cell populations | |
| AU2012203441B2 (en) | Mesoderm and definitive endoderm cell populations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |